[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2014039899A1 - Pyrazolopyrimidine compounds as kinase inhibitors - Google Patents

Pyrazolopyrimidine compounds as kinase inhibitors Download PDF

Info

Publication number
WO2014039899A1
WO2014039899A1 PCT/US2013/058614 US2013058614W WO2014039899A1 WO 2014039899 A1 WO2014039899 A1 WO 2014039899A1 US 2013058614 W US2013058614 W US 2013058614W WO 2014039899 A1 WO2014039899 A1 WO 2014039899A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
pyrazolo
fluoro
pyrimidin
Prior art date
Application number
PCT/US2013/058614
Other languages
French (fr)
Inventor
Tim Owens
Erik Verner
Original Assignee
Principia Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201380046810.4A priority Critical patent/CN104822681B/en
Priority to EA201590230A priority patent/EA027213B9/en
Application filed by Principia Biopharma Inc. filed Critical Principia Biopharma Inc.
Priority to AU2013312296A priority patent/AU2013312296B2/en
Priority to ES13762703.0T priority patent/ES2644964T3/en
Priority to US14/374,788 priority patent/US9266895B2/en
Priority to PL13762703T priority patent/PL2892900T3/en
Priority to BR112015003859-0A priority patent/BR112015003859B1/en
Priority to JP2015531259A priority patent/JP6203848B2/en
Priority to EP17152898.7A priority patent/EP3181567B1/en
Priority to PL17152898T priority patent/PL3181567T3/en
Priority to MX2015002955A priority patent/MX361815B/en
Priority to SI201330822T priority patent/SI2892900T1/en
Priority to NZ630925A priority patent/NZ630925A/en
Priority to CA2882367A priority patent/CA2882367C/en
Priority to KR1020157008939A priority patent/KR102203990B1/en
Priority to EP13762703.0A priority patent/EP2892900B1/en
Priority to SG11201501815UA priority patent/SG11201501815UA/en
Publication of WO2014039899A1 publication Critical patent/WO2014039899A1/en
Priority to US14/464,602 priority patent/US8940744B2/en
Priority to IL237285A priority patent/IL237285B/en
Priority to ZA2015/01615A priority patent/ZA201501615B/en
Priority to HK16100044.8A priority patent/HK1211942A1/en
Priority to US14/997,330 priority patent/US9994576B2/en
Priority to HRP20171601TT priority patent/HRP20171601T1/en
Priority to US15/978,041 priority patent/US10533013B2/en
Priority to IL26500719A priority patent/IL265007B/en
Priority to CY20191100638T priority patent/CY1122611T1/en
Priority to US16/708,340 priority patent/US11040980B2/en
Priority to US17/324,674 priority patent/US20220073522A1/en
Priority to US18/344,167 priority patent/US20240174676A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present disclosure provides certain small-molecule compounds that are tyrosine kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases. Also provided are certain pharmaceutical compositions containing such compounds and processes for preparing such compounds.
  • BTK Bruton's tyrosine kinase
  • the human genome contains at least 500 genes encoding protein kinases. Many of these kinases have been implicated in human disease and as such represent potentially attractive therapeutic targets.
  • BTK a member of the Tec family non-receptor tyrosine kinases, is essential for B cell signaling downstream from the B-cell receptor. It is expressed in B cells and other hematopoietic cells such as monocytes, macrophages, and mast cells. BTK is reported to function in various aspects of B cell function that maintain the B cell repertoire ⁇ see Gauld S. B. et al., B cell antigen receptor signaling: roles in cell development and disease. Science, 296: 1641-2. 2002.)).
  • BTK is reported to be required for B cell development because patients with the disease X-linked agammaglobulinemia ⁇ see Rosen F. S., et al., The primary immunodeficiencies. N Engl J Med. 333:431-40. 1995) lack of antibodies in their bloodstream.
  • small-molecule BTK inhibitors in pre-clinical development have been reported to be efficacious in collagen-induced arthritis ⁇ see Pan Z., et al., Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. J. Med. Chem. 2:58-61. 2007).
  • the potential advantage of a small molecule BTK inhibitor (beyond the inherent advantage of a small-molecule over a biologic) is that modulation of BTK can inhibit B cell function without permanent removal of the B cell itself. Therefore, the long periods of low B cell levels experienced with the biologic Rituxan should be avoidable by targeting BTK with a small molecule BTK inhibitor.
  • the disease modifying activities of BTK are expected to extend beyond those of Rituxan because of effects on addition cellular targets that are involved in propagation of disease.
  • antigen induced mast cell degranulation is reportedly impaired in mast cells derived from the bone marrow of BTK deficient mice, demonstrating that BTK is downstream of the FceFU receptor (see Setoguchi R., et al., Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and BTK-deficient mice. Immunol Lett. 64: 109-18. 1998).
  • a similar signaling module exists in monocytes and macrophages for the FcyR1 receptor indicating BTK inhibition is highly likely to modulate TNF production in response to IgG. Both mast cells and macrophages are thought to contribute to propagation of the inflammatory cytokine environment of the diseased synovium.
  • BTK inhibition reportedly will have bone protective effects in an inflamed joint (see Gravallese E. M., et al., Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43:250-8. 2000). Studies with mice that are either deficient in BTK or have impaired BTK function have reportedly demonstrated that Rank ligand-induced osteoclast differentiation is impaired in the absence of BTK function (see Lee S. H., et. al., The tec family tyrosine kinase BTK Regulates RANKL-induced osteoclast maturation. /. Biol. Chem.
  • BTK inhibitors could inhibit or reverse the bone destruction that occurs in RA patients.
  • BTK inhibitors could also have utility in other autoimmune diseases such as systemic lupus erythematosus (see Shlomchik M. J., et. al, The role of B cells in lpr/lpr-induced autoimmune diseases
  • platelet aggregation in response to collagen or collagen-related peptide is reportedly impaired in XLA patients who lack BTK function (see Quek L. S, et al., A role for Bruton's tyrosine kinase (BTK) in platelet activation by collagen. Curr. Biol. 8: 1 137-
  • ITK Interleukin-2 Inducible T cell Kinase (Itk) and Bruton's Tyrosine Kinase (Btk) Severely Impairs
  • BMX Another family member, is reportedly involved in supporting tumor angiogenesis through it's role in the tumor vascular endothelium (see Tu T, et al., Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res. 68:2861-9. 2008) and is also progressively up- regulated during bladder cancer progression ⁇ see Guo S., et al, Tyrosine Kinase ETK BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy. PLoS One. 6:el7778. 2011), which can be interpreted to suggest a potential therapeutic target in this type cancer.
  • the B lymphoid kinase (hereafter, sometimes expressed as "BLK”) is reportedly linked through genetic association with a variety of rheumatic diseases including systemic lupus erythematosus and systemic sclerosis (see Ito I, et al., Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum. 62:890-5. 2010).
  • R and R are independently hydrogen, alkyl, halo, or alkoxy
  • R 3 is hydrogen or halo
  • R c is: (a) -C(CH3)2-(4-R 5 -piperazin-l-yl) where R 5 is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
  • the compound or salt thereof of Formula (II) is where R 1 is hydrogen, alkyl, halo, or alkoxy and R 2 is alkyl, halo, or alkoxy.
  • R 3 is fluoro.
  • the compound or salt thereof of Formula (II) is where R 1 is hydrogen, alkyl, halo, or alkoxy and R 2 is alkyl, halo, or alkoxy and R c is -C(CH 3 )2-(4-R 5 - piperazin-l-yl) where R 5 is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl.
  • R 3 is fluoro.
  • the compound or salt thereof of Formula (II) is where R 1 and R 2 are hydrogen and R c is -C(CH 3 )2-(4-R 5 -piperazin-l-yl) where R 5 is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl.
  • R is fluoro.
  • R 3 is hydrogen and R° is -C(CH 3 )2-(4-R 5 -piperazin-l-yl) where R 5 is hydrogen, alkyl, or oxetan-3-yl.
  • R 5 is hydrogen, alkyl, or oxetan-3-yl.
  • the compound or salt therof of Formula (IA) is where R c is -C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 ) 2 -(4-methylpiperazin-l-yl), -C(CH 3 ) 2 -(4-ethylpiperazin- 1-yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -N(CH 2 CH 3 )oxetan-3-yl, -C(CH 3 ) 2 - N(cyclopropyl)-oxetan-3-yl, -C(CH 3 ) 2 -NHoxetan-3-yl, -C(CH 3 ) 2 -2-oxa-6-azaspiro- [3.3]heptan-6-yl, -C(CH 3 ) 2 -CH 2 morpholine-4-y
  • the compound or salt thereof of Formula (IA) is where R c is - C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 ) 2 -(4-methylpiperazin-l-yl), -C(CH 3 ) 2 -(4-ethyl-piperazin- 1 -yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -N(CH 2 CH 3 )oxetan-3-yl,
  • the compound or salt thereof of Formula (IA) is where R c is -C(CH 3 ) 2 -(3-oxo-4-methylpiperazin- 1 -yl), -C(CH 3 ) 2 -[4-(2-methoxyethyl)-piperazin- 1 -yl], -C(CH 3 ) 2 -(4-tert-butylpiperazin-l -yl), -C(CH 3 ) 2 -(4-isopropylpiperazin-l-yl), -C(CH 3 ) 2 -(2,5- dimethyl-piperazin-l-yl), -C(CH 3 ) 2 -(3,5-dimethylpiperazin-l-yl), -C(CH 3 ) 2 -(3,4,5-trimethyl- piperazin- 1 -yl), -C(CH 3 ) 2 -(2,4,5-trimethylpiperazin- 1 -yl), -C(CH
  • the compound or salt thereof of Formula (IA) is where R c is -C(CH 3 ) 2 -(3-oxo-4-methylpiperazin-l-yl) or -C(CH 3 ) -[4-(2-methoxyethyl)-piperazin-l- yl]-
  • the compound of Formula (IA) is chosen from:
  • R c is -C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 )2-(4-methylpiperazin-l-yl), -C(CH 3 ) 2 -(4- ethylpiperazin- 1 -yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -N(CH 2 CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -N(cyclopropyl)oxetan-3-yl, -C(CH 3 ) 2 -NHoxetan-3-yl, or -C(CH 3 ) 2 -2-oxa-6- azaspiro[3.3]heptan-6-yl;
  • the compound of Formula (I) is chosen from:
  • R° is 3-methyloxetan-3-yl, -C(CH3)2-(azetidin-l-yl), -C(CH 3 ) 2 -(3-hydroxyazetidin-l- yl), -C(CH 3 ) 2 -(4-hydroxypiperidin-l-yl), -C(CH 3 ) 2 -(pyrrolidin-l -yl), or -C(CH 3 ) 2 CH 2 OH; and/or a pharmaceuti
  • R c is not 3- methyloxetan-3-yl, and/or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (IB) is chosen from:
  • the compound or a pharmaceutical acceptable salt is:
  • the compound is chosen from 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4- methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4- methyl-4-[ethyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4- methyl-4-(oxetan-3-ylamino)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4- [methyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4- [ethyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4- (oxetan-3-yl)aminopent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]-pyrimidin- 1 -yl] -piperidin- 1 -y l]carbonyl] -4- methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l-yl]-piperidin-l-yl]carbonyl]-4- methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-((R)-3-(4-amino-3-(2-fluoro- 4-phenoxy-phenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(3- hydroxyazetidin-l-yl)-4-methylpent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from (R)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4- (4- methyl-3-oxopiperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from (R)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-(4-(2- methoxyethyl)piperazin-l-yl)-4-methylpent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from 2-[[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l-yl]-piperidin-l-yl]carbonyl]-4- methyl-4-(piperazin-l-yl)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from (R)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4- (oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from (S)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4- (oxetan-3-yl)piperazin-l -yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from (R)-2-(3-(4-amino-3-(4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4- (oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from (S)-2-(3-(4-amino-3-(4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-
  • the compound is chosen from (R)-2-(2-((4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)- 4-methyl-4-(4-(oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compound is chosen from (S)-2-(2-((4-amino-3-(2-fluoro- 4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)methyl)pyrrolidine-l-carbonyl)-4- methyl-4-(4-(oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
  • the compounds of the present disclosure are reversible covalent inhibitors. In another embodiment, the compounds of the present disclosure form a reversible covalent bond to Cys 481 of BTK.
  • Another embodiment disclosed herein is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound and/or a pharmaceutically salt of any embodiment disclosed herein and a pharmaceutically acceptable excipient.
  • Another embodiment disclosed herein is a method of treating a disease treatable by inhibition of a tyrosine kinase such as BLK, BMX, , HER2, HER4, ITK, TEC, BTK, and TXK, such as BTK, in a patient in need of such treatment which method comprises administering to the patient in recognized need thereof, a pharmaceutical composition comprising a compound and /or a pharmaceutically acceptable salt of any embodiment disclosed herein and a pharmaceutically acceptable excipient in an amount effective to achieve the treatment (therapeutic amount).
  • the patient is in recognized need of such treatment.
  • the disease is chosen from autoimmune diseases, inflammatory diseases, and cancers.
  • the patient in need or recognized need is suffering from an autoimmune disease, e.g., inflammatory bowel disease, such as ulcerative colitis, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjogren's syndrome, Sjogren's dry eye, non-Sjogren's dry eye disease, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma
  • an autoimmune disease
  • the patient in need or recognized need is suffering from a heteroimmune condition or disease, e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic
  • the patient in need or recognized need is suffering from an inflammatory disease, e.g., asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephriti
  • an inflammatory disease e.g., asthma, appendicitis, blepharitis, bronchio
  • the patient in need or recognized need is suffering from inflammatory skin disease, such as dermatitis, contact dermatitis, eczema, urticaria, rosacea, and scarring psoriatic lesions in the skin, joints, or other tissues or organs.
  • inflammatory skin disease such as dermatitis, contact dermatitis, eczema, urticaria, rosacea, and scarring psoriatic lesions in the skin, joints, or other tissues or organs.
  • the patient in need or recognized need is suffering from a cancer.
  • the cancer is a B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-ALL, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplamascytic lymphoma/ Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, bur
  • lymphoma/leukemia lymphomatoid granulomatosis
  • the patient in need or recognized need is suffering from a thromboembolic disorder, e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, and deep venous thrombosis.
  • a thromboembolic disorder e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, and deep venous thrombosis.
  • the disclosure is also directed to the use of any compound and/or a pharmaceutical salt thereof disclosed herein as a medicament.
  • the use of any of the compounds and/or a pharmaceutically acceptable salt thereof disclosed herein is for treating a disease mediated by a kinase, in particular BTK, for treating a disease chosen from autoimmune and inflammatory diseases and proliferative diseases, such as cancers.
  • the disclosure is also directed to the use of any compound and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an inflammatory disease in a patient in need of such treatment in which the activity of a tyrosine kinase, such as BLK, BMX, HER2, HER4, ITK, TEC, BTK, and TXK, in particular BTK, contributes to the pathology and/or symptoms of the disease.
  • a tyrosine kinase such as BLK, BMX, HER2, HER4, ITK, TEC, BTK, and TXK, in particular BTK
  • the patient is in recognized need of such treatment.
  • the disease is an autoimmune or inflammatory disease (e.g., arthritis, asthma) or a proliferative disease e.g., B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-ALL, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplamascytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary eff
  • combination therapy can also be implicated, i.e., the compounds and/or a pharmaceutically acceptable salt disclosed herein can be
  • the at least additional agent is chosen from alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds, such as cisplatin, cladribine, daunorubicin/doxorubicin /idarubicin, irinotecan, fludarabine, 5-fluorouracil, gemtuzamab, methotrexate, paclitaxel, TaxolTM, docetaxol, temozolomide, thioguanine, and classes of drugs including hormones (an antiestrogen, an antiandrogen, or gonadotropin releasing hormone analogues, interferons such as alpha interferon, nitrogen mustards such as busulfan or melphalan or mechlorethamine, retinoids such as tretinoin
  • obinutuzumab IPI-145, GS-1101, BKM-120, GDC-0941, DGDC-0980, GS-9820, CAL-263, Revlimid®, thalidomide®, pomalidomide®, Velcade ®, Kyprolis ®, delanzomib, U0126, PD98059, PD184352, PD0325901 , ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, Nexavar®, Tarceva®, Sutent®, Tykerb®, Sprycel®, Crizotinib, Xalkori®, or LY294002or agents to treat signs or symptoms induced by such therapy including allopurinol, filgrastim, granisetron/ondansetron/ palonosetron, dronabinol When combination therapy is used, the agents can be administered simultaneously or sequentially.
  • R c is:
  • R 4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
  • R° is -C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 ) 2 -(4-methylpiperazin-l- yl), -C(CH 3 ) 2 -(4-ethylpiperazin-l-yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 - N(CH 2 CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -NHoxetan-3-yl, or -C(CH 3 ) 2 -2-oxa-6- azaspiro[3.3]heptan-6-yl); and/or
  • X 3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
  • R c is -C(CH ) 2 -(piperazin-l-yl), -C(CH 3 ) 2 -(4-methylpiperazin-l-yl), -C(CH 3 ) 2 -(4-ethylpiperazin- 1 -yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 - N(CH 2 CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -NHoxetan-3-yl, or -C(CH 3 ) 2 -2-oxa-6- azaspiro[3.3]heptan-6-yl); or (b)
  • R 4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
  • R b is hydrogen, alkyl, or cycloalkyl
  • X 3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
  • R c is -C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 ) 2 -(4-methylpiperazin-l-yl), -C(CH 3 ) 2 -(4-ethylpiperazin- 1 -yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 - N(CH 2 CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -NHoxetan-3-yl, or -C(CH 3 ) 2 -2-oxa-6- azaspiro[3.3]heptan-6-yl) ;
  • X is a leaving group, capable of being displaced by the nitrogen atom of the Z group under amide coupling reaction conditions
  • Z is
  • R° is -C(CH3)2-(4-methylpiperazin-l-yl).
  • Z is or and R c is -C(CH 3 ) 2 -(piperazin-l-yl).
  • Z is or and R c is -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl.
  • Z is L N "" J or
  • R c is -C(CH 3 ) 2 -NHoxetan-3-yl.
  • Z is or
  • Z is
  • R c is -C(CH 3 ) 2 -N(ethyl)piperazin-l-yl.
  • Z is
  • R c is -C(CH 3 )?-(4-methyl-3-oxopiperazin-l-yl).
  • Z is
  • R c is -C(CH 3 ) 2 -(4-(2-ethoxyethyl)-piperazin-l-yl).
  • Z is or and R c is -C(CH 3 ) 2 -4-(oxetan-3-yl)-piperazin-l-yl.
  • the compound of Formula (IA) (and embodiments thereof) is prepared by method (a) by reacting a compound of formula (1):
  • R 4 is hydrogen, alkyl, alkoxyalkyi, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
  • R b is hydrogen, alkyl, or cycloalkyl; where one or two of X , X "" and X 3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
  • R c is -C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 ) 2 -(4-methylpiperazin-l-yl), -C(CH 3 ) 2 -(4-ethylpiperazin-l-yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 - N(CH 2 CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -NHoxetan-3-yl, -C(CH 3 ) 2 -2-oxa-6-azaspiro[3.3]heptan- 6-yl, -C(CH 3 ) 2 -CH 2 morpholine-4- yl; (in one embodiment R c is -C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 ) 2 -(4-methylpipe
  • the compound of Formula (IA) (and embodiments thereof) is prepared by method (b) by reacting a compound of formula (2):
  • R c is -C(CH 3 ) 2 -(piperazin-l-yl), -C(CH 3 )2-(4-methylpiperazin-l-yl), -C(CH 3 ) 2 -(4-ethylpiperazin-l-yl), -C(CH 3 ) 2 -N(CH 3 )oxetan-3-yl, -C(CH 3 ) 2 -
  • Alkyl means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like.
  • Alkoxy means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or ieri-butoxy, and the like.
  • Alkoxyalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with an alkoxy group, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2- ethoxyethyl, and the like.
  • Hydrocarbon radical means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with a hydroxy group, as defined above, e.g., 2-hydoxyethyl, 1 , 3-dihydoxypropyl, and the like.
  • Alkylsulfonyl means a -S0 2 R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
  • Alkoxycarbonyl means a -C(0)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
  • Acyl means a -COR radical where R is alkyl as defined above.
  • Cycloalkyl means a cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms wherein one or two carbon atoms may be replaced by an oxo group, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like.
  • Halo means fluoro, chloro, bromo, or iodo, such as fluoro or chloro.
  • Haloalkyl means alkyl radical as defined above, which is substituted with one or more halogen atoms, such as one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., -CH 2 C1, -CF 3 , -CHF 2 , -CH2CF3, -CF2CF3, -CF(CH 3 ) 2 , and the like.
  • a “pharmaceutically acceptable salt” of a compound means a salt that is
  • Such salts include:
  • acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid,
  • cyclopentanepropionic acid glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4- hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,
  • benzenesulfonic acid 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4- toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3- hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid; or
  • the compounds of the present disclosure may have asymmetric centers. Certain compounds of the present disclosure containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well-known in the art how to prepare optically active forms, such as by resolution of materials. All chiral, diastereomeric, and racemic forms are within the scope of this disclosure, unless the specific stereochemistry or isomeric form is specifically indicated.
  • Certain compounds of the present disclosure can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. "Optional” or “optionally” means that the subsequently described event or
  • a "pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for human pharmaceutical use.
  • a pharmaceutically acceptable carrier/excipient includes both one and more than one such excipient.
  • Treating” or “treatment” of a disease includes:
  • preventing the disease i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or
  • a “therapeutically effective amount” means the amount of a compound of the present disclosure that, when administered to a patient in need or recognized need of treatment for treating a disease, is sufficient to effect such treatment for the disease.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal to be treated.
  • the compounds disclosed herein are tyrosine kinase inhibitors, in particular BTK and hence are useful in the treatment of autoimmune disease, e.g., inflammatory bowel disease, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjogren's syndrome, including Sjogren's dry eye, non-Sjogren's dry eye, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis
  • the compounds disclosed herein are also useful in the treatment of a heteroimmune condition or disease.
  • the patient in need or recognized need is suffering from a heteroimmune condition or disease, e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis.
  • a heteroimmune condition or disease e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis.
  • the patient in need or recognized need is suffering from an inflammatory disease, e.g., asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis
  • an inflammatory disease
  • the patient in need or recognized need is suffering from inflammatory skin disease which includes, by way of example, dermatitis, contact dermatitis, eczema, rosacea, and scarring psoriatic lesions in the skin, joints, or other tissues or organs.
  • inflammatory skin disease includes, by way of example, dermatitis, contact dermatitis, eczema, rosacea, and scarring psoriatic lesions in the skin, joints, or other tissues or organs.
  • the patient in need or recognized need is suffering from a cancer.
  • the cancer is a B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, chromic myleogenous leukemia, B-ALL, Philadelphia chromosome positive B-ALL lymphoplamascytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt
  • B-cell proliferative disorder e.g., diffuse large B cell lympho
  • the compound disclosed herein is administered in combination with another an anti-cancer agent e.g., the anti-cancer agent is an inhibitor of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002.
  • the anti-cancer agent is an inhibitor of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002.
  • the patient in need or recognized need is suffering from a thromboembolic disorder, e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, and deep venous thrombosis.
  • a thromboembolic disorder e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, and deep venous thrombosis.
  • Yet another embodiment disclosed herein is the use of compounds and/or a pharmaceutically acceptable salt thereof disclosed herein for use as a medicament.
  • the use is for treating inflammatory disease or proliferative diseases.
  • a compound and/or a pharmaceutically acceptable salt thereof disclosed herein in the manufacture of a medicament for treating an inflammatory disease in a patient in need or recognized need of such treatment in which the activity of BTK or other tyrosine kinases contribute to the pathology and/or symptoms of the disease.
  • the tyrosine kinase protein is BTK.
  • the disease is chosen from respiratory, cardiovascular, and proliferative diseases.
  • the compound and/or a pharmaceutically acceptable salt thereof disclosed herein is administered in combination with at least one additional agent chosen from alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds such as cisplatin, cladribine,
  • the agents can be administered simultaneously or sequentially.
  • the kinase inhibitory activity of the compounds of the present disclosure can be tested by methods well known the the art.
  • the BTK inhibitory activity of the compounds and/or a pharmaceutically acceptable salt thereof of the present disclosure can be tested using the in vitro and in vivo assays described in Biological Examples 1-3 below. A determination of kinase inhibitory activity by any of those assays is considered to be kinase inhibitory activity within the scope of this disclosure even if any or all of the other assays do not result in a determination of kinase inhibitory activity.
  • the cysteine sulfhydryl group and a carbon atom forming part of the carbon- carbon double bond (i.e. olefin) of the compound of the present disclosure can form a reversible, i.e., labile, covalent bond, defined herein, such as wherein Cys 481 attacks an electron deficient carbon atom of the carbon-carbon double bond (olefin) in the compound of present disclosure to form a thiol adduct (e.g., Michael reaction with cysteine).
  • the electron deficient carbon atom of the olefin is distal to the carbon attached to the cyano group and to the electron withdrawing -Z-CO- moiety (see Formula I, IA, IB, II) in the compounds of the present disclosure. Therefore, the combination of the cyano and the "-Z-CO-" moieties and the olefinic moiety to which they are bonded in the compounds of the present disclosure can increase the reactivity of the olefin to form a thiol adduct with the active site cysteine residue in BTK.
  • the compounds of the present disclosure bind with BTK in two different manners. In addition to the labile covalent binding, discussed above, they also form non-covalent binding(e.g., via van der Waals binding, hydrogen binding, hydrophobic binding, hydrophilic binding, and/or electrostatic charge binding) with BTK, the non-covalent binding being sufficient to at least partially inhibit the kinase activity of the BTK.
  • non-covalent binding e.g., via van der Waals binding, hydrogen binding, hydrophobic binding, hydrophilic binding, and/or electrostatic charge binding
  • the labile covalent binding between the the compound of the disclosure and BTK occurs between the olefin in the inhibitor and the cysteine 481 residue thiol side chain at or near the site where the compound has the aforementioned non-covalent binding with the BTK.
  • the compounds of the present disclosure which are reversible covalent inhibitors have both a cysteine-mediated covalent binding and a non-covalent binding with the BTK. This is in contrast with non-covalent reversible inhibitors which inhibit the BTK only via non-covalent binding and lack the cysteine-mediated covalent binding.
  • the result of the binding of the compounds of the present disclosure with BTK in the two different manners is a reversible covalent inhibitor having a slow off -rate and a protracted duration of action, in some instances comparable to an irreversible covalent inhibitor without forming permanent irreversible protein adducts.
  • the difference between irreversible and reversible covalent inhibitors, particulary the compounds disclosed herein can be ascertained utilizing assays disclosed herein.
  • the binding involved in an inhibitor that forms a reversible covalent bond with BTK i.e., the compounds disclosed herein, is stable when the BTK is in certain configurations and susceptible to being broken when the BTK is in different configurations (in both cases under physiologic conditions), whereas the interaction between an inhibitor that forms an irreversible covalent bond is stable under physiologic conditions even when the BTK is in different configurations.
  • a reversible covalent bond often imparts unique properties related to the residence time of the compound within the cysteine-containing binding site.
  • residence time refers to the temporal duration of the compound-target complex under different conditions (see Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5(9), 730-739 (2006).
  • a reversible covalent bond in a reversible covalent inhibitor as disclosed herein can lead to an extended residence time when compared to a compound that does not form a covalent bond with BTK.
  • the compounds of the present disclosure that are reversible covalent inhibitors have a residence time of at least about 1 h, residence time may be measured using an occupancy assay in a biochemical or cellular environment (see Biological Example 7 below). Additionally, residence time may be measured using a functional assay following a defined wash-out period.
  • Sequence ID Q06187 and the olefinic bond in the compound of the disclosure, can be determined by the assays described in Biological Examples 5-8 below.
  • a determination of the binding reversibility of the covalent bond between the cysteine residue and the olefinic bond of the compound of the disclosure by any of Biological Examples 5-8 below is considered to be binding reversibility within the scope of this disclosure even if one or more of the other methods does not result in a determination of binding reversibility.
  • the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
  • Therapeutically effective amounts of the compounds disclosed herein may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses.
  • a suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range, the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day.
  • compositions can be provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1 , 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient.
  • the actual amount administered of the compound and/or a pharmaceutically acceptable salt thereof of this disclosure, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound and/or pharmaceutically acceptable salt thereof being utilized, the route and form of administration, and other factors.
  • compositions will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), topically, or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • routes e.g., oral, systemic (e.g., transdermal, intranasal or by suppository), topically, or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • parenteral e.g., intramuscular, intravenous or subcutaneous
  • compositions can take the form of tablets, capsules, semisolids, powders, sustained release formulations, enteric coated or delayed release formulation, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently,
  • compositions are comprised of, in general, a compound and/or pharmaceutically acceptable salt disclosed herein in combination with at least one pharmaceutically acceptable excipient such as binders, surfactants, diluents, buffering agents, antiadherents, glidants, hydrophilic or hydrophobic polymers, retardants, stabilizing agents or stabilizers, disintegrants or superdisintegrants, antioxidants, antifoaming agents, fillers, flavors, colors, lubricants, sorbents, preservatives, plasticizers,and sweeteners.
  • Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound disclosed herein.
  • excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
  • Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
  • Liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
  • the compounds and/or pharmaceutically acceptable salt of the present disclosure can also be administered intranasally.
  • Intranasal formulations are known in the art e.g., see U.S. Patent Nos. 4,476, 116, 5,116,817 and 6,391,452, each of which is incorporated herein by reference.
  • the choice of excipients will depend upon the nature of the nasal dosage form e.g., solutions, suspensions, or powder.
  • the compounds and/or pharmaceutically acceptable salts of the present disclosure may be in the form of solutions, suspensions, and powders.
  • formulations are administered as an aerosol, a mist, or a powder and can be delivered from pressurized packs or a nebulizer with a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, nitrogen, carbon dioxide, etc.
  • a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, nitrogen, carbon dioxide, etc.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges for use in an inhaler may be formulated containing a powder mix of the compound disclosed herein and a suitable powder base such as lactose or starch.
  • Topical formulation can be liquids, suspension, emulsions, and the like, and can be prepared by methods well known in the art.
  • the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound and/or pharmaceutically acceptable salt disclosed herein based on the total formulation, with the balance being one or more suitable pharmaceutical excipients amd can be administered in single or multiple doses.
  • suitable excipients include polymers, surfactants, buffering or pH adjusting agents, tonicity and osmotic adjusting agent(s), preservatives, and dispersing agents.
  • the level of the compound in a formulation can vary within the full range employed by those skilled in the art.
  • the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound and/or pharmaceutically acceptable salt disclosed herein based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
  • the compounds and/or pharmaceutically acceptable salts of the present disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of the present disclosure or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone.
  • Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present disclosure.
  • a pharmaceutical composition in unit dosage form containing such other drugs and the compound and/or pharmaceutically acceptable salt of the present disclosure is preferred.
  • the combination therapy may also include therapies in which the compound and/or pharmaceutically acceptable salt of the present disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds and/or pharmaceutically acceptable salts of the present disclosure and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present disclosure also include those that contain one or more other active ingredients, in addition to a compound and/or pharmaceutically acceptable salt of the present disclosure.
  • combinations include combinations of a compound of the present disclosure not only with one other active compound, but also with two or more other active compounds.
  • compounds and/or pharmaceutically acceptable salts of the present disclosure may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present disclosure are useful.
  • Such other drugs may be administered, by a route and in an amount commonly used therefore by those skilled in the art,
  • a compound and/or pharmaceutically acceptable salt of the present disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound and/or
  • compositions of the present disclosure also include those that also contain one or more other active ingredients, in addition to a compound and/or pharmaceutically acceptable salt of the present disclosure.
  • the weight ratio of the compound and/or pharmaceutically acceptable salt of the present disclosure to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
  • a compound and/or pharmaceutically acceptable salt of present disclosure can be used in with one or more of the following therapeutic agents in any combination: immunosuppressants (e.g., tacrolimus,
  • glucocorticoids e.g., prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone
  • non- steroidal anti-inflammatory drugs e.g., salicylates, arylalkanoic acids, 2-arylpropionic acids, N-arylanthranilic acids, oxicams, coxibs, or sulphonanilides
  • Cox-2-specific inhibitors e.g., valdecoxib, celecoxib, or rofecoxib
  • leflunomide gold
  • binding proteins e.g., infliximab, etanercept, or adalimumab
  • abatacept anakinra
  • interferon-.beta. interferon- .gamma.
  • interleukin-2 allergy vaccines, antihistamines, antileukotrienes, beta-agonists, theophylline, and anticholinergics.
  • the patient can be treated with a compound and/or pharmaceutically acceptable salt disclosed herein in any combination with one or more other anti-cancer agents.
  • one or more of the anti-cancer agents are proapoptotic agents.
  • anti-cancer agents include, but are not limited to, any of the following: gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis- inducing ligand (TRAIL), 5-aza-2'- deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (GleevecTM), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17- AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 1 1-7082, PKC412, or PD 184352, TaxolTM, also referred to as "paclitaxel", which is a well-known anti-cancer drug which acts by enhancing and stabilizing microtubule
  • TaxotereTM Compounds that have the basic taxane skeleton as a common structure feature, have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules and may be useful for treating cancer in combination with the compounds described herein.
  • anti-cancer agents for use in combination with a compound disclosed herein include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126,
  • anti-cancer agents that can be employed in combination with a compound disclosed herein include Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin;
  • bleomycin sulfate brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin;
  • cedefingol chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate;
  • eflornithine hydrochloride elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; camrabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine;
  • idarubicin hydrochloride ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl ; interferon alfa-n3; interferon beta- la; interferon gamma- 1 b; iproplatin; irinotecan hydrochloride;
  • lanreotide acetate lanreotide acetate
  • letrozole leuprolide acetate
  • liarozole hydrochloride lometrexol sodium; lomustine; losoxantrone hydrochloride
  • masoprocol maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril;
  • methotrexate methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane;
  • mitoxantrone hydrochloride mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide;
  • vincristine sulfate vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.
  • anti-cancer agents that can be employed in combination with a compound and/or pharmaceutically acceptable salt disclosed herein include: 20-epi-l, 25
  • antineoplaston antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1 ; axinastatin 2; axinastatin 3; azasetron; azatoxin;
  • azatyrosine baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists;
  • benzochlorins benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine;
  • calcipotriol calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine;
  • carboxamide-amino-triazole carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4;
  • combretastatin analogue conagenin; crambescidin 816; crisnatol; cryptophycin 8;
  • cryptophycin A derivatives curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone;
  • didemnin B didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl . spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin
  • epirubicin epristeride
  • estramustine analogue epristeride
  • estrogen agonists epristeride
  • estrogen antagonists epristeride
  • estramustine analogue epristeride
  • estrogen agonists epristeride
  • estrogen antagonists epristeride
  • etanidazole etoposide phosphate; exemestane; fadrozole; trasrabine; fenretinide; filgrastim; fmasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor;
  • leuprolide+estrogen+progesterone leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine;
  • marimastat masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor;
  • mifepristone miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+ diethylstilbestrol cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N- substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridron
  • palmitoylrhizoxin pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine;
  • pegaspargase peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors;
  • plasminogen activator inhibitor platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor;
  • protein kinase C inhibitors microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; R.sub.l 1 retinamide; rogletimide; rohitukine;
  • romurtide roquinimex; rubiginone B l ; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived 1 ; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol;
  • somatomedin binding protein sonermin; sparfosic acid; spicamycin D; spiromustine;
  • splenopentin spongistatin 1 ; squalamine
  • stem cell inhibitor stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist
  • suradista suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide;
  • tetrazomine thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic;
  • thymalfasin thymopoietin receptor agonist
  • thymotrinan thyroid stimulating hormone
  • tin ethyl etiopurpurin tirapazamine
  • titanocene bichloride topsentin
  • toremifene totipotent stem cell factor
  • translation inhibitors tretinoin
  • triacetyluridine triciribine; trimetrexate
  • triptorelin triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
  • anticancer agents that can be employed in combination with a compound disclosed herein include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes
  • nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.
  • alkyl sulfonates e.g., busulfan
  • nitrosoureas e.g., carmustine, lomusitne, etc.
  • triazenes e.g., triazenes
  • antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
  • folic acid analog e.g., methotrexate
  • pyrimidine analogs e.g., Cytarabine
  • purine analogs e.g., mercaptopurine, thioguanine, pentostatin.
  • Examples of natural products useful in combination with a compound or a pharmaceutically acceptable salt disclosed herein include but are not limited to vinca alkaloids (e.g., diethylstilbestrol, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
  • vinca alkaloids e.g., diethylstilbestrol, vincristine
  • epipodophyllotoxins e.g., etoposide
  • antibiotics e.g., daunorubicin, doxorubicin, bleomycin
  • enzymes e.g., L-asparaginase
  • biological response modifiers e.g., interferon alpha
  • alkylating agents that can be employed in combination a compound or a pharmaceutically acceptable salt disclosed herein include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates
  • nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.
  • ethylenimine and methylmelamines e.g., hexamethlymelamine, thiotepa
  • alkyl sulfonates e.g., hexamethlymelamine, thiotepa
  • nitrosoureas e.g., carmustine, lomusitne, semustine, streptozocin, etc.
  • triazenes decarbazine, etc.
  • antimetabolites include, but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin.
  • hormones and antagonists useful in combination a compound or a pharmaceutically acceptable salt disclosed herein include, but are not limited to,
  • adrenocorticosteroids e.g., prednisone
  • progestins e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate
  • estrogens e.g., diethylstilbestrol, ethinyl estradiol
  • antiestrogen e.g., tamoxifen
  • androgens e.g., testosterone propionate, fluoxymesterone
  • antiandrogen e.g., flutamide
  • gonadotropin releasing hormone analog e.g., leuprolide
  • platinum coordination complexes e.g., cisplatin, carboblatin
  • anthracenedione e.g., mitoxantrone
  • substituted urea e.g., hydroxyurea
  • methyl hydrazine derivative e.g., procarbazine
  • adrenocortical suppressant e.g., mitotane, aminoglutethimide
  • anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with an BTK inhibitor compound and/or a pharmaceutically acceptable salt of the disclosure include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP- XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1 , Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and
  • Epothilones such as Epothilone A, Epothilone B, Epothilone C (also known as
  • Epothilone A or dEpoA desoxyepothilone A or dEpoA
  • Epothilone D also referred to as OS-862, dEpoB, and desoxyepothilone B
  • Epothilone E Epothilone F
  • Epothilone B N-oxide Epothilone A N- oxide
  • 16-aza-epothilone B 21-aminoepothilone B (also known as BMS-310705)
  • 21- hydroxyepothilone D also known as Desoxyepothilone F and dEpoF
  • Auristatin PE also known as NSC-654663
  • Soblidotin also known as TZT-1027
  • LS-4559- P Pulacia, also known as LS-4577
  • LS-4578 also known as LS-477-P
  • LS- 4477 Pharmacia
  • the patient can be treated with a compound and/or pharmaceutically acceptable salt disclosed herein in any combination with one or more other anti- thromboembolic agents.
  • a thromboembolic disorder e.g., stroke
  • the patient can be treated with a compound and/or pharmaceutically acceptable salt disclosed herein in any combination with one or more other anti- thromboembolic agents.
  • anti-thromboembolic agents include, but are not limited any of the following: thrombolytic agents (e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatran etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban, DX- 9065a, otamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel, LY640315), ximelagatran, or BIBR 1048.
  • thrombolytic agents e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator
  • N,N-dimethylformamide (20 mL)
  • 3- (2-fluoro-4-phenoxyphenyl)- 1 - [(3R)-piperidin-3 -yl] - 1 H-pyrazolo[3 ,4-d]pyrimidin-4-amine (8.04 g, 19.88 mmol, 1.00 equiv)
  • 2-cyanoacetic acid 2.0 g, 23.51 mmol, 1.18 equiv
  • HATU (9.12 g, 24.00 mmol, 1.21 equiv)
  • TEA 21.2 mL, 10.00 equiv).
  • the resulting mixture was concentrated under vacuum and the residue was dissolved in DCM.
  • the resulting mixture was washed with 20 mL of aqueous potassium carbonate.
  • the organic layer was dried over anhydrous sodium sulfate, concentrated to give the crude product.
  • the crude product was purified by re-crystallization from ether.
  • Example 8 A Proceeding as described above but substituting 2-methyl-2-(4-methylpiperazin- l-yl)propanal with 2-methyl-2-(4-ethylpiperazin-l-yl)propanal, 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]-methyl]pyrrolidine-l -carbonyl]-4- methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile was synthesized.
  • the 2-methylpropanal (1 mL, 10.96 mmol) was stirred in DCM (10 mL) while being cooled with an ice bath. Bromine (0.62 mL, 12.05 mmol) was slowly added via addition funnel over a 15 min period. After 1 hr of stirring at 0 °C, the reaction was concentrated to a light yellow liquid. This was redissolved in DCM (10 mL) and cooled with an ice bath while the tert-butyl piperazine-l -carboxylate (2.04 g, 10.96 mmol) was slowly added (diluted with 5-10 mL of DCM) over a 30 minute period.
  • the 2-methylpropanal (0.5 mL, 5.48 mmol) was stirred in DCM (10 mL) while being cooled with an ice bath. Bromine (0.31 mL, 6.03 mmol) was slowly added via addition funnel over a 15 min period. After 1 h of stirring at 0 °C, the reaction was concentrated to a light yellow liquid. This was redissolved in DCM (5 mL) and cooled with an ice bath while the N- methyloxetan-3-amine (0.49 mL, 5.48 mmol) was slowly added (diluted with 5-10 mL of DCM) over a 10 minute period. Then the cooling bath was removed and the reaction mixture was stirred at room temperature overnight.
  • the mixture was washed with brine, then the remaining DCM layer was washed by 0.5N HC1.
  • the combined aq. layer was adjusted with KOH to pH 10- 1 1 , extracted with CH2CI2, and the combined organic layer was washed with brine and dried by Na 2 S04, filtered and concentrated to collect 2-methyl-2-[methyl(oxetan-3- yl)amino]propanal as a light yellow liquid.
  • the crude material was used in the next step directly without further purification.
  • reaction mixture was cooled to 0° C, followed by addition of TMS-Cl (0.06 mL, 0.51 mmol, the ice bath was removed and reaction mixture was stirred for 10 minutes before adding 3-[(2S)-2-[[4-amino- 3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l -yl]methyl]pyrrolidin-l -yl]-3-oxo- propanenitrile (60 mg, 0.13 mmol). The mixture was stirred for 50 minutes and the reaction was deemed finished by checking progress through TLC and LC-MS. The reaction mixture was washed by 15 ml Sat.Na 2 HC0 3 and the layers separated.
  • Step 1 2-Methylpropanal (0.5 mL, 5.48 mmol) was stirred in DCM (10 mL) while being cooled with an ice bath. Bromine (0.31 mL, 6.03 mmol) was slowly added via addition funnel over a 15 min period. After 1 hof stirring at 0 °C, the reaction was concentrated to a light yellow liquid. This was redissolved in DCM (5 mL) cooled with an ice bath while the oxetan- 3-amine (0.39 mL, 5.48 mmol) was slowly added (diluted with 5-10 mL of DCM) over a 10 minute period, then the cooling bath was removed and the reaction mixture was stirred at room temperature overnight.
  • the mixture was then washed with brine and the remaining DCM layer was washed by 0.5N HC1 .
  • the combined aq . layer was adjusted with KOH to pH 10-1 1 , extracted with CH2CI2, and the combined organic layer was washed with brine and dried over Na 2 S04, filtered and concentrated to collect 2-methyl-2-(oxetan-3- ylamino)propanal as a light yellow liquid.
  • the crude material was used in the next step directly without further purification.
  • Step 1 The mixture of 3-(2-fluoro-4-phenoxy-phenyl)-lH-pyrazolo[3,4-d]pyrimidin-4-amine (500 mg, 1.56 mmol), PPh 3 (1.22 g, 4.67 mmol ) and tert-butyl 3-(hydroxymethyl)azetidine- 1-carboxylate (437 mg, 2.33 mmol) in THF (10 mL) was cooled in an ice bath and DIAD (0.6 lmL, 3.1 1 mmol) in 5 ml THF was dropwise added to the reaction mixture. The mixture was stirred for 5 h. To the residue was added 30 ml water and the aq. layer extracted with EtOAc.
  • reaction mixture was loaded onto the silica gel column, purified with 0- 3% gradient MeOH:CH 2 CL 2 , to get 3-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin- l -yl]methyl]azetidin-l -yl]-3-oxo-propanenitrile (201 mg) as yellow oil.
  • Step 1 A mixture of 3-iodo-lH-pyrazolo[3,4-d]pyrimidin-4-amine (3 g, 1 1.49 mmol), PPh3 (9.03 g, 34.5 mmol) tert-butyl 3-hydroxyazetidine-l-carboxylate (2.09 g, 12.1 mmol) in THF (60 mL) was cooled in an ice bath. DIAD (4.52 mL, 23.0 mmol) in 30 ml THF in dropping funnel was slowly added to the reaction mixture, and the reaction mixture was stirred for overnight. The solvent was removed and H 2 0 was added. The aq.
  • the reaction tube was sealed and heated in a microwave oven at 180° C for 2 h, 15 min.
  • the solvent was removed and water and EtOAc were added.
  • the mixture was filtered through celite and separated.
  • the aq. layer was extracted by EtOAc and the combined organic layer, washed with brine, dried over Na 2 SC>4, filtered, and the solvent removed to obtain the crude tert-butyl 3-(4-amino-3-(2-fluoro-4- phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)azetidine-l-carboxylate (800 mg) which was used directly in the next step.
  • Step 3 The (2S,6R)-tert-butyl 4-(5-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)-2,6- dimethylpiperazine-l-carboxylate (103.5mg, 0.1400mmol) was dissolved in 4N HC1 in dioxane, and stirrred at rt for 3 hours. The solvent was removed and 2mL of MeOH was added to the residues. The mixture was neutralized to pH around 7-8 and extracted with DCM.
  • a Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, MA) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure.
  • Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 ⁇ ) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH 2 (1 ⁇ ) at room temperature for 3 h.
  • the reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated. This value is presented as the IC50.
  • the IC 5 o for certain compounds of the disclosure are provided below.
  • the potency of compounds for inhibition of BTK activity can be assessed by binding of compounds to the target in human Ramos B cells that contain BTK.
  • the extent of BTK occupancy is measured after treating the cells with compounds and detecting unoccupied BTK through binding of N-(2-(4-((E)-4-((R)-3-(4-amino-3-(4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-oxobut-2-en- 1 -yl)piperazin- 1 -yl)ethyl)-6-(6- (5-(2-oxohexahydro-lH-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanamido)hexanamide as the probe.
  • Ramos cells were added to 96 well plates at a density of 10 6 cells per well. Serial dilutions of the compounds to be tested for potency were added such the final concentrations started at 1 ⁇ and were memorially diluted 3 fold for a total of 8 serial dilutions. The final DMSO concentration was 0.09% in each well. The compounds were allowed to interact with the cells for 1 hr. A BTK selective probe was then added to each well for a final concentration of 330 nM. Treatment with the probe was for 1 hr. The cells were then collected centrifugation and lysed for 15 - 30 minutes on ice.
  • the binding of the probe to BTK was then detected by Alphascreen (Perkin Elmer) using a kit for the specific label on the BTK probe.
  • the percent occupancy of BTK at each compound concentration was then calculated based on detection of unoccupied BTK bound by the labeled probe.
  • BTK occupancy was then plotted as a function of the log of the compound concentration and the IC 50 values were calculated.
  • the assay to measure BTK occupancy was modified to measure the durability of BTK binding in cells by removing the compound from the culture medium and incubating the cells for varying time periods followed by measurement of remaining occupancy as described above. For the durability measurements, the range of occupancy for the compounds disclosed herein (except for compounds disclosed in examples nos. 9, 14, 15, 3, 16, 17, 10a, 13b, 30, 22 and 26) after 18 hrs of washout was about 3 - 80%.
  • BTK inhibitors have been shown to block B cell activation as measured by CD69 expression (see Karp, R., et. al, Inhibition of BTK with AVL-292
  • CD69 was expressed following B cell activation as a measure of BTK activity in whole blood. Aliquots of whole blood were pre-incubated with serial dilutions of test compound for 30 minutes followed by activation with anti-IgM (goat Fab'2, 50 ⁇ g/ml). Samples were incubated overnight at 37° C and then stained with PE labeled anti-CD20 and APC labeled anti-CD69 (BD Pharmingen) for 30 minutes according to the manufacturer's directions. Whole blood was then lysed and cells gated on CD20 expression were quantified for CD 69 expression by FACS.
  • the percent inhibition was calculated based on a DMSO control for no inhibition and plotted as a function of test compound concentration from which an IC50 value was calculated.
  • the range of IC50 values for the compounds disclosed herein (except for compounds disclosed in examples nos. 2, 5, 17, 13b, 30, and 22),was about 1.4 - 0.08 ⁇ .
  • mCIA murine collagen-induced arthritis
  • mice are injected with an emulsion of Type II collagen in Complete Freund's Adjuvant. Mice are boosted 21 days later to synchronize development of disease. After development of mild disease, animals are enrolled in the study and randomized. Dosing is oral, Q.D. typically for 1 1 days with test compound or dexamethasone (0.2 mg/kg) as control. One group receives vehicle alone. Clinical scoring (0 - 4) is based on the extent of swelling and severity of arthritis. Scores for all four paws are added for maximum score of 16. Anti-collagen antibodies and total Ig are measured for each animal by Elisa at the end of the study (Bolder BioPath, Boulder, CO). Example 5
  • a compound and/or pharmaceutically acceptable salt of the present disclosure at a concentration 10 times greater than its IC50 value was added to a solution of protein kinase (5 nM) in a buffer containing 20 mM Hepes [pH 7.5], 5 mM MgCl 2 , 0.01 % Triton X-100, and 1 mM dithiothreitol.
  • the reactions were transferred to a dialysis cassette (0.1-0.5 mL Slide- A-Lyzer, MWCO 10 kDa, Pierce) and dialyzed against 1 L of buffer (20 mM Hepes [pH 7.5], 5 mM MgCl 2 , 0.01 % Triton X-100, and 1 mM dithiothreitol.) at 22° C.
  • the dialysis buffer was exchanged twice per day until the end of the experiment. Aliquots were removed from the dialysis cassettes every 24 h and analyzed for protein kinase activity. Kinase activity for each sample was normalized to the DMSO control for that time point and expressed as the mean ⁇ SD.
  • a protein kinase that is inhibited by compound and/or pharmaceutically acceptable salt of the present disclosure may be subjected to mass spectral analysis to assess the formation of permanent, irreversible covalent adducts.
  • Suitable analytical methods to examine intact full protein or peptide fragments generated upon tryptic cleavage of the protein kinase are generally known in the art. Such methods identify permanent, irreversible covalent protein adducts by observing a mass peak that corresponds to the mass of a control sample plus the mass of an irreversible adduct. Two such methods are described below.
  • a protein kinase (5 ⁇ ) is incubated with a compound of the present disclosure (25 ⁇ , 5 equiv) for 1 h at room temperature in buffer (20 mM Hepes [pH 8.0], 100 mM NaCl, 10 mM MgC12).
  • a control sample is also prepared which does not have a compound of the present disclosure.
  • the reaction isstopped by adding an equal volume of 0.4% formic acid, and the samples are analyzed by liquid chromatography (Microtrap CI 8 Protein column [Michrom Bioresources], 5% MeCN, 0.2% formic acid, 0.25 mL/min; eluted with 95% MeCN, 0.2% formic acid) and in-line ESI mass spectrometry (LCT Premier, Waters).
  • a protein (10-100 pmols) is incubated with a compound and/or pharmaceutically acceptable salt of the present disclosure (100-1000 pmols, 10 equiv) for 3h prior to tryptic digestion.
  • Iodoacetamide may be used as the alkylating agent after compound incubation.
  • a control sample is also prepared which does not utilize the compound and/or pharmaceutically acceptable salt of the present disclosure.
  • Cellular assays are also optionally used to assess the inhibiting properties of a compound of the present disclosure .
  • Cellular assays include cells from any appropriate source, including plant and animal cells (such as mammalian cells). The cellular assays are also optionally conducted in human cells.
  • Cellular assays of BTK inhibition are well known in the art, and include methods in which an inhibitor is delivered into the cell (e.g. by electroporation, passive diffusion, microinjection and the like) and an activity endpoint is measured, such as the amount of phosphorylation of a cellular substrate, the amount of expression of a cellular protein, or some other change in the cellular phenotype known to be affected by the catalytic activity of BTK.
  • an inhibitor is delivered into the cell (e.g. by electroporation, passive diffusion, microinjection and the like) and an activity endpoint is measured, such as the amount of phosphorylation of a cellular substrate, the amount of expression of a cellular protein, or some other change in the cellular
  • phosphorylated cellular substrate followed by western blotting techniques and visualization using any appropriate means (e.g. fluorescent detection of a fluorescently labeled antibody).
  • Measuring the reduction in the BTK catalytic activity in the presence of the present disclosure relative to the activity in the absence of the present disclosure is optionally performed using a variety of methods known in the art, such as the assays described in the Examples section below. Other methods for assaying BTK activity are known in the art.
  • Example 7
  • the following is a protocol that can be used to distinguish whether a compound displays a slow or non-existent dissociation rate from BTK, such as typically would occur if a covalent bond is formed between the compound and the target.
  • the read-out for slow dissociation is the ability of the compound of interest to block binding of a high affinity fluorescent tracer molecule to the kinase active site, as detected using time-resolved fluorescence resonance energy transfer (TR-FRET).
  • TR-FRET time-resolved fluorescence resonance energy transfer
  • the first step of the procedure was incubation of 500 nM BTK (Invitrogen Cat.
  • the competition solution also contained 80 nM of an Anti-polyhistidine antibody coupled to Europium (Invitrogen Cat. #PV5596) which is designed to bind the polyhistidine purification tag in BTK.
  • Binding of the tracer to BTK is detected using TR-FRET between the Europium moiety of the Anti-histidine antibody and the AlexaFluor 647 group of Tracer 178. Binding was evaluated using a Perkin Elmer Envision instrument (Model 2101) equipped with filters and mirrors compatible with LA CE-type TR-FRET experiments. Data were plotted at percentage of signal obtained in the absence of competitor compound. The background signal was obtained by omission of BTK from the reaction. If the compound is an irreversible covalent inhibitor, tracer will be completely blocked from binding to the target throughout the entire course of the experiment. If the compound is a reversible covalent inhibitor, the tracer will bind the target as the compound dissociates from the target.
  • a parenteral pharmaceutical composition suitable for administration by injection 100 mg of a water-soluble salt of a compound disclosed herein is dissolved in 2% HPMC, 1 % Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL. The mixture is incorporated into a dosage unit form suitable for administration by injection.
  • a pharmaceutical composition for inhalation delivery 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
  • an inhalation delivery unit such as a nebulizer
  • a pharmaceutical topical gel composition 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropyl celluose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topical
  • Ophthalmic Solution Composition
  • a pharmaceutical opthalmic solution composition 100 mg of a compound disclosed herein is mixed with 0.9 g of NaCI in 100 mL of purified water and filterd using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.
  • a pharmaceutical nasal spray solution 10 g of a compound disclosed herein is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 ⁇ of spray for each application.
  • a 0.05M phosphate buffer solution pH 4.4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides compounds of Formula (IA) and/ or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

Description

PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
The present disclosure provides certain small-molecule compounds that are tyrosine kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases. Also provided are certain pharmaceutical compositions containing such compounds and processes for preparing such compounds.
The human genome contains at least 500 genes encoding protein kinases. Many of these kinases have been implicated in human disease and as such represent potentially attractive therapeutic targets. BTK, a member of the Tec family non-receptor tyrosine kinases, is essential for B cell signaling downstream from the B-cell receptor. It is expressed in B cells and other hematopoietic cells such as monocytes, macrophages, and mast cells. BTK is reported to function in various aspects of B cell function that maintain the B cell repertoire {see Gauld S. B. et al., B cell antigen receptor signaling: roles in cell development and disease. Science, 296: 1641-2. 2002.)). Clinical validation of the role of B cells in RA has been provided by the efficacy of the biologic Rituxan (an anti-CD20 antibody), which depletes B cells as a mechanism of action {see Perosa F., et al., CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med. 267:260-77 '. 2010 and Dorner T, et al. Targeting B cells in immune-mediated inflammatory disease: a
comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther. 125:464-75. 2010.). BTK is reported to be required for B cell development because patients with the disease X-linked agammaglobulinemia {see Rosen F. S., et al., The primary immunodeficiencies. N Engl J Med. 333:431-40. 1995) lack of antibodies in their bloodstream. Notably, small-molecule BTK inhibitors in pre-clinical development have been reported to be efficacious in collagen-induced arthritis {see Pan Z., et al., Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. J. Med. Chem. 2:58-61. 2007).
The potential advantage of a small molecule BTK inhibitor (beyond the inherent advantage of a small-molecule over a biologic) is that modulation of BTK can inhibit B cell function without permanent removal of the B cell itself. Therefore, the long periods of low B cell levels experienced with the biologic Rituxan should be avoidable by targeting BTK with a small molecule BTK inhibitor.
In addition, the disease modifying activities of BTK are expected to extend beyond those of Rituxan because of effects on addition cellular targets that are involved in propagation of disease. For instance, antigen induced mast cell degranulation is reportedly impaired in mast cells derived from the bone marrow of BTK deficient mice, demonstrating that BTK is downstream of the FceFU receptor (see Setoguchi R., et al., Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and BTK-deficient mice. Immunol Lett. 64: 109-18. 1998). A similar signaling module exists in monocytes and macrophages for the FcyR1 receptor indicating BTK inhibition is highly likely to modulate TNF production in response to IgG. Both mast cells and macrophages are thought to contribute to propagation of the inflammatory cytokine environment of the diseased synovium.
In addition to the peripheral and synovial effects of BTK inhibition described above, BTK inhibition reportedly will have bone protective effects in an inflamed joint (see Gravallese E. M., et al., Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43:250-8. 2000). Studies with mice that are either deficient in BTK or have impaired BTK function have reportedly demonstrated that Rank ligand-induced osteoclast differentiation is impaired in the absence of BTK function (see Lee S. H., et. al., The tec family tyrosine kinase BTK Regulates RANKL-induced osteoclast maturation. /. Biol. Chem. 283: 1 1526-34. 2008). Taken together, these studies can be interpreted as suggesting that a BTK inhibitor could inhibit or reverse the bone destruction that occurs in RA patients. Given the importance of B cells in autoimmune disease, BTK inhibitors could also have utility in other autoimmune diseases such as systemic lupus erythematosus (see Shlomchik M. J., et. al, The role of B cells in lpr/lpr-induced
autoimmunity. J. Exp Med. 180: 1295-1306. 1994). Notably, an irreversible BTK inhibitor has been reported to display efficacy in the mouse MRL/lpr lupus model, reducing autoantibody production and renal damage (see Honigberg L. A., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. 107: 13075-80. 2010).
There is also potential for BTK inhibitors for treating allergic diseases (see
Honigberg, L., et. al., The selective BTK inhibitor PCI-32765 blocks B cell and mast cell activation and prevents mouse collagen indiced arthritis. Clin. Immunol. Ill SI :S 1 1 1. 2008). In addition, the irreversible inhibitor reportedly suppresses passive cutaneous anaphylaxis (PCA) induced by IgE antigen complex in mice (see Honigberg, L., et. al., The selective BTK inhibitor PCI-32765 blocks B cell and mast cell activation and prevents mouse collagen indiced arthritis. Clin. Immunol. 127 S 1 :S 111. 2008). These reported findings are in agreement with those noted with BTK-mutant mast cells and knockout mice and can be interpreted as suggesting that BTK inhibitors may be useful for the treatment of asthma, an IgE-dependent allergic disease of the airway.
In addition, platelet aggregation in response to collagen or collagen-related peptide is reportedly impaired in XLA patients who lack BTK function (see Quek L. S, et al., A role for Bruton's tyrosine kinase (BTK) in platelet activation by collagen. Curr. Biol. 8: 1 137-
40.1998). This is manifested by changes downstream from GPIV, such as phosphorylation of PLCgamma2 and calcium flux, which can be interpreted as suggesting potential utility in treating thromboembolic diseases.
Preclinical studies with a selective inhibitor of BTK have reportedly shown effects on spontaneous canine B cell lymphomas suggesting a potential utility in human lymphomas or other hematologic malignancies including chronic lymphocytic leukemia. In addition, clinical trials with PCI-32765 can be interpreted as indicating utility for a BTK inhibitor in both chronic lymphocytic leukemia and mantle cell lymphoma (see Fowler, N et al., The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory Bcell malignancies: results from a phase I study. Blood 2010; 1 16 (21 )
:425; Byrd J. C, et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. J Clin Oncol 201 1 ;29 :6508).
ITK, a member of the TEC kinase family, is reportedly involved in activation of T cells and mast cells (see Iyer A. S. et al.. Absence of Tec Family Kinases Interleukin-2 Inducible T cell Kinase (Itk) and Bruton's Tyrosine Kinase (Btk) Severely Impairs
Fc{epsilon}RI-dependent Mast Cell Responses. /. Biol Chem.; 286:9503-13. 201 1) and is a potential target in inflammatory immune diseases such as asthma. Mice deficient in ITK are reportedly resistant to development of allergic asthma (see Sahu N, et al., Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine-mediated migration. /. Immunol. 180:3833-8. 2008). Another family member, BMX, is reportedly involved in supporting tumor angiogenesis through it's role in the tumor vascular endothelium (see Tu T, et al., Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res. 68:2861-9. 2008) and is also progressively up- regulated during bladder cancer progression {see Guo S., et al, Tyrosine Kinase ETK BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy. PLoS One. 6:el7778. 2011), which can be interpreted to suggest a potential therapeutic target in this type cancer. The B lymphoid kinase (hereafter, sometimes expressed as "BLK") is reportedly linked through genetic association with a variety of rheumatic diseases including systemic lupus erythematosus and systemic sclerosis (see Ito I, et al., Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum. 62:890-5. 2010).
Accordingly, there is a need for compounds that inhibit tyrosine kinases, and particularly BTK inhibitors, thereby providing treatment for diseases such as autoimmune diseases, inflammatory diseases, thromboembolic diseases, and cancer. The present disclosure is directed to such treatment.
In an embodiment, provided is a compound of Formula (II):
Figure imgf000005_0001
1 2
R and R are independently hydrogen, alkyl, halo, or alkoxy;
R3 is hydrogen or halo; and
Rc is: (a) -C(CH3)2-(4-R5-piperazin-l-yl) where R5 is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(2- or 3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, cycloalkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(c) -C(CH3)2-NRboxetan-3-yl where Rb is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or cycloalkyl;
(d) -C(CH3)2-RC where Rc is
Figure imgf000006_0001
where one or two of X1, X2 and X are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yi;
and/or a pharmaceutically acceptable salt thereof.
In one embodiment, the compound or salt thereof of Formula (II) is where R1 is hydrogen, alkyl, halo, or alkoxy and R2 is alkyl, halo, or alkoxy. Within this embodiment, in one group of compounds R3 is fluoro.
In another embodiment, the compound or salt thereof of Formula (II) is where R1 is hydrogen, alkyl, halo, or alkoxy and R2 is alkyl, halo, or alkoxy and Rc is -C(CH3)2-(4-R5- piperazin-l-yl) where R5 is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl. Within this embodiment, in one group of compounds R3 is fluoro.
In yet another embodiment, the compound or salt thereof of Formula (II) is where R1 and R2 are hydrogen and Rc is -C(CH3)2-(4-R5-piperazin-l-yl) where R5 is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl. Within this embodiment, in one group of compounds R is fluoro. Within this embodiment, in another group of compounds R3 is hydrogen and R° is -C(CH3)2-(4-R5-piperazin-l-yl) where R5 is hydrogen, alkyl, or oxetan-3-yl. In another embodiment, provided is a compound of Formula (IA):
Figure imgf000007_0001
(a) -C(CH3)2-(4-R4-piperazin-l-yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(3-oxo-4-Ra-piperazin-l -yl) where Ra is hydrogen, alkyl, cycloalkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(c) -C(CH3)2-NRboxetan-3-yl where Rb is hydrogen, alkyl, alkoxyalkyl, or cycloalkyl;
(d) -C(CH3)2-RC where Rc
Figure imgf000007_0002
where one or two of X1, X2 and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yi;
and/or a pharmaceutically acceptable salt thereof.
In one embodiment, the compound or salt therof of Formula (IA) is where Rc is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4-ethylpiperazin- 1-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-N(CH2CH3)oxetan-3-yl, -C(CH3)2- N(cyclopropyl)-oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, -C(CH3)2-2-oxa-6-azaspiro- [3.3]heptan-6-yl, -C(CH3)2-CH2morpholine-4-yl, -C(CH3)2-(4-methylsulfonyl-piperazin-l- yl), -C(CH3)2-(3-oxo-4-methylpiperazin-l-yl), -C(CH3)2-[4-(2-methoxyethyl)-piperazin-l- yl], -C(CH3)2-(4-tert-butylpiperazin-l -yl), -C(CH3)2-(4-acetylpiperazin-l-yl), -C(CH3)2-(4- 2,2,2-trifluoroethyl-piperazin- 1 -yl),-C(CH3)2-(4-isopropylpiperazin- 1 -yl), -C(CH3)2-(2,5- dimethyl-piperazin-l-yl), -C(CH3)2-(3,5-dimethylpiperazin-l-yl), -C(CH3)2-(3,4,5- trimethylpiperazin-l-yl), -C(CH3)2-(2,4,5-trimethylpiperazin-l-yl), -C(CH3)2-(4-oxetan-3- ylpiperazin-l -yl), -C(CH3)2-(4-methoxycarbonylpiperazin-l -yl), -C(CH3)2-(3,5- dimethylpiperazin- 1 -yl),
Figure imgf000008_0001
and/or a pharmaceuticallty acceptable salt thereof.
In another embodiment, the compound or salt thereof of Formula (IA) is where Rc is - C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4-ethyl-piperazin- 1 -yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-N(CH2CH3)oxetan-3-yl,
-C(CH3)2-N(cyclopropyl)-oxetan-3-yl, or -C(CH3)2-NHoxetan-3-yl.
In yet another embodiment, the compound or salt thereof of Formula (IA) is where Rc is -C(CH3)2-(3-oxo-4-methylpiperazin- 1 -yl), -C(CH3)2-[4-(2-methoxyethyl)-piperazin- 1 -yl], -C(CH3)2-(4-tert-butylpiperazin-l -yl), -C(CH3)2-(4-isopropylpiperazin-l-yl), -C(CH3)2-(2,5- dimethyl-piperazin-l-yl), -C(CH3)2-(3,5-dimethylpiperazin-l-yl), -C(CH3)2-(3,4,5-trimethyl- piperazin- 1 -yl), -C(CH3)2-(2,4,5-trimethylpiperazin- 1 -yl), -C(CH3)2-(4-oxetan-3-ylpiperazin- 1 -y piperazin- 1 -yl),
Figure imgf000008_0002
In yet another embodiment, the compound or salt thereof of Formula (IA) is where Rc is -C(CH3)2-(3-oxo-4-methylpiperazin-l-yl) or -C(CH3) -[4-(2-methoxyethyl)-piperazin-l- yl]-
In yet another embodiment, the compound of Formula (IA) is chosen from:
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyljpyrrolidine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ; 2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile;
2- [(2R)-2- [ [4-amino-3-(2-fluoro-4-phenoxy-pheny l)pyrazolo [3 ,4-d]pyrimidin- 1 - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2- [(2S)-2- [ [4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo [3,4-d]pyrimidin- 1 - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-raethyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl] -piperidin- 1 -yljcarbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-arnino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine- 1 -carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l -carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)raethyl)pyrrolidine- 1 -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l -yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l -yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin- l -yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l -yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; (S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-(4-isopropylpiperazin-l-yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(4-isopropylpiperazin-l-yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3 -(4-amino-3 -(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3 ,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3 -(4-amino-3 -(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3 ,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-((R)-hexahydropyrazino[2, l-c][l ,4]oxazin-8(lH)-yl)-4- methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((R)-hexahydropyrazino [2, 1 -c] [ 1 ,4] oxazin-8 ( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino[2, 1 -c] [ 1 ,4]oxazin-8(l H)-yl)-4- methylpent-2-enenitrile ;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino[2, 1 -c] [ 1 ,4]oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile; (S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3 -(4-amino-3 -(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3 ,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- y piperidine- 1 -carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((2R,5S)-2,5-dimethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-((2R,5S)-2,5-diraethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2S,5R)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-((2S,5R)-2,4,5-trimethylpiperazin-l-yl)pent-2- enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyriraidin-l- yl)piperidine- 1 -carbonyl)-4-(5,6-dihydroimidazo[ 1 ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(methylsulfonyl)piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(methylsulfonyl)piperazin- 1 -yl)pent-2-enenitrile;
(R)-2-(3 -(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3 ,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2-enenitrile;
(R)-4-(4-acetylpiperazin-l-yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-methylpent-2-enenitrile;
(S)-4-(4-acetylpiperazin- 1 -yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H- pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methylpent-2-enenitrile;
(R)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(S)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
or a mixture of R and S isomers thereof;
or an individual E or Z isomer of any of the above compounds; and/or
a pharmaceutically acceptable salt of any of the above compounds.
In another embodiment, provided is a compound of Formula (I):
Figure imgf000014_0001
(I)
where:
-Z- is:
Figure imgf000014_0002
Rc is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4- ethylpiperazin- 1 -yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-N(CH2CH3)oxetan-3-yl, -C(CH3)2-N(cyclopropyl)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, or -C(CH3)2-2-oxa-6- azaspiro[3.3]heptan-6-yl;
and/or a pharmaceuticallty acceptable salt thereof.
In one embodiment, the compound of Formula (I) is chosen from:
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine- 1 -carbonyl]-4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fIuoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile; 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]piperidine-l -carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]-pyrimidin- l-yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l -yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l - yl]-piperidin-l -yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-((RS)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(piperazin-l-yl)pent-2-enenitrile;
2-((S)-3-(4-arnino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; (R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrirnidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(R)-2-(3-(4-araino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-raethyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine- 1 -carbonyl]-4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l -yl]- methyl]pyrrolidine- 1 -carbonyl]-4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile;
2-[(2R)-2- [ [4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo [3,4-d]pyrimidin- 1 -yl] - methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin- l-yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile; 2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)methyl)pyrrolidine- 1 -carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l -carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine-l -carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-araino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyriraidin-l - yl)piperidine- l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; or an individual E or Z isomer of any of the above compounds; and/or
a pharmaceutically acceptable salt of any of the above compounds.
In yet another embodiment, provided is a compound of Formula (IB):
Figure imgf000017_0001
(IB)
where:
-Z- is:
Figure imgf000018_0001
R° is 3-methyloxetan-3-yl, -C(CH3)2-(azetidin-l-yl), -C(CH3)2-(3-hydroxyazetidin-l- yl), -C(CH3)2-(4-hydroxypiperidin-l-yl), -C(CH3)2-(pyrrolidin-l -yl), or -C(CH3)2CH2OH; and/or a pharmaceuti
provided that
Figure imgf000018_0002
, then Rc is not 3- methyloxetan-3-yl, and/or a pharmaceutically acceptable salt thereof.
In one embodiment, the compound of Formula (IB) is chosen from:
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-hydroxypiperidin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-hydroxypiperidin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-(4-hydroxypiperidin- 1 -yl)-4-methylpent-2-enenitrile;
2-((RS)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d] pyrimidin-1- yl)piperidine- 1 -carbonyl)-4-(azetidin- 1 -yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d] pyrimidin-l-yl) piperidine- 1 -carbonyl)-4-(azetidin- 1 -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d] pyrimidin-l-yl) piperidine- 1 -carbonyl)-4-(azetidin- 1 -yl)-4-methylpent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-5-hydroxy-4,4-dimethylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-5-hydroxy-4,4-dimethylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-5-hydroxy-4,4-dimethylpent-2-enenitrile; 2-((RS)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-3-(3-methyloxetan-3-yl)acrylonitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- l-carbonyl)-3-(3-methyloxetan-3-yl)acrylonitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-3-(3-methyloxetan-3-yl)acrylonitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-methyl-4-(pyrrolidin-l-yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-methyl-4-(pyrrolidin-l-yl)pent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]-pyrimidin- 1 - yl)methyl)pyrrolidine- 1 -carbonyl)-4-methyl-4-(pyrrolidin- 1 -yl)pent-2-enenitrile;
2-((RS)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)piperidine- l-carbonyl)-4-(3-hydroxyazetidin-l -yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- 1 -carbonyl)-4-(3-hydroxyazetidin- 1 -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(3-hydroxyazetidin- 1 -yl)-4-methylpent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine- 1 -carbonyl)-4-(3-hydroxyazetidin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine- 1 -carbonyl)-4-(3-hydroxyazetidin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l-carbonyl)-4-(3-hydroxyazetidin-l -yl)-4-methylpent-2-enenitrile; or an individual E or Z isomer of any of the above compounds; and/or a pharmaceutically acceptable salt of any of the above compounds.
In yet another embodiment, provided is a compound chosen from:
(RS)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]azetidine-l-carbonyl]-4-methyl-pent-2-enenitrile;
(R)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]azetidine-l-carbonyl]-4-methyl-pent-2-enenitrile;
(S)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl] methyl] azetidine- 1 -carbonyl] -4-methyl-pent-2-enenitrile; 2- [3- [ [4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3 ,4-d]pyrimidin- 1 - yl]methyl] azetidine- 1 -carbonyl]-4-methyl-pent-2-enenitrile;
(RS)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]azetidine-l-carbonyl]-4-methyl-4-morpholino-pent-2-enenitrile;
(R)-2- [2- [[4-amino-3 -(2-fluoro-4-phenoxy-phenyl)pyrazolo [3 ,4-d]pyrimidin- 1 - yl]methyl]azetidine-l-carbonyl]-4-methyl-4-morpholino-pent-2-enenitrile;
(S)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrirnidin-l- yl]methyl]azetidine-l-carbonyl]-4-methyl-4-morpholino-pent-2-enenitrile;
(RS)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl]azetidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
(R)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]azetidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
(S)-2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl]azetidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- azetidine-l-carbonyl]-4-methyl-pent-2-enenitrile; or an individual E or Z isomer of any of the above compounds; and/or a pharmaceutically acceptable salt of any of the above compounds.
In yet another embodiment, the compound or a pharmaceutical acceptable salt is:
(R)-2-(3-(4-amino-3-(2-fluoro-4-(3-hydroxyphenoxy)phenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4,4-dimethylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-(4-hydroxyphenoxy)phenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4,4-dimethylpent-2-enenitrile ; or
an individual E or Z isomer thereof.
In another embodiment, the compound is chosen from 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4- methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4- methyl-4-[ethyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4- methyl-4-(oxetan-3-ylamino)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4- [methyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4- [ethyl(oxetan-3-yl)amino]pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4- (oxetan-3-yl)aminopent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]-pyrimidin- 1 -yl] -piperidin- 1 -y l]carbonyl] -4- methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l-yl]-piperidin-l-yl]carbonyl]-4- methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-((R)-3-(4-amino-3-(2-fluoro- 4-phenoxy-phenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(3- hydroxyazetidin-l-yl)-4-methylpent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (R)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4- (4- methyl-3-oxopiperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (R)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-(4-(2- methoxyethyl)piperazin-l-yl)-4-methylpent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from 2-[[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l-yl]-piperidin-l-yl]carbonyl]-4- methyl-4-(piperazin-l-yl)pent-2-enenitrile, or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (R)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4- (oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (S)-2-(3-(4-amino-3-(2-fluoro- 4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4- (oxetan-3-yl)piperazin-l -yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (R)-2-(3-(4-amino-3-(4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4- (oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (S)-2-(3-(4-amino-3-(4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-
(oxetan-3-yl)piperazin-l -yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (R)-2-(2-((4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)- 4-methyl-4-(4-(oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In another embodiment, the compound is chosen from (S)-2-(2-((4-amino-3-(2-fluoro- 4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)methyl)pyrrolidine-l-carbonyl)-4- methyl-4-(4-(oxetan-3-yl)piperazin-l-yl)pent-2-enenitrile; or an individual E or Z isomer thereof; and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
In one embodiment, the compounds of the present disclosure are reversible covalent inhibitors. In another embodiment, the compounds of the present disclosure form a reversible covalent bond to Cys 481 of BTK.
Another embodiment disclosed herein is a pharmaceutical composition comprising a compound and/or a pharmaceutically salt of any embodiment disclosed herein and a pharmaceutically acceptable excipient.
Another embodiment disclosed herein is a method of treating a disease treatable by inhibition of a tyrosine kinase such as BLK, BMX, , HER2, HER4, ITK, TEC, BTK, and TXK, such as BTK, in a patient in need of such treatment which method comprises administering to the patient in recognized need thereof, a pharmaceutical composition comprising a compound and /or a pharmaceutically acceptable salt of any embodiment disclosed herein and a pharmaceutically acceptable excipient in an amount effective to achieve the treatment (therapeutic amount). In one embodiment, the patient is in recognized need of such treatment. In one embodiment, the disease is chosen from autoimmune diseases, inflammatory diseases, and cancers.
In one aspect of above embodiment, the patient in need or recognized need is suffering from an autoimmune disease, e.g., inflammatory bowel disease, such as ulcerative colitis, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjogren's syndrome, Sjogren's dry eye, non-Sjogren's dry eye disease, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, dysautonomia, endometriosis, interstitial cystitis, neuromyotonia, scleroderma, and vulvodynia. In one embodiment, the disease is rheumatoid arthritis or psoriatic arthritis. In another embodiment, the autoimmune disease is lupus.
In yet another embodiment disclosed herein, the patient in need or recognized need is suffering from a heteroimmune condition or disease, e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic
conjunctivitis, allergic rhinitis, and atopic dermatitis. In yet another embodiment disclosed herein, the patient in need or recognized need is suffering from an inflammatory disease, e.g., asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis, such as asthma. In yet another embodiment disclosed herein, the patient in need or recognized need is suffering from inflammatory skin disease, such as dermatitis, contact dermatitis, eczema, urticaria, rosacea, and scarring psoriatic lesions in the skin, joints, or other tissues or organs.
In yet another embodiment disclosed herein, the patient in need or recognized need is suffering from a cancer. In one embodiment, the cancer is a B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-ALL, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplamascytic lymphoma/ Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt
lymphoma/leukemia, and lymphomatoid granulomatosis.
In yet another embodiment, the patient in need or recognized need is suffering from a thromboembolic disorder, e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, and deep venous thrombosis.
The disclosure is also directed to the use of any compound and/or a pharmaceutical salt thereof disclosed herein as a medicament. In one embodiment, the use of any of the compounds and/or a pharmaceutically acceptable salt thereof disclosed herein is for treating a disease mediated by a kinase, in particular BTK, for treating a disease chosen from autoimmune and inflammatory diseases and proliferative diseases, such as cancers. The disclosure is also directed to the use of any compound and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an inflammatory disease in a patient in need of such treatment in which the activity of a tyrosine kinase, such as BLK, BMX, HER2, HER4, ITK, TEC, BTK, and TXK, in particular BTK, contributes to the pathology and/or symptoms of the disease. In one embodiment, the patient is in recognized need of such treatment. In one embodiment the disease is an autoimmune or inflammatory disease (e.g., arthritis, asthma) or a proliferative disease e.g., B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-ALL, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplamascytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, and lymphomatoid granulomatosis.
In any of the aforementioned embodiments disclosed herein involving the treatment of proliferative disorders, including cancer, combination therapy can also be implicated, i.e., the compounds and/or a pharmaceutically acceptable salt disclosed herein can be
administered in combination with at least one additional antiproliferative and/or anticancer agent. In one embodiment, the at least additional agent is chosen from alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds, such as cisplatin, cladribine, daunorubicin/doxorubicin /idarubicin, irinotecan, fludarabine, 5-fluorouracil, gemtuzamab, methotrexate, paclitaxel, Taxol™, docetaxol, temozolomide, thioguanine, and classes of drugs including hormones (an antiestrogen, an antiandrogen, or gonadotropin releasing hormone analogues, interferons such as alpha interferon, nitrogen mustards such as busulfan or melphalan or mechlorethamine, retinoids such as tretinoin, topoisomerase inhibitors such as irinotecan or topotecan, tyrosine kinase inhibitors such as gefinitinib or imatinib, ofatumumab, bendamustine, rituximab,
obinutuzumab, IPI-145, GS-1101, BKM-120, GDC-0941, DGDC-0980, GS-9820, CAL-263, Revlimid®, thalidomide®, pomalidomide®, Velcade ®, Kyprolis ®, delanzomib, U0126, PD98059, PD184352, PD0325901 , ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, Nexavar®, Tarceva®, Sutent®, Tykerb®, Sprycel®, Crizotinib, Xalkori®, or LY294002or agents to treat signs or symptoms induced by such therapy including allopurinol, filgrastim, granisetron/ondansetron/ palonosetron, dronabinol When combination therapy is used, the agents can be administered simultaneously or sequentially.
Also disclosed herein is a process of preparing a compound of Formula (IA):
Figure imgf000026_0001
Rc is:
(a) -C(CH3)2-(4-R4-piperazin-l-yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(c) -C(CH3)2-NRboxetan-3 alkyl, or cycloalkyl;
(d) -C(CH3)2-RC where Rc
Figure imgf000026_0002
where one or two of X1, X2 and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yl; ((in one embodiment R° is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l- yl), -C(CH3)2-(4-ethylpiperazin-l-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2- N(CH2CH3)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, or -C(CH3)2-2-oxa-6- azaspiro[3.3]heptan-6-yl); and/or
a pharmaceutically acceptable salt thereof;
comprising:
(a) reacting a compound
Figure imgf000027_0001
where:
-Z- is as defined above;
with an aldehyde of formula RcCHO where Rc is:
(a) -C(CH3)2-(4-R4-piperazin-l-yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH )2-(3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(c) - -NRboxetan-3-yl where Rb is hydrogen, alkyl, or cycloalkyl;
Figure imgf000027_0002
and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yl; (in one embodiment Rc is -C(CH )2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4-ethylpiperazin- 1 -yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2- N(CH2CH3)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, or -C(CH3)2-2-oxa-6- azaspiro[3.3]heptan-6-yl); or (b) reacting a compound
Figure imgf000028_0001
(2)
where:
-Z- is as defined above;
with a compound of formula RcCH=C(CN)C02H or RcCH=C(CN)COX where Rc is:
(a) -C(CH3)2-(4-R4-piperazin-l-yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
- -NRboxetan-3-yl where Rb is hydrogen, alkyl, or cycloalkyl;
Figure imgf000028_0002
and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yl; (in one embodiment Rc is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4-ethylpiperazin- 1 -yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2- N(CH2CH3)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, or -C(CH3)2-2-oxa-6- azaspiro[3.3]heptan-6-yl) ;
where X is a leaving group, capable of being displaced by the nitrogen atom of the Z group under amide coupling reaction conditions;
(c) optionally making an acid addition salt of a compound obtained from Steps (a) or (b) above;
(d) optionally making a free base of a compound obtained from Steps (a), (b), or (c) above; (e) optionally separating individual stereoisomers of the compounds obtained from Steps (a), (b), (c), or (d) above; and
(f) optionally separating individual (E) and (Z) isomers of the compounds obtained from Steps (a), (b), (c), (d), or (e) above.
In one embodiment of the disclosed process, Z is
In another embodiment of the disclosed process, Z i
Figure imgf000029_0001
s
and R° is -C(CH3)2-(4-methylpiperazin-l-yl).
In yet another embodiment of the disclosed process , Z is
Figure imgf000029_0002
or and Rc is -C(CH3)2-(piperazin-l-yl).
In yet another embodiment of the disclosed process , Z is
Figure imgf000029_0003
or and Rc is -C(CH3)2-N(CH3)oxetan-3-yl.
In et another embodiment of the disclosed process, Z is L N"" J or
Figure imgf000029_0004
and Rc is -C(CH3)2-NHoxetan-3-yl. In yet another embodiment of the disclosed process , Z is
Figure imgf000030_0001
or
Figure imgf000030_0002
-C(CH3)2-N(ethyl)oxetan-3-yl.
In yet another embodiment of the disclosed process, Z is
Figure imgf000030_0003
and Rc is -C(CH3)2-N(ethyl)piperazin-l-yl.
In yet another embodiment of the disclosed process, Z is
Figure imgf000030_0004
and Rc is -C(CH3)?-(4-methyl-3-oxopiperazin-l-yl).
In yet another embodiment of the disclosed process, Z is
Figure imgf000030_0005
and Rc is -C(CH3)2-(4-(2-ethoxyethyl)-piperazin-l-yl).
In yet another embodiment of the disclosed process, Z is
Figure imgf000030_0006
or and Rc is -C(CH3)2-4-(oxetan-3-yl)-piperazin-l-yl.
In another embodiment of the disclosed process, the compound of Formula (IA) (and embodiments thereof) is prepared by method (a) by reacting a compound of formula (1):
Figure imgf000031_0001
where:
-Z- is as defined above;
with an aldehyde of formula RcCHO where Rc is:
(a) -C(CI¾)2-(4-R4-piperazin-l-yl) where R4 is hydrogen, alkyl, alkoxyalkyi, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, alkoxyalkyi, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
-C(CH3)2-NRboxetan-3-yl where Rb is hydrogen, alkyl, or cycloalkyl;
Figure imgf000031_0002
where one or two of X , X"" and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yl; (in one embodiment Rc is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4-ethylpiperazin-l-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2- N(CH2CH3)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan- 6-yl, -C(CH3)2-(4-methyl-3-oxopiperazin-l-yl, or -C(CH3)2-(4-(2-ethoxyethyl)- piperazin-1- yl), such as -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4- ethylpiperazin-l-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-N(CH2CH3)oxetan-3-yl, - C(CH3)2-NHoxetan-3-yl, -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl);
in the presence of pyrrolidine and trimethylsilyl chloride. In another embodiment of the disclosed process, the compound of Formula (IA) (and embodiments thereof) is prepared by method (b) by reacting a compound of formula (2):
Figure imgf000032_0001
2
where:
-Z- is as defined above;
with a compound of formula RcCH=C(CN)COOH or RcCH=C(CN)COX where Rc is:
(a) -C(CH3)2-(4-R4-piperazin-l-yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(c) -C(CH )2-NRboxetan-3 alkyl, or cycloalkyl;
(d) -C(CH3)2-RC where Rc
Figure imgf000032_0002
where one or two of X1, X2 and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yl; (in one embodiment Rc is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4-ethylpiperazin-l-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-
N(CH2CH3)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan- 6-yl, -C(CH3)2-(4-methyl-3-oxopiperazin-l-yl, or -C(CH3)2-(4-(2-ethoxyethyl)- piperazin-1- yl), such as -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4- ethylpiperazin-l-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-N(CH2CH3)oxetan-3-yl, - C(CH3)2-NHoxetan-3-yl, -C(CH3)2-2-oxa-6-azaspiro [3.3]heptan-6-y 1) ; where X is a leaving group, capable of being displaced by the nitrogen atom of the Z group under amide coupling reaction conditions.
Definitions:
Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:
"Alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like.
"Alkoxy" means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or ieri-butoxy, and the like.
"Alkoxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with an alkoxy group, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2- ethoxyethyl, and the like.
"Hydroxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with a hydroxy group, as defined above, e.g., 2-hydoxyethyl, 1 , 3-dihydoxypropyl, and the like.
"Alkylsulfonyl" means a -S02R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
"Alkoxycarbonyl" means a -C(0)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
"Acyl" means a -COR radical where R is alkyl as defined above.
"Cycloalkyl" means a cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms wherein one or two carbon atoms may be replaced by an oxo group, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like.
"Halo" means fluoro, chloro, bromo, or iodo, such as fluoro or chloro.
"Haloalkyl" means alkyl radical as defined above, which is substituted with one or more halogen atoms, such as one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., -CH2C1, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, and the like.
The present disclosure also includes amorphous and polymorphic forms and deuterated forms of compounds disclosed herein. A "pharmaceutically acceptable salt" of a compound means a salt that is
pharmaceutically acceptable and that possesses the desired pharmacological activity of the compound from which the salt is made (hereafter, sometimess referred to as "parent compound.")- Such salts include:
acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid,
cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4- hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,
benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4- toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3- hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid; or
salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985 and Berge et al., Journal of Pharmaceutical Sciences, January 1977, Volume 66, Number 1, 1-19 which is incorporated herein by reference.
The compounds of the present disclosure may have asymmetric centers. Certain compounds of the present disclosure containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well-known in the art how to prepare optically active forms, such as by resolution of materials. All chiral, diastereomeric, and racemic forms are within the scope of this disclosure, unless the specific stereochemistry or isomeric form is specifically indicated.
Certain compounds of the present disclosure can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. "Optional" or "optionally" means that the subsequently described event or
circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
A "pharmaceutically acceptable carrier or excipient" means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for human pharmaceutical use.
"A pharmaceutically acceptable carrier/excipient" as used in the specification and claims includes both one and more than one such excipient.
"Treating" or "treatment" of a disease includes:
(1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or
(3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
A "therapeutically effective amount" means the amount of a compound of the present disclosure that, when administered to a patient in need or recognized need of treatment for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal to be treated.
The compounds disclosed herein are tyrosine kinase inhibitors, in particular BTK and hence are useful in the treatment of autoimmune disease, e.g., inflammatory bowel disease, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjogren's syndrome, including Sjogren's dry eye, non-Sjogren's dry eye, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, dysautonomia, endometriosis, interstitial cystitis, neuromyotonia, scleroderma, and vulvodynia.
The compounds disclosed herein are also useful in the treatment of a heteroimmune condition or disease. In another embodiment described herein, the patient in need or recognized need is suffering from a heteroimmune condition or disease, e.g., graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis.
In another embodiment disclosed herein, the patient in need or recognized need is suffering from an inflammatory disease, e.g., asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, and vulvitis. In one embodiment, the inflammatory disease is asthma.
In another embodiment disclosed herein, the patient in need or recognized need is suffering from inflammatory skin disease which includes, by way of example, dermatitis, contact dermatitis, eczema, rosacea, and scarring psoriatic lesions in the skin, joints, or other tissues or organs.
In yet another embodiment disclosed herein, the patient in need or recognized need is suffering from a cancer. In one embodiment, the cancer is a B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, chromic myleogenous leukemia, B-ALL, Philadelphia chromosome positive B-ALL lymphoplamascytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt
lymphoma/leukemia, or lymphomatoid granulomatosis. In some embodiments, the compound disclosed herein is administered in combination with another an anti-cancer agent e.g., the anti-cancer agent is an inhibitor of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002.
In yet another embodiment disclosed herein, the patient in need or recognized need is suffering from a thromboembolic disorder, e.g., myocardial infarction, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, and deep venous thrombosis.
Yet another embodiment disclosed herein is the use of compounds and/or a pharmaceutically acceptable salt thereof disclosed herein for use as a medicament. In one embodiment, the use is for treating inflammatory disease or proliferative diseases.
In yet another embodiment disclosed herein is the use of a compound and/or a pharmaceutically acceptable salt thereof disclosed herein in the manufacture of a medicament for treating an inflammatory disease in a patient in need or recognized need of such treatment in which the activity of BTK or other tyrosine kinases contribute to the pathology and/or symptoms of the disease. In one embodiment the tyrosine kinase protein is BTK. In another embodiment , the disease is chosen from respiratory, cardiovascular, and proliferative diseases.
In any of the aforementioned embodiments disclosed herein involving the treatment of proliferative disorders, including cancer, are further embodiments involving combination therapy. In those embodiments, the compound and/or a pharmaceutically acceptable salt thereof disclosed herein is administered in combination with at least one additional agent chosen from alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds such as cisplatin, cladribine,
aunorubicin/doxorubicin/idarubicin, irinotecan, fludarabine, 5-fluorouracil, gemtuzamab, methotrexate, paclitaxel, taxol™, docetaxol, temozolomide, thioguanine, or classes of drugs including hormones (an antiestrogen, an antiandrogen, and gonadotropin releasing hormone analogues, interferons such as alpha interferon, nitrogen mustards, such as busulfan, melphalan, and mechlorethamine, retinoids, such as tretinoin, topoisomerase inhibitors, such as irinotecan and topotecan, tyrosine kinase inhibitors such as gefinitinib and imatinib, and agents to treat signs or symptoms induced by such therapy including, for example, allopurinol, filgrastim, granisetron/ ondansetron/palonosetron, and dronabinol. When combination therapy is used, the agents can be administered simultaneously or sequentially. The kinase inhibitory activity of the compounds of the present disclosure can be tested by methods well known the the art. The BTK inhibitory activity of the compounds and/or a pharmaceutically acceptable salt thereof of the present disclosure can be tested using the in vitro and in vivo assays described in Biological Examples 1-3 below. A determination of kinase inhibitory activity by any of those assays is considered to be kinase inhibitory activity within the scope of this disclosure even if any or all of the other assays do not result in a determination of kinase inhibitory activity.
Without being bound to any specific mechanistic theory, in those embodiments wherein the compound of the present disclosure is a reversible covalent inhibitor, it is believed that the cysteine sulfhydryl group and a carbon atom forming part of the carbon- carbon double bond (i.e. olefin) of the compound of the present disclosure can form a reversible, i.e., labile, covalent bond, defined herein, such as wherein Cys 481 attacks an electron deficient carbon atom of the carbon-carbon double bond (olefin) in the compound of present disclosure to form a thiol adduct (e.g., Michael reaction with cysteine).
In some embodiments, the electron deficient carbon atom of the olefin is distal to the carbon attached to the cyano group and to the electron withdrawing -Z-CO- moiety (see Formula I, IA, IB, II) in the compounds of the present disclosure. Therefore, the combination of the cyano and the "-Z-CO-" moieties and the olefinic moiety to which they are bonded in the compounds of the present disclosure can increase the reactivity of the olefin to form a thiol adduct with the active site cysteine residue in BTK.
The compounds of the present disclosure bind with BTK in two different manners. In addition to the labile covalent binding, discussed above, they also form non-covalent binding(e.g., via van der Waals binding, hydrogen binding, hydrophobic binding, hydrophilic binding, and/or electrostatic charge binding) with BTK, the non-covalent binding being sufficient to at least partially inhibit the kinase activity of the BTK.
As disclosed herein, the labile covalent binding between the the compound of the disclosure and BTK occurs between the olefin in the inhibitor and the cysteine 481 residue thiol side chain at or near the site where the compound has the aforementioned non-covalent binding with the BTK.
As is evident, the compounds of the present disclosure which are reversible covalent inhibitors have both a cysteine-mediated covalent binding and a non-covalent binding with the BTK. This is in contrast with non-covalent reversible inhibitors which inhibit the BTK only via non-covalent binding and lack the cysteine-mediated covalent binding. The result of the binding of the compounds of the present disclosure with BTK in the two different manners is a reversible covalent inhibitor having a slow off -rate and a protracted duration of action, in some instances comparable to an irreversible covalent inhibitor without forming permanent irreversible protein adducts. The difference between irreversible and reversible covalent inhibitors, particulary the compounds disclosed herein, can be ascertained utilizing assays disclosed herein.
In general, the binding involved in an inhibitor that forms a reversible covalent bond with BTK, i.e., the compounds disclosed herein, is stable when the BTK is in certain configurations and susceptible to being broken when the BTK is in different configurations (in both cases under physiologic conditions), whereas the interaction between an inhibitor that forms an irreversible covalent bond is stable under physiologic conditions even when the BTK is in different configurations.
A reversible covalent bond often imparts unique properties related to the residence time of the compound within the cysteine-containing binding site. In this context, residence time refers to the temporal duration of the compound-target complex under different conditions (see Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5(9), 730-739 (2006).
The presence of a reversible covalent bond in a reversible covalent inhibitor as disclosed herein can lead to an extended residence time when compared to a compound that does not form a covalent bond with BTK. In one embodiment disclosed herein the compounds of the present disclosure that are reversible covalent inhibitors have a residence time of at least about 1 h, residence time may be measured using an occupancy assay in a biochemical or cellular environment (see Biological Example 7 below). Additionally, residence time may be measured using a functional assay following a defined wash-out period.
Compounds that form an irreversible covalent bond in an irreversible covalent inhibitor share these extended residence time properties but may nonetheless be differentiated from a reversible covalent inhibitor using a reversibility assay. The ability of the compound of the disclosure to form reversible covalent bond with Cys481 of BTK (UniprotKB
Sequence ID Q06187) and the olefinic bond in the compound of the disclosure, can be determined by the assays described in Biological Examples 5-8 below. A determination of the binding reversibility of the covalent bond between the cysteine residue and the olefinic bond of the compound of the disclosure by any of Biological Examples 5-8 below is considered to be binding reversibility within the scope of this disclosure even if one or more of the other methods does not result in a determination of binding reversibility.
In general, the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of the compounds disclosed herein may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses. A suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range, the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day. For oral administration, the compositions can be provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1 , 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount administered of the compound and/or a pharmaceutically acceptable salt thereof of this disclosure, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound and/or pharmaceutically acceptable salt thereof being utilized, the route and form of administration, and other factors.
In general, compounds and/or pharmaceutically acceptable salts of this disclosure will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), topically, or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, capsules, semisolids, powders, sustained release formulations, enteric coated or delayed release formulation, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently,
pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4, 107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
The compositions are comprised of, in general, a compound and/or pharmaceutically acceptable salt disclosed herein in combination with at least one pharmaceutically acceptable excipient such as binders, surfactants, diluents, buffering agents, antiadherents, glidants, hydrophilic or hydrophobic polymers, retardants, stabilizing agents or stabilizers, disintegrants or superdisintegrants, antioxidants, antifoaming agents, fillers, flavors, colors, lubricants, sorbents, preservatives, plasticizers,and sweeteners. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound disclosed herein. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
The compounds and/or pharmaceutically acceptable salt of the present disclosure can also be administered intranasally. Intranasal formulations are known in the art e.g., see U.S. Patent Nos. 4,476, 116, 5,116,817 and 6,391,452, each of which is incorporated herein by reference. The choice of excipients will depend upon the nature of the nasal dosage form e.g., solutions, suspensions, or powder. For administration by inhalation, the compounds and/or pharmaceutically acceptable salts of the present disclosure may be in the form of solutions, suspensions, and powders. These formulations are administered as an aerosol, a mist, or a powder and can be delivered from pressurized packs or a nebulizer with a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, nitrogen, carbon dioxide, etc. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges for use in an inhaler may be formulated containing a powder mix of the compound disclosed herein and a suitable powder base such as lactose or starch.
Topical formulation can be liquids, suspension, emulsions, and the like, and can be prepared by methods well known in the art. The formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound and/or pharmaceutically acceptable salt disclosed herein based on the total formulation, with the balance being one or more suitable pharmaceutical excipients amd can be administered in single or multiple doses. Suitable excipients include polymers, surfactants, buffering or pH adjusting agents, tonicity and osmotic adjusting agent(s), preservatives, and dispersing agents.
Other suitable pharmaceutical excipients and their formulations are described in
Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound and/or pharmaceutically acceptable salt disclosed herein based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
The compounds and/or pharmaceutically acceptable salts of the present disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of the present disclosure or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present disclosure. When a compound and/or pharmaceutically acceptable salt of the present disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound and/or pharmaceutically acceptable salt of the present disclosure is preferred. However, the combination therapy may also include therapies in which the compound and/or pharmaceutically acceptable salt of the present disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds and/or pharmaceutically acceptable salts of the present disclosure and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present disclosure also include those that contain one or more other active ingredients, in addition to a compound and/or pharmaceutically acceptable salt of the present disclosure.
The above combinations include combinations of a compound of the present disclosure not only with one other active compound, but also with two or more other active compounds. Likewise, compounds and/or pharmaceutically acceptable salts of the present disclosure may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present disclosure are useful. Such other drugs may be administered, by a route and in an amount commonly used therefore by those skilled in the art,
contemporaneously or sequentially with a compound and/or pharmaceutically acceptable salt of the present disclosure. When a compound and/or pharmaceutically acceptable salt of the present disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound and/or
pharmaceutically acceptable salt of the present disclosure is preferred. Accordingly, the pharmaceutical compositions of the present disclosure also include those that also contain one or more other active ingredients, in addition to a compound and/or pharmaceutically acceptable salt of the present disclosure. The weight ratio of the compound and/or pharmaceutically acceptable salt of the present disclosure to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
Where the patient is suffering from or at risk of suffering from an autoimmune disease, an inflammatory disease, or an allergy disease, a compound and/or pharmaceutically acceptable salt of present disclosure can be used in with one or more of the following therapeutic agents in any combination: immunosuppressants (e.g., tacrolimus,
diethylstilbestrol, rapamicin, methotrexate, cyclophosphamide, azathioprine, mercaptopurine, mycophenolate, or FTY720), glucocorticoids (e.g., prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone), non- steroidal anti-inflammatory drugs (e.g., salicylates, arylalkanoic acids, 2-arylpropionic acids, N-arylanthranilic acids, oxicams, coxibs, or sulphonanilides), Cox-2-specific inhibitors (e.g., valdecoxib, celecoxib, or rofecoxib), leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline, TNF-. alpha, binding proteins (e.g., infliximab, etanercept, or adalimumab), abatacept, anakinra, interferon-.beta., interferon- .gamma., interleukin-2, allergy vaccines, antihistamines, antileukotrienes, beta-agonists, theophylline, and anticholinergics.
Where the patient is suffering from or at risk of suffering from a B-cell proliferative disorder (e.g., plasma cell myeloma), the patient can be treated with a compound and/or pharmaceutically acceptable salt disclosed herein in any combination with one or more other anti-cancer agents. In some embodiments, one or more of the anti-cancer agents are proapoptotic agents. Examples of anti-cancer agents include, but are not limited to, any of the following: gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis- inducing ligand (TRAIL), 5-aza-2'- deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec™), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17- AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 1 1-7082, PKC412, or PD 184352, Taxol™, also referred to as "paclitaxel", which is a well-known anti-cancer drug which acts by enhancing and stabilizing microtubule formation, and docetaxol, such as
Taxotere™. Compounds that have the basic taxane skeleton as a common structure feature, have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules and may be useful for treating cancer in combination with the compounds described herein.
Further examples of anti-cancer agents for use in combination with a compound disclosed herein include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126,
PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).
Other anti-cancer agents that can be employed in combination with a compound disclosed herein include Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin;
altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat;
benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin;
bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin;
cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate;
eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine;
fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea;
idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl ; interferon alfa-n3; interferon beta- la; interferon gamma- 1 b; iproplatin; irinotecan hydrochloride;
lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril;
mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane;
mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide;
pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride;
semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate;
vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.
Other anti-cancer agents that can be employed in combination with a compound and/or pharmaceutically acceptable salt disclosed herein include: 20-epi-l, 25
dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole;
andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti- dorsalizing morphogenetic protein-1 ; antiandrogen, prostatic carcinoma; antiestrogen;
antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1 ; axinastatin 2; axinastatin 3; azasetron; azatoxin;
azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists;
benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine;
calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine;
carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4;
combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8;
cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone;
didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl . spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin
SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur;
epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists;
etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon;
leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine;
lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A;
marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor;
mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+ diethylstilbestrol cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N- substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine;
palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine;
pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors;
picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B;
plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor;
protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; R.sub.l 1 retinamide; rogletimide; rohitukine;
romurtide; roquinimex; rubiginone B l ; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived 1 ; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol;
somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine;
splenopentin; spongistatin 1 ; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide;
tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic;
thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate;
triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
Yet other anticancer agents that can be employed in combination with a compound disclosed herein include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes
(decarbazine, etc.). Examples of antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
Examples of natural products useful in combination with a compound or a pharmaceutically acceptable salt disclosed herein include but are not limited to vinca alkaloids (e.g., diethylstilbestrol, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
Examples of alkylating agents that can be employed in combination a compound or a pharmaceutically acceptable salt disclosed herein include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates
(e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc.). Examples of antimetabolites include, but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin.
Examples of hormones and antagonists useful in combination a compound or a pharmaceutically acceptable salt disclosed herein include, but are not limited to,
adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide). Other agents that can be used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).
Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with an BTK inhibitor compound and/or a pharmaceutically acceptable salt of the disclosure include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP- XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1 , Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and
Spongistatin 9), Cemadotin hydrochloride (also known as LU- 103793 and NSC-D-669356), Epothilones (such as Epothilone A, Epothilone B, Epothilone C (also known as
desoxyepothilone A or dEpoA), Epothilone D (also referred to as OS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N- oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21- hydroxyepothilone D (also known as Desoxyepothilone F and dEpoF), 26-fluoroepothilone), Auristatin PE (also known as NSC-654663), Soblidotin (also known as TZT-1027), LS-4559- P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS- 4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ- 3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651 ), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM- 97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, also known as AVE-8062, AVE- 8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-l 38067 (Tularik, also known as T-67, TL- 138067 and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin Al (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B. Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF- 569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asia Medica), A- 105972 (Abbott), Hemiasterlin, 3-B AABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-l 38026
(Tularik), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, also known as T-900607), RPR-1 15781 (Aventis), Eleutherobins (such as Desmethyleleutherobin,
Desaetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A- 293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-4341 1 (Zentaris, also known as D- 81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-1 10, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).
Where the patient is suffering from or at risk of suffering from a thromboembolic disorder (e.g., stroke), the patient can be treated with a compound and/or pharmaceutically acceptable salt disclosed herein in any combination with one or more other anti- thromboembolic agents. Examples of anti-thromboembolic agents include, but are not limited any of the following: thrombolytic agents (e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatran etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban, DX- 9065a, otamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel, LY640315), ximelagatran, or BIBR 1048.
Examples
The following preparations of intermediates (References) and final compounds (Examples) disclosed herein are given to enable those skilled in the art to more clearly understand and to practice the present disclosure. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof. The line at the alkene carbon, in the compounds below, denotes that the compounds are isolated as an undefined mixture of (E) and (Z) isomers.
Reference 1
Synthesis of 3-iodo-lH-pyrazolo[3,4-d]pyrimidin-4-amine
Figure imgf000051_0001
A mixture of lH-pyrazolo[3,4-d]pyrimidin-4-amine (150 g, 1.1 1 mol, 1.00 equiv) and N-iodo-succinimide (375 g, 1.67 mol, 1.58 equiv) in N,N-dimethylformamide (2.5 L) was stirred at 80°C for 5 h. The reaction mixture was cooled to room temperature and then diluted with 10 L of water. The solid was collected by filtration, washed with 2x1 L of saturated aqueous sodium sulfite, and dried under vacuum to give 150 g of 3-iodo-lH-pyrazolo[3,4- d]pyrimidin-4-amine as a yellow solid.
Reference 2
Synthesis of (R)-tert-butyl 3-(4-amino-3-iodo-lH-pyrazolo[3,4-d]pyrimidin-l-yl)piperidine- -carboxylate
Figure imgf000051_0002
To a stirred mixture of 3-iodo-lH-pyrazolo[3,4-d]pyrimidin-4-amine (5.9 g, 22.6 mmol, 1.00 equiv), (S)-tert-butyl 3-hydroxypiperidine-l -carboxylate (lOg, 50 mmol, 2.2 equiv) and triphenylphosphine (1 1.8g, 45 mmol, 2.0 equiv) in tetrahydrofuran (300 mL) at 10 °C was added a solution of diisopropyl azodicarboxylate in tetrahydrofuran (30 mL) dropwise in 30 min. The resulting mixture was stirred at room temperature for 12 h and then concentrated under vacuum. The residue was purified on a silica gel column eluted with dichloromethane/methanol (100/1) to give 3g of (R)-tert-butyl 3-(4-amino-3-iodo-lH- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carboxylate as a yellow solid.
Proceeding as described above but substituting (S)-tert-butyl 3-hydroxypiperidine-l - carboxylate with (S)-tert-butyl 2-(hydroxymethyl)-pyrrolidine-l -carboxylate gave tert-butyl (S)-2-([4-amino-3-iodo- 1 H-pyrazolo[3,4-d]pyrimidin- l-yl]methyl)pyrrolidine- 1 -carboxylate
Reference 3
Synthesis of (2-fluoro-4-phenoxyphenyl)-boronic acid
Figure imgf000052_0001
Step 1
Into a 250 mL round-bottom flask, was placed a solution of 4-bromo-3-fluorophenol (5 g, 26.18 mmol, 1.00 equiv) in dichloromethane (100 mL), phenylboronic acid (3.5 g, 28.70 mmol, 1.10 equiv), Cu(AcO)2 (5.7 g), triethylamine (5.3 g), and 4A molecular sieves (15 g). The resulting solution was stirred overnight at room temperature. The solids were filtered out. The filtrate was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was loaded onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 : 100-1 :50). This resulted in 2 g of l-bromo-2-fluoro-4-phenoxybenzene as colorless oil. Step 2
Into a 100 mL 3-necked round-bottom flask purged and maintained under an inert atmosphere of nitrogen, was placed a solution of 1 -bromo-2-fluoro-4-phenoxybenzene (2 g,
7.49 mmol, 1.00 equiv) in tetrahydrofuran (20 mL). BuLi (1M, 8 mL) was added dropwise with stirring at -70 to -80 °C. The resulting solution was stirred for 30 min at -70— 80 °C in a liquid nitrogen bath. Tris(propan-2-yl)borate (1.7 g, 9.04 mmol, 1.21 equiv) was added dropwise with stirring at -70 to -80 °C. The resulting solution was allowed to react, with stirring, for an additional 2 h while the temperature was maintained at -70 to -80 °C. The reaction was then quenched by the addition of 100 mL of water, extracted with ethyl acetate and the organic layers were combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was loaded onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :20) to give 1.6 g of (2-fluoro-4-phenoxyphenyl)boronic acid as a white solid.
Reference 4
Synthesis of 2-cyano-4-methylpent-2-enoic
Figure imgf000053_0001
To a solution of 2-cyanoacetic acid (8.7g, 102 mmol) in methanol (200mL) was added 2-methylpropanal (18.6 mL, 204 mmol) and the solution was stirred with a slight exotherm noted. After 30 minutes, added piperidine (1 1.1 mL, 1 12 mmol) and continued stirring for 1 h before removing solvent in vacuo with gentle heating. The thick material was diluted with ether and washed with 125mL of 1.0M HC1 and then washed with brine. The organic phase was dried over sodium sulfate and concentrated to afford a colorless oil weighing 11.2 g of 2- cyano-4-methylpent-2-enoic acid which precipitated on standing.
Reference 5
Synthesis of 2-cyan -4,4-dimethylpent-2-enoic acid
Figure imgf000053_0002
Following the procedure used in reference for but using pivalaldehyde in place of 2- methylpropanal affords. 2-cyano-4,4-dimethylpent-2-enoic acid.
Example 1
Synthesis of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- l-yl)piperidine-l-carbonyl)-3-(3-methyloxetan-3-yl)acrylonitrile trifluoroacetic acid salt
Figure imgf000054_0001
Step 1
Into a 100-mL round-bottom flask, was placed 1,4-dioxane (40 mL), water (10 mL), tert-butyl (3R)-3-[4-amino-3-iodo-l H-pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l- carboxylate (3.108 g, 7.00 mmol, 1.00 equiv), (2-fluoro-4-phenoxyphenyl)boronic acid
(1.624 g, 7.00 mmol, 1.00 equiv), potassium carbonate (2.898 g, 32.89 mmol, 4.70 equiv) and Pd(dppf)Cl2 (57.1 mg, 0.4 mmol, 0.06 equiv). The resulting solution was stirred overnight at 80° C in an oil bath. The solids were then filtered out and the resulting solution was diluted with water. The resulting mixture was extracted ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtrated, and
concentrated. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :3). This resulted in 2.7 g of tert-butyl (3R)-3-[4-amino-3-(2-fluoro-4- phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carboxylate as a black solid. Step 2
Into a 100-mL round-bottom flask, was placed tert-butyl (3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl]piperidine- 1 -carboxylate (2.7 g, 5.35 mmol, 1.00 equiv) and dichloromethane (20 mL). This was followed by the addition of trifluoroacetic acid (5 mL). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 2.6 g (crude) of 3-(2- fluoro-4-phenoxyphenyl)-l-[(3R)-piperidin-3-yl]-lH-pyrazolo[3,4-d]pyrimidin-4-amine as a brown oil.
Step 3
Into a 50-mL round-bottom flask, was placed TEA (5.05 g, 49.91 mmol, lO.Oequiv)
3-(2-fluoro-4-phenoxyphenyl)-l-[(3R)-piperidin-3-yl]-lH-pyrazolo[3,4-d]pyrimidin-4- amine (2.02 g, 4.99 mmol, 1.00 equiv), 2-cyanoacetic acid (510 mg, 6.00 mmol, 1.20 equiv), HATU
(2.28 g, 6.00 mmol, 1.20 equiv) and N,N-dimethylformamide (40 mL). The resulting solution was stirred for 4 h at room temperature and then diluted with 200 mL of water. The resulting solution was extracted with of ethyl acetate and the organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtrated and concentrated under vacuum. This resulted in 600 mg of 3-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin- l -yl]piperidin-l -yl]-3-oxopropanenitrile as a light yellow solid. Step 4
Into a 50-mL round-bottom flask, was placed a solution of 3-[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yljpiperidin- 1 -yl]-3- oxopropanenitrile (300 mg, 0.64 mmol, 1.00 equiv) in toluene (10 mL), 3-methyloxetane-3- carbaldehyde (127.4 mg, 1.27 mmol, 2.00 equiv) and piperidine (108.2 mg, 1.27 mmol, 2.00 equiv). The resulting solution was stirred for 4 h at 1 10° C in an oil bath and then cooled and concentrated under vacuum. The residue was applied onto a silica gel column and purified with ethyl acetate. This resulted in product (80 mg), which was re-purified by Prep-HPLC with the following conditions (l#-Pre-HPLC-005 (Waters)): Column, SunFire Prep C I 8 19* 150mm 5um; mobile phase, water with 0.05% trifluoroacetic acid and CH3CN (10% CH3CN up to 70% in 10 min); Detector, 254 nm. This resulted in 22.9 mg (5%) of 2-((R)-3- (4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 - carbonyl)-3-(3-methyloxetan-3-yl)acrylonitrile trifluoroacetic acid salt as a white solid. LC- MS (ES, m/z): [M-CF3COOH+H]+ 554.
Proceeding as described in Steps 1 , 2 and 3 above but substituting tert-butyl (3R)-3- [4-amino-3-iodo-l H-pyrazolo[3,4-d]pyrimidin- l-yl]piperidine- l -carboxylate with tert-butyl (S)-2-([4-amino-3-iodo- lH-pyrazolo[3,4-d]pyrimidin-l -yl]methyl)pyrrolidine- l-carboxylate, (S)-3-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)- methyl)pyrrolidin-l -yl)-3-oxopropanenitrile was synthesized. Example 2
Synthesis of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(azetidin- 1 -yl)-4-methylpent-2-enenitrile bis (2,2,2- trifluoroacetate)
Figure imgf000056_0001
Stepl
To a solution of 2-bromo-2-methylpropanal (0.6 g, 4 mmol, 1.0 equiv) in Et20 (20 mL) at 0 °C was added azetidine (684 mg, 12 mmol, 3.0 equiv) dropwise. The resulting mixture was stirred at 0°C for 2 hours. The mixture was diluted with water, and extracted with Et20. The combined organic layer was dried over anhydrous sodium sulfate. The solids were filtered and the solvent concentrated under vacuum. This resulted in 208 mg (41 %) of 2- (azetidin-l-yl)-2-methylpropanal as a colorless oil.
Step2
A solution of 3-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin-l-yl) piperidin-l-yl)-3-oxopropanenitrile (200 mg, 0.43 mmol, 1.0 equiv), 2- (azetidin-l-yl)-2-methylpropanal (136.5 mg, 2.15 mmol, 5.0 equiv) and piperidine (73.1 mg, 0.86 mmol, 2.0 equiv) in toluene (10 mL) was stirred at 120 °C for 3 hours. The mixture was then concentrated and the crude product was purified by prep-HPLC. This resulted in 39.8 mg of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo [3, 4-d] pyrimidin-l-yl) piperidine- 1 -carbonyl)-4-(azetidin- 1 -yl)-4-methylpent-2-enenitrile bis (2,2,2-trifluoroacetate) as a white solid. LCMS (ESI, pos. ion) m/z: 581 (M-2TFA+1).
Example 3
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-5 -hydroxy-4,4-dimethylpent-2-enenitrile
Figure imgf000057_0001
Step 1
To a mixture of 2,2-dimethylpropane- 1 ,3-diol (5.g, 48.01mmol) and imidazole (4.9g, 71.97mmol) in DCM (lOOmL) was added TMS-C1 (7.9g, 52.42mmol) and the resultant slurry stirred at rt for lh. After washing with water and brine, the organic phase was dried over sodium sulfate, filtered, concentrated and purified via column chomatography with 90: 10 Hexanes: ethyl acetate to yield 6.5 g of 3-((tert-butyldimethylsilyl)oxy)-2,2-dimethylpropan-
1 - ol as a colorless oil.
Step 2
A crude mixture of 3-[tert-butyl(dimethyl)silyl]oxy-2,2-dimethyl-propanal (1.15g,
5.31mmol) was prepared by addition of 1.1 equivalents of Dess-Martin periodinane to a solution of 3-((tert-butyldimethylsilyl)oxy)-2,2-dimethylpropan-l-ol in 25 mL of DCM at 0° C. After 1 h.the slurry was diluted with hexanes and filtered over a plug of silica. The residue was concentrated to a thick oil and then dissolved in DCM (lOmL). 3-[(3R)-3-[4-Amino-3- (2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l -yl]-l -piperidyl]-3-oxo- propanenitrile (236.79 mg, 0.5000 mmol) was added, then TMS-C1 (0.2 mL, 1.59 mmol), followed by pyrrolidine (0.13 mL, 1.59 mmol). The solution was stirred at rt, monitoring the reaction by LCMS. After 16 h, the mixture was partitioned between water and DCM and then the organic phase was washed with brine and dried over sodium sulfate. Filtration and removal of solvents afforded a colorless oil that was purified by silica gel choromatography (9: 1 to 90: 10 methylene chloride:MeOH gradient) to afford -350 mg of (R)-2-(3-(4-amino-3- (2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-5- ((tert-butyldimethylsilyl)oxy)-4,4-dimethylpent-2-enenitrile.
Step 3
To a solution of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]piperidine-l-carbonyl]-5-[tert-butyl(dimethyl)silyl]oxy-4,4-dimethyl-pent-
2- enenitrile (350 mg, 0.5200 mmol) in DCM (5 mL) was added approximately 2.5 ml of TFA and the solution was stirred at rt overnight. The next day the compound was partitioned between water and dichloromethane and the organic phase was dried over sodium sulfate. After filtration and removal of solvents the crude material was flash purified (99: 1-92:8 gradient DCM:MeOH). The clean fractions were concentrated, dissolved in a minimum of acetonitrile and water, frozen and lyophilized to obtain a colorless powder weighing 46 mg of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-5-hydroxy-4,4-dimethylpent-2-enenitrile. LC-MS (ES, m/z): 557 [M+H].
Example 4
Synthesis of 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]- pyrimidin- 1 -yl] -piperidin- 1 -yl]carbonyl] -4-methyl -4-(4-methy lpiperazin- 1 -yl)pent-2-
Figure imgf000058_0001
Step 1
Into a 50-mL 3-necked round-bottom flask, was placed a solution of 2-bromo-2- methylpropanal (2 g, 13.24 mmol, 1.00 equiv) in ether (10 mL). This was followed by the addition of 1-methylpiperazine (4.66 g, 46.52 mmol, 3.51 equiv) dropwise at 0° C. The resulting solution was stirred at room temperature overnight. The solid was filtered off. The filtrate was diluted with water. The resulting mixture was washed with ether. The pH value of the aqueous layers was adjusted to 12 with potassium carbonate. The resulting solution was extracted with dichloromethane and the organic layers combined, washed with brine, dried over sodium sulfate and concentrated under vacuum. This resulted in 740 mg of 2-methyl-2- (4-methylpiperazin-l-yl)propanal as a yellow oil.
Step 2
Into a 500-mL round-bottom flask, was placed N,N-dimethylformamide (20 mL), 3- (2-fluoro-4-phenoxyphenyl)- 1 - [(3R)-piperidin-3 -yl] - 1 H-pyrazolo[3 ,4-d]pyrimidin-4-amine (8.04 g, 19.88 mmol, 1.00 equiv), 2-cyanoacetic acid (2.0 g, 23.51 mmol, 1.18 equiv), HATU (9.12 g, 24.00 mmol, 1.21 equiv) and TEA (21.2 mL, 10.00 equiv). The resulting solution was stirred for 4 h at room temperature and then diluted with 500 mL of water. The resulting solution was extracted with 4x300 mL of ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, filtrated and concentrated under vacuum. This resulted in 6.2 g of 3-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin-l-yl]piperidin-l-yl]-3-oxopropanenitrile as a yellow solid.
Step 3
Into a 100-mL round-bottom flask, was placed a solution of toluene (10 mL), 3- [(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl]piperidin-l-yl]-3-oxopropanenitrile (300 mg, 0.64 mmol, 1.00 equiv), 2-methyl-2-(4- methylpiperazin- 1 -yl)propanal (541.45 mg, 3.18 mmol, 5.00 equiv), and piperidine (108.29 mg, 1.27 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at 120° C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate:MeOH (5: 1). The crude product (70 mg) was purified by Flash- Prep-HPLC with the following conditions (IntelFlash-1): Column, C\$ silica gel; mobile phase, H2O(0.5%TFA)/CH3CN=10% increasing to H2O(0.5%TFA)/CH3CN=40% within 10 min; Detector, UV 254 nm. This resulted in 46.4 mg (12%) of 2-[[(3R)-3-[4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl]piperidin- 1 -yl]carbonyl]-4- methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile as a white solid. LC-MS-PH-PBF-003- 96-0: (ES, m/z): [M+H]+ 625
Example 5
Synthesis of (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]- pyrimidin- 1 -yl)-methyl)pyrrolidine- 1 -carbonyl)-4-methyl-4-(pyrrolidin- 1 -yl)pent-2-
Figure imgf000059_0001
To a solution of 2-methylpropanal (5.6 mL, 61.8 mmol) in DCM (75 mL) cooled with an ice bath was added bromine (3.2 mL, 61.8 mmol) dropwise. After 1 hr, the solution was evaporated, stirred in DCM (8 ml) at room temperature and pyrrolidine (0.94 mL, 1 1.26 mmol) was added. After stirring 4 h, the mixture was diluted with brine and the layers separated. The organic layer was washed with 1M HC1 and then the aqueous layer was basified with KOH to pH = 10-11. This was then extracted with DCM and the organic layers were combined, dried (MgSC ), filtered and concentrated to isolate 2-methyl-2- pyrrolidin-l-yl-propanal oil as an oil.
Step2
To a mixture of (S)-3-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin-l-yl)methyl)pyrrolidin-l-yl)-3-oxopropanenitrile (285 mg, 0.60 mmol), 2- methyl-2-pyrrolidin-l -yl-propanal (719 mg, 5.1 mmol) and pyrrolidine (0.23 mL, 2.8 mmol) in DCM (6 mL) at room temperature was added chloro(trimethyl)silane (0.23 mL, 1.8 mmol). After stirring 90 min, the solution was diluted with sat. NaHC(¾ and extracted with DCM. The organic layers were combined, dried (MgS04), filtered and concentrated. The crude material was purified by Isolera (10 g column:0%-15% iPrOH/DCM) to obtain 270 mg of (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(pyrrolidin-l-yl)pent-2-enenitrile. MS (pos. ion) m/z: 595 (M+l ).
Example 6
Synthesis of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- -yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile
Figure imgf000060_0001
Stepl
Into a 250-mL round-bottom flask, was placed a solution of 2-bromo-2- methylpropanal (5 g, 33.11 mmol, 1.00 equiv) and tert-butyl piperazine-l-carboxylate (18.6 g, 99.87 mmol, 3.02 equiv) in ether (80 mL). The resulting solution was stirred overnight at 25° C. The solids were filtered out. The organic filtrate was washed with water, dried over anhydrous sodium sulfate and concentrated under vacuum to give 6 g of tert-butyl 4-(2- methyl-l-oxopropan-2-yl)piperazine-l -carboxylate as a white solid.
Step2
Into a 100-mL round-bottom flask, was placed 3-[(3R)-3-[4-amino-3-(2-fluoro-4- phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl]piperidin-l-yl]-3-oxopropanenitrile (300 mg, 0.64 mmol, 1.00 equiv), piperidine (1 10 mg, 1 .29 mmol, 2.03 equiv), toluene (30 mL) and tert-butyl 4-(2-methyl-l-oxopropan-2-yl)piperazine-l -carboxylate (820 mg, 3.20 mmol, 5.03 equiv). The resulting solution was heated to reflux overnight. The reaction was quenched by the addition of water. The resulting solution was extracted with ethyl acetate and the organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :3 to 1 :5). This resulted in 170 mg of (R)-tert- butyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidin-l-yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine-l-carboxylate as yellow oil.
Step3
Into a 30-mL round-bottom flask cooled to 0°C, was placed dichloromethane (8 mL), (R)-tert-butyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 -carboxylate (170 mg, 0.24 mmol, 1.00 equiv), and trifluoroacetic acid (2 mL). The resulting solution was stirred for 3 h at 25° C. The resulting mixture was concentrated under vacuum and the residue was dissolved in DCM. The resulting mixture was washed with 20 mL of aqueous potassium carbonate. The organic layer was dried over anhydrous sodium sulfate, concentrated to give the crude product. The crude product was purified by re-crystallization from ether. This resulted in 27 mg of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- djpyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile as a light yellow solid.LCMS (ESI, pos. ion) m/z: 610 (M+l). Example 7
Synthesis of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4- -hydroxyazetidin- 1 -yl)-4-methylpent-2-enenitrile
Figure imgf000062_0001
Step 1
To a solution of azetidin-3-ol hydrochloride (5.1 1 g, 46.7 mmol, 1.0 equiv) and 1H- imidazole (9.52 g, 140 mmol, 3.0 equiv) in DCM (100 mL) at 0° C was added TBDPSC1 (19.18 g, 70 mmol, 1.5 equiv) dropwise. The resulting mixture was stirred at rt overnight and then diluted with water, and extracted with DCM. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was eluted over a silica gel with DCM/MeOH= 100/1 to 10/1 to give 12 g of 3-(tert- butyldiphenylsilyloxy) azetidine as a colorless oil.
Step 2
To a solution of 2-bromo-2-methylpropanal (2.14 g, 14.3 mmol, 1.0 equiv) in Et20 (150 mL) at 0° C was added 3-(tert-butyldiphenylsilyloxy)azetidine (13.3 g, 42.9 mmol, 3.0 equiv) dropwise. The resulting mixture was stirred at 0° C for 3 h. The mixture was diluted with water and then extracted with Et20. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was applied onto a silica gel with petroleum ether/ethyl acetate = 20/1 to 5/1. This resulted in 2.4 g (44%) of 2-(3-(tert-butyldiphenylsilyloxy) azetidin-l-yl)-2-methylpropanal as a colorless oil.
Step3
To a solution of 3-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3, 4- d]pyrimidin-l-yl)piperidin-l-yl)-3-oxopropanenitrile (471 mg, 1 mmol, l .O equiv), 2-(3-(tert- butyldiphenylsilyloxy)azetidin-l-yl)-2-methylpropanal (762 mg, 2 mmol, 2.0 equiv) and pyrrolidine (284 mg, 4 mmol, 4.0 equiv) in DCM (20 mL) was added dropwise
chlorotrimethylsilane (216 mg, 2 mmol, 2.0 equiv). The resulting mixture was stirred at rt overnight. The mixture was concentrated and the crude product was purified by column chromatography using ethyl acetate/ MeOH = (100/1 to 20/1). This resulted in 0.3 g (36%) of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo [3, 4-d]pyrimidin-l-yl) piperidine- 1 -carbonyl)-4-(3-(tert-butyldiphenylsilyloxy)azetidin- 1 -yl)-4-methylpent-2- enenitrile as a light yellow solid.
Step 4
To a solution of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo [3, 4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(3-(tert-butyldiphenylsilyloxy)azetidin- 1 -yl)-4- methylpent-2-enenitrile (300 mg, 0.36 mmol, 1.0 equiv) in THF (8 mL) was added a solution of 1 M TBAF in THF ( 0.432 mL, 0.432 mmoL). The resulting mixture was stirred at rt overnight. The mixture was concentrated and the crude product was purified by prep-HPLC eluting with CH3CN/H20 (0.05%TFA). The organic phase was removed under reduced pressure and the resulting aqueous solution was diluted with sat.Na2C03 solution and extracted with DCM. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This resulted in 18.1 mg of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3, 4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-(3-hydroxyazetidin-l-yl)-4-methylpent-2-enenitrile as a white solid. LCMS (ESI, pos. ion) m/z: 597 (M+l).
Example 8
Synthesis of 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l- yl] -methyljpyrrolidine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile
Figure imgf000064_0001
To a solution of 2-methyl-2-(4-methylpiperazin-l -yl)propanal (108.3 mg, 0.6400 mmol ) in MeCN (6 mL), was added pyrrolidine (0.1 1 mL, 1.27 mmol). The reaction mixture was cooled to 0° C, followed by the addition TMS-C1 (0.11 mL, 0.85 mmol). The ice bath was removed and the mixture stirred for 10 min before adding 3-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidin-l-yl]-3-oxo- propanenitrile (100 mg, 0.210 mmol). The mixture was stirred for 3 h at room temperature, checking progress by TLC and LC-MS. To the mixture was added 15 ml water and extracted with dichloromethane. The combined organic layer was washed by brine, dried over by Na2S04, filtered, and evaporated. The residues was loaded on TLC plate and purified using MeOH:CH2Cl2 =9 : 100 to get pure product 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4- methylpiperazin-l-yl)pent-2-enenitrile (93mg,0.1491 mmol, 70.30 2% yield) as a light yellow powder. LC-MS (ES, m/z): 625 [M+H].
Example 8 A: Proceeding as described above but substituting 2-methyl-2-(4-methylpiperazin- l-yl)propanal with 2-methyl-2-(4-ethylpiperazin-l-yl)propanal, 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]-methyl]pyrrolidine-l -carbonyl]-4- methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile was synthesized.
Example 9
esis of 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine- 1 -carbonyl]-4-methyl-4-piperazin- 1 -yl-pent-2-enenitrile
Figure imgf000065_0001
Ste l
The 2-methylpropanal (1 mL, 10.96 mmol) was stirred in DCM (10 mL) while being cooled with an ice bath. Bromine (0.62 mL, 12.05 mmol) was slowly added via addition funnel over a 15 min period. After 1 hr of stirring at 0 °C, the reaction was concentrated to a light yellow liquid. This was redissolved in DCM (10 mL) and cooled with an ice bath while the tert-butyl piperazine-l -carboxylate (2.04 g, 10.96 mmol) was slowly added (diluted with 5-10 mL of DCM) over a 30 minute period. The cooling bath was removed and the reaction mixture was stirred at room temperature overnight, the mixture was washed with brine , then the remaning DCM layer was dried by Na2S04, filtered and concentrated to collect tert-butyl 4-(l , l-dimethyl-2-oxo-ethyl)piperazine-l-carboxylate as a light yellow solid which was used directly without further purification.
Step 2
To a solution of tert-butyl 4-(l,l-dimethyl-2-oxo-ethyl)piperazine-l-carboxylate (326.2 mg, 1.27 mmol) in DCM (6 mL), was added pyrrolidine (0.17 mL, 2.04 mmol). The reaction mixture was cooled to 0 °C, followed by the addition TMS-C1 (0.13 mL, 1.02 mmol). The ice bath was removed and the mixture stirred for 10 min before adding 3-[(2S)-
2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methy]]pyrrolidin- l-yl]-3-oxo-propanenitrile (120 mg, 0.250 mol). The mixture was stirred for 4 h at room temperature, at which point TLC and LC-MS showed the reaction was finished. To the mixture was added 30 ml water, the layers separated and the aq. layer was extracted with
CH2C12. The combined organic layer was washed with brine, dried over Na2S04, filtered, and the solvent removed in vacuo. The residue was dissolved in minimum CH2C12, loaded on a silica gel column and purified by MeOH/CH2Cl2(l/4) : EtOAc 20- 30% gradient to get pure product tert-butyl 4-[4-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin- 1 -yl]methyl]pyrrolidin- 1 -yl]-3-cyano- 1 , 1 -dimethyl-4-oxo-but-2-enyl]piperazine-
1- carboxylate as light yellow oil
Step 3
To a solution of 4N HC1 in dioxane (0.5 mL, 0.050 mmol) in THF (lmL) in the ice bath, was added tert-butyl 4-[4-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l -yl]methyl]pyrrolidin-l -yl]-3-cyano- l , l -dimethyl-4-oxo- but-2-enyl]piperazine- l -carboxylate (32.9 mg, 0.050 mmol). The ice bath was removed, the reaction mixture was stirred for 4 h at room temperature at which point TLC and LC-MS showed the reaction was finished. The mixture was concentrated in vacuo, adjusted with NaHC03 to pH 6-7, and the aq. layer extracted with CH2CI2. The combined organic layer was washed by brine, dried over Na2S04, filtered, and the solvent removed to get product 2-[(2S)-
2- [[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l -yl]methyl]- pyrrolidine- l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile (24 mg, 0.039 mmol, 85 % yield) as an off white powder. LC-MS (ES, m/z): 610 [M+H]
Example 10
Synthesis of 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- 1 - yl]methyl]pyrrolidine- l -carbony -4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile
Figure imgf000066_0001
Step 1
The 2-methylpropanal (0.5 mL, 5.48 mmol) was stirred in DCM (10 mL) while being cooled with an ice bath. Bromine (0.31 mL, 6.03 mmol) was slowly added via addition funnel over a 15 min period. After 1 h of stirring at 0 °C, the reaction was concentrated to a light yellow liquid. This was redissolved in DCM (5 mL) and cooled with an ice bath while the N- methyloxetan-3-amine (0.49 mL, 5.48 mmol) was slowly added (diluted with 5-10 mL of DCM) over a 10 minute period. Then the cooling bath was removed and the reaction mixture was stirred at room temperature overnight. The mixture was washed with brine, then the remaining DCM layer was washed by 0.5N HC1. The combined aq. layer was adjusted with KOH to pH 10- 1 1 , extracted with CH2CI2, and the combined organic layer was washed with brine and dried by Na2S04, filtered and concentrated to collect 2-methyl-2-[methyl(oxetan-3- yl)amino]propanal as a light yellow liquid. The crude material was used in the next step directly without further purification.
Step 2
To a solution of 2-methyl-2-[methyl(oxetan-3-yl)amino]propanal (100.0 mg, 0.6400 mmol) in DCM (5 mL), was added pyrrolidine (0.06 mL, 0.760 mmol). The reaction mixture was cooled to 0° C, followed by addition of TMS-Cl (0.06 mL, 0.51 mmol, the ice bath was removed and reaction mixture was stirred for 10 minutes before adding 3-[(2S)-2-[[4-amino- 3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l -yl]methyl]pyrrolidin-l -yl]-3-oxo- propanenitrile (60 mg, 0.13 mmol). The mixture was stirred for 50 minutes and the reaction was deemed finished by checking progress through TLC and LC-MS. The reaction mixture was washed by 15 ml Sat.Na2HC03 and the layers separated. The aq. layer was extracted with CH2CI2 and the combined organic layer was washed with brine, dried over Na2S04, filtered, and the solvent removed. The residue was loaded on silica gel column and purified by [MeOH:CH2Cl2(l :4) } : EtOAc 20%, 30% to get pure product 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- l-yl]methyl]pyrrolidine- l -carbonyl]-4- methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile (61 .8mg,0.1012mmol, 79.5% yield) as off white solid. LC-MS (ES, m/z): 612 [M+H]
Figure imgf000067_0001
Proceeding as described above but substituting (R)-3-(2-((4-amino-3-(2-fluoro-4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)methyl)pyrrolidin- 1 -yl)-3- oxopropanenitrile for (S)-3-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin-l-yl)methyl)pyrrolidin-l-yl)-3-oxopropanenitrile, (R)-2-(2-((4-amino-3-(2- fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)- 4-(methyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile was obtained. LC-MS (ES, mlz): 612 [M+H]
Example 10b
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)- -(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile
Figure imgf000068_0001
Proceeding as described above but substituting N-ethyloxetan-3-amine for N- methyloxetan-3-amine, (S)-2-(2-((4-arnino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent- 2-enenitrile was obtained. LC-MS (ES, m/z): 626 [M+H]
Example 1 1
Synthesis of 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile
Figure imgf000068_0002
Step 1 2-Methylpropanal (0.5 mL, 5.48 mmol) was stirred in DCM (10 mL) while being cooled with an ice bath. Bromine (0.31 mL, 6.03 mmol) was slowly added via addition funnel over a 15 min period. After 1 hof stirring at 0 °C, the reaction was concentrated to a light yellow liquid. This was redissolved in DCM (5 mL) cooled with an ice bath while the oxetan- 3-amine (0.39 mL, 5.48 mmol) was slowly added (diluted with 5-10 mL of DCM) over a 10 minute period, then the cooling bath was removed and the reaction mixture was stirred at room temperature overnight. The mixture was then washed with brine and the remaining DCM layer was washed by 0.5N HC1 . The combined aq . layer was adjusted with KOH to pH 10-1 1 , extracted with CH2CI2, and the combined organic layer was washed with brine and dried over Na2S04, filtered and concentrated to collect 2-methyl-2-(oxetan-3- ylamino)propanal as a light yellow liquid. The crude material was used in the next step directly without further purification.
Step 2
To a solution of 2-methyl-2-(oxetan-3-ylamino)propanal (106.3 mg, 0.7400 mmol) in DCM (5 mL) was added pyrrolidine (0.07 mL, 0.890 mmol). The reaction mixture was cooled to 0 °C, followed by addition TMS-C1 (0.08 mL, 0.59 mmol). The ice bath was removed and the reaction mixture was stirred at room temperature for 10 minutes before adding 3-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidin-l-yl]-3-oxo-propanenitrile (70 mg, 0.1500mmol). The mixture was stirred for 50 minutes at which point it was deemed finished by checking TLC and LC-MS. The mixture was washed with saturated Na2HC03 and the layers separated. The aq. layer was extracted with CH2CI2, and the combined organic layer was washed with brine, dried over Na2S04, filtered, and the solvent removed. The residue was loaded on silica gel plate, flashed by [MeOH:CH2Cl2(l :4) } : EtOAc 50%, 60% to get pure product 2-[(2S)-2-[[4-amino- 3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l- carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile (35.6 mg,0.0597 mmol, 40.2% yield) as an off white solid. LC-MS (ES, m/z): 598 [M+H].
Example 11a
Synthesis of (R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)-4-methyl-4-(oxetan-3-ylamino)pent-2- enenitrile
Figure imgf000070_0001
Proceeding as described above but substituting 3-[(2R)-2-[[4-amino-3-(2-fluoro-4- phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l -yl]methyl]pyrrolidin-l -yl]-3-oxo-propanenitrik for 3-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- l - yI]methyl]pyrrolidin- l -yl]-3-oxo-propanenitrile, (R)-2-(2-((4-amino-3-(2-fluoro-4- phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- l -yl)methyl)pyrrolidine- l -carbonyl)-4- methyl-4-(oxetan-3-ylamino)pent-2-enenitrile was obtained. LC-MS (ES, m/z): 598 [M+H] .
Example 12
Synthesis of 2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- 1■ yl]methyl]azetidine- l-carbonyl]-4-methyl-pent-2-enenitrile
Figure imgf000070_0002
To a mixture of 3-(2-fluoro-4-phenoxy-phenyl)-lH-pyrazolo[3,4-d]pyrimidin-4- amine (300 mg, 0.930 mmol), tert-butyl 2-(hydroxymethyl)azetidine-l-carboxylate (0.33 mL, 1.9 mmol) and PPh3 (733.86 mg, 2.8 mmol) in THF (10 mL) in ice bath, the DIAD (0.37 mL, 1.87 mmol) as a solution in 5 ml THF was slowly added. The mixture was stirred at RT overnight and then the solvent was removed. To the residue was added H20 and the mixture was extracted with EtOAc . The combined organic layer was washed with NaHC03, then brine, and dried over Na2S04. The solvent was removed to get tert-butyl 2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]azetidine-l-carboxylate weighing 800 mg, which was used without further purification for the next step.
Step 2
To the crude tert-butyl 2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]methyl]azetidine-l-carboxylate (800 mg, 1.63 mmol) dissolved in DCM (4mL) in ice bath, was dropwise added TFA (2 mL) slowly, stirring for 10 min at which point nostarting material remained by TLC analysis. The solvent was removed and EtOAc added, which was washed with 2M HC1. The combined aq. solution was adjusted with NaOH to pH around 10, and the aq. layer extracted with EtOAc. The combined organic layer was washed with brine, dried over Na2S0 , and the solvent removed to get 450 mg of l-(azetidin-2- ylmethyl)-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-4-amine, which was used in the next step directly without further purification.
Step 3
To a solution of 2-cyano-4-methyl-pent-2-enoic acid (30.7 mg, 0.220 mmol), 1- (azetidin-2-ylmethyl)-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-4-amine (57.5 mg, 0.150 mmol in DCM (2 mL) was added PyAOP (86.2 mg, 0.160 mmol) and TEA (0.06 mL, 0.440 mmol) and the resulting yellow solution stirred at rt for lh. LCMS showed that the reaction was complete and the crude mixture was directly loaded onto a silica gel cartridge for purification (3 to 5% MeOH: CH2C12). Removal of solvent from cleanest fractions afforded 30mg of the desired compound 2-[2-[[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l -yl]methyl]azetidine-l-carbonyl]-4-methyl-pent-2- enenitrile (30mg,0.0586mmol, 39.8% yield) as judged by LCMS. (M+l = 512).
Example 13
Synthesis of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile
Figure imgf000072_0001
The mixture of 2-methyl-2-[methyl(oxetan-3-yl)amino]propanal (66.69 mg, 0.42 mmol), 3-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]-l- piperidyl]-3-oxo-propanenitrile (lOOmg, 0.2100 mmol) and pyrrolidine (0.1 mL, 1.27 mmol ) was stirred at room temperature for 10 min. The reaction mixture was cooled to 0° C, followed by addition of TMS-C1 (0.1 1 mL, 0.85 mmol). The ice bath was removed and the reaction mixture was stirred for another 1 hour at room temperature, checking process by TLC and LC-MS. The solvent was removed and the resultant residue purified by column chromatography (MeOH, CH2C12, MeOH gradient from 0 to 10% to get 2-[(3R)-3-[4- amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]- 4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile (1 18.5 mg) as a white powder. LC- MS (ES, m/z): 612 [M+H]
Example 13a
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)- -(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile
Figure imgf000072_0002
Proceeding as described above but substituting N-ethyloxetan-3-amine for N- methyloxetan-3-amine, (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile was obtained. LC-MS (ES, m/z): 626 [M+H].
Example 13b
Synthesis of (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-
Figure imgf000073_0001
Proceeding as described in ex. 13 but substituting N-cyclopropyloxetan-3-amine N-methyloxetan-3-amine, (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H- pyrazolo[3,4-d]pyrirnidin-l -yl)raethyl)pyrrolidine- l -carbonyl)-4-(cyclopropyl(oxetan-3- yl)amino)-4-methylpent-2-enenitrile was obtained. LC-MS (ES, m/z): 626 [M+H]
Example 14
Synthesis of 2-[3-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl] azetidi - 1 -carbonyl]-4-methyl-pent-2-enenitrile
Figure imgf000073_0002
Step 1 The mixture of 3-(2-fluoro-4-phenoxy-phenyl)-lH-pyrazolo[3,4-d]pyrimidin-4-amine (500 mg, 1.56 mmol), PPh3 (1.22 g, 4.67 mmol ) and tert-butyl 3-(hydroxymethyl)azetidine- 1-carboxylate (437 mg, 2.33 mmol) in THF (10 mL) was cooled in an ice bath and DIAD (0.6 lmL, 3.1 1 mmol) in 5 ml THF was dropwise added to the reaction mixture. The mixture was stirred for 5 h. To the residue was added 30 ml water and the aq. layer extracted with EtOAc. The combined organic layer was washed with brine, dried over Na2S04, filtered, the solvent removed, and the crude tert-butyl 3-[[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]azetidine-l-carboxylate used in the next step directly.
Step 2
tert-Butyl 3-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]azetidine-l -carboxylate (780 mg) in DCM (2 mL) was cooled in an ice bath. To this was added TFA (4 mL, 1 .59 mmol), the ice bath was removed and the reaction mixture was stirred at room temperature for 1 hour, checking reaction by TLC and LC-MS. After two hours the solvent was removed, and to the residue was added water. The water layer was extracted with by EtOAc and the combined organic layer washed with 2N HC1. The combined aqueous layer was adjusted with NaOH to pH 9-10, extracted with EtOAc, and the combined organic layer washed with brine, dried over Na2S04 and filtered. The solvent was removed to obtain 2-cyano-4-methyl-pent-2-enoic acid (48.12 mg, 0.350 mmol) , l-(azetidin- 3-ylmethyl)-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-4-amine which was used in the next step without further purification.
Step 3
To a solution of 2-cyano-4-methyl-pent-2-enoic acid (48.12 mg, 0.350 mmol) ,1- (azetidin-3-ylmethyl)-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-4-amine (90 mg, 0.230 mmol) in DCM (2 mL) was added PyAOP (134.9 mg, 0.250 mmol) and TEA (0.1 mL, 0.690 mmol) and the resulting yellow solution stirred at rt for lh. LCMS showed that the reaction was completed and the crude mixture was directly loaded onto a silica gel cartridge for purification (0.2 to 3% MeOH: CH2C12). Removal of solvent from cleanest fractions afforded afforded 2-[3-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]azetidine-l-carbonyl]-4-methyl-pent-2-enenitrile (12 mg LCMS. (M+l = 512).
Example 15 esis of 2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin yl] methyl] azeti dine- 1 -carbonyl] -4-methyl-4-morpholino-pent-2-enenitrile
Figure imgf000075_0001
Step 1
To a mixture of l -(azetidin-2-ylmethyl)-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-4-amine (236.4 mg, 0.610 mmol), 2-cyanoacetic acid (77.2 mg, 0.910 mmol) in DCM (8mL) in ice bath, was added T3P (0.36 mL, 1.21 mmol) and TEA (0.34 mL, 2.42 mmol). The ice bath was removed and the reaction mixture was stirred at room temperature overnight. The reaction mixture was loaded onto the silica gel column, purified with 0- 3% gradient MeOH:CH2CL2, to get 3-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin- l -yl]methyl]azetidin-l -yl]-3-oxo-propanenitrile (201 mg) as yellow oil.
Step 2
To the mixture of 3-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin- l -yl]methyl]azetidin- l -yl]-3-oxo-propanenitrile (90.6 mg, 0.200 mmol), 2- methyl-2-morpholino-propanal (98.3 mg, 0.590 mmol) in DCM (2 mL) in an ice bath was added pyrrodidine (0.1 mL, 1.19mmol) and TMS-C1 (0.1 mL, 0.79 mmol). The ice bath was removed and the reaction mixture was stirred at room temperature for 1 hour and the reaction mixture directly loaded on silca gel plate, purified by EtOH:CH2Cl2 5% to get pure product 2- [2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- l-yl]methyl]azetidine- 1 -carbonyl] -4-methyl-4-morpholino-pent-2-enenitrile (23 mg) as a white powder. LC-MS (ES, m/z): 597 [M+H]
Example 16
Synthesis of 2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl] azeti dine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile
Figure imgf000076_0001
To a mixture of 3-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin- l -yl]methyl]azetidin- l -yl]-3-oxo-propanenitrile (100.6 mg, 0.220 mmol) and 2- methyl-2-(4-methylpiperazin-l -yl)propanal (1 18.2 mg, 0.660 mmol) in DCM (5 mL) in an ice bath was added pyrrolidine (0.1 1 mL, 1.32 mmol) and TMS-Cl (0.1 1 mL, 0.880 mmol). The ice bath was removed and the reaction mixture was stirred at room temperature for 1 hour. The crude reaction mixture was loaded on silca gel plate, purified by MeOHiCt^Cl? to obtain 2-[2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- l - yl] methyl] azeti dine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile (19 mg) as a white powder. LC-MS (ES, m/z): 610 [M+H]
Example 17
Synthesis of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- l - yl] azetidine- 1 -carbonyl] -4-methyl-pent-2-enenitrile
Figure imgf000076_0002
Step 1 A mixture of 3-iodo-lH-pyrazolo[3,4-d]pyrimidin-4-amine (3 g, 1 1.49 mmol), PPh3 (9.03 g, 34.5 mmol) tert-butyl 3-hydroxyazetidine-l-carboxylate (2.09 g, 12.1 mmol) in THF (60 mL) was cooled in an ice bath. DIAD (4.52 mL, 23.0 mmol) in 30 ml THF in dropping funnel was slowly added to the reaction mixture, and the reaction mixture was stirred for overnight. The solvent was removed and H20 was added. The aq. layer was extracted with EtOAc and the combined organic layer was washed with brine, dried over Na2S04, filtered, and the solvent removed to obtain tert-butyl 3-[3-iodo-4-[(triphenyl-{5 }- phosphanylidene)amino]pyrazolo[3,4-d]pyrimidin- 1 -yl]azetidine-l -carboxylate which was used as is for the next step.
Step 2
The mixture of tert-butyl 3-[3-iodo-4-[(triphenyl-{ 5 }-phosphanylidene)amino]- pyrazolo[3,4-d]pyrimidin-l-yl]azetidine-l-carboxylate (1.2 g, 1.77 mmol), (2-fluoro-4- phenoxy-phenyl)boronic acid (0.82 g, 3.55 mmol), Tetrakis(triphenylphosphane)palladium(0) (102.4 mg, 0.089 mmol) and K2C03 (514 mg, 3.73 mmol) in 1,4 dioxane (16 ml) and H20 (4 ml), was flushed with Ar2 for 15 minutes. The reaction tube was sealed and heated in a microwave oven at 180° C for 2 h, 15 min. The solvent was removed and water and EtOAc were added. The mixture was filtered through celite and separated. The aq. layer was extracted by EtOAc and the combined organic layer, washed with brine, dried over Na2SC>4, filtered, and the solvent removed to obtain the crude tert-butyl 3-(4-amino-3-(2-fluoro-4- phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)azetidine-l-carboxylate (800 mg) which was used directly in the next step.
Step 3
tert-Butyl 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)azetidine-l -carboxylate (800 mg) in TFA (8 mL) was stirred for 1 hour. To the residue was added EtOAc and 1 water and the layers were separated. The aqueous layer was extracted with EtOAc and the combined organic layer was evaporated to around 50 ml and washed with 2M HC1. The combined aqueous layer was adjusted with NaOH to pH 8-9, extracted with EtOAc and the combined organic layer washed with brine, and dried over Na2S0 . The solvent was removed to obtain 600 mg of l-(azetidin-3-yl)-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin-4-amine.
Step 4
The mixture of l-(azetidin-3-yl)-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-4-amine (80 mg, 0.210 mmol, 2-cyano-4-methyl-pent-2-enoic acid (44.4 mg, 0.320 mmol), PyAOP (121.9 mg, 0.230 mmol) and TEA (0.09 mL, 0.640 mmol) in DCM (3 mL), were stirred overnight at room temperature. The solvent was removed and the residue was purified on a silica gel plate using 6:94 MeOH:CH2Ci2 to get 2-[3-[4-amino-3-(2-fluoro- 4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]azetidine-l-carbonyl]-4-methyl-pent-2- enenitrile (34 mg) as white powder. LC-MS (ES, m/z): 498 [M+H].
Example 18
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4-hydroxypiperidin- 1 -yl)-4-methylpent-2-enenitrile
Figure imgf000078_0001
Stepl
To a solution of 2-methylpropanal (0.82 mL, 9.0 mmol) in DCM (10 mL) cooled with an ice bath was added bromine (0.5 mL, 9.9 mmol) over a 10 min period. 1.5 hr later, the reaction was concentrated to a weight of 1.4 g, and then restirred in DCM (10 mL) at room temperature. To this, was added piperidin-4-ol (1.82 g, 18.0 mmol) dissolved in DCM (7 mL). The reaction was stirred overnight at room temperature and then diluted with DCM and washed with aq. NaHC03 and 0.5 N HC1 . The aqueous acid layer was then adjusted to pH = 12 with NaOH. A white ppt/oil formed and then the water layer was washed with DCM. The organic layer was dried (MgSC^), filtered and concentrated to collect 0.49 g of 2-(4- hydroxypiperidin-l-yl)-2-methylpropanal as a yellow oil.
Step2
A mixture of (R)-3-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin-l-yl)piperidin-l-yl)-3-oxopropanenitrile (150 mg, 0.31 mmol), 2-(4-hydroxy-l- piperidyl)-2-methyl-propanal (167 mg, 0.98 mmol), pyrrolidine (0.03 mL, 0.31 mmol) and DCM (lOmL) was stirred at room temp for 2 days and then diluted with aq. NaHC03 (40 mL) and extracted with DCM . The organic was dried (MgSC>4), filtered and concentrated to an oil. The crude material was purified at Isolera (25 g column: 30% iPrOH/DCM) to obtain the product which was isolated by lyophilization to provide 61 mg (32% yield) of (R)-2-(3- (4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 - carbonyl)-4-(4-hydroxypiperidin-l-yl)-4-methylpent-2-enenitrile as a powder. MS (pos. ion) m/z: 625 (M+l).
Example 19
Synthesis of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-m ]heptan-2-yl)pent-2-enenitrile
Figure imgf000079_0001
Stepl
To a solution of 2-methylpropanal (5.6 mL, 61.8 mmol) in DCM (75mL) cooled with an ice bath was added bromine (3.2 mL, 61.8 mmol) dropwise. After 1 hr, the resulting 2- bromo-2-methylpropanal solution was evaporated to a weight of 8.5 g. This material was stirred in DCM (8 ml) at room temperature and 6-oxa-2-azaspiro[3.3]heptane; 1/2 oxalate (1.57mL, 7.19mmol) was added along with TEA (10 mL) and MeOH (3 mL). After stirring 2 days, the mixture was diluted with brine (30 mL) and the layers separated. The organic layer was washed with 1M HC1 (50 mL) and then the aqueous layer was basified with KOH to pH = 10-11. This was then extracted with DCM and the organic layers were combined, dried (MgS04), filtered and concentrated to isolate 2-methyl-2-(6-oxa-2-azaspiro[3.3]heptan-2- yl)propanal as an oil used directly in the next step.
Step2:
To a mixture of (R)-3-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-3-oxopropanenitrile (222 mg, 0.46mmol), 2-methyl-2-(6- oxa-2-azaspiro[3.3]heptan-2-yl)propanal (231.17mg, 1.37mmol) and pyrrolidine (0.23 mL,
2.73 mmol) in DCM (lOmL) at room temperature was added chloro(trimethyl)silane (0.17 mL, 1.37 mmol). After stirring 2 h, the solution was diluted with sat. NaHC03 and extracted with DCM. The organic layers were combined, dried (MgS04), filtered and concentrated. The crude material was purified by chromatography to obtain 133 mg of 2-[(3R)-3-[4-amino-3- (2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l -carbonyl]-4-methyl- 4-(6-oxa-2-azaspiro[3.3]heptan-2-yl)pent-2-enenitrile. MS (pos. ion) m/z: 623 (M+l).
Example 19a
Synthesis of (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4- d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6- yl
Figure imgf000080_0001
Proceeding as described above but substituting (S)-3-(2-((4-amino-3-(2-fluoro-4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)methyl)pyrrolidin- 1 -yl)-3- oxopropanenitrile for (R)-3-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin-l-yl)piperidin-l-yl)-3-oxopropanenitrile afforded 2-[(2S)-2-[[4-amino-3-(2- fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]piperidine-l-carbonyl]-4- methyl-4-(6-oxa-2-azaspiro[3.3]heptan-2-yl)pent-2-enenitrile. MS (pos. ion) m/z: 623 (M+l).
Example 20
Synthesis of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]-pyrimidin-l- yl]piperidine- 1 -carbonyl] -4-(4-ethylpiperazin- 1 -yl)-4-methyl-pent-2-enenitrile
Figure imgf000081_0001
Step 1
To a cooled (0 °C) solution of 2-bromo-2-methyl-propanal (2504 mg, 16.58mmol), prepared as in Exampe 5, in 15 mL of DCM was added 1 -ethylpiperazine (2.53mL, 19.9 mmol) and TEA (2.3 ImL, 16.58mmol) and the solution stirred at rt for 24 hours. The mixture was worked up with IN HCl (50 mL) and DCM (50 mL x 2). The aqueous was basified with KOH to pH ~ 1 1 and washed with DCM (50 mL x 3). The organic layers were washed with saturated sodium chloride, dried (MgS04), and then concentrated to obtain 2-(4- ethylpiperazin-l -yl)-2-methyl-propanal (90% yield) as an oil.
Step 2
To the solution of 3-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]-l-piperidyl]-3-oxo-propanenitrile (0.32mL, 0.57mmol DCM (20mL) , 2- (4-ethylpiperazin-l-yl)-2-methyl-propanal (21 1.84mg, 1.15mmol ) and pyrrolidine (0.14mL, 1.72 mmol ) was stirred at room temperature for 10 minutes then added
chloro(trimethyl)silane (0.29mL, 2.3mmol). The mixture was allowed to stirred at room temperature for 18h. The mixture was worked up with saturated NaHC03 (50 mL) and DCM (50 mL x 2), washed with saturated sodium chloride, dried (MgS04) and concentrated to yield an oil which was purified over silica gel (5%-50% iPA/DCM) to obtain 2-[(3R)-3-[4- amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]- 4-(4-ethylpiperazin-l-yl)-4-methyl-pent-2-enenitrile 265 mg (72.3% yield). MS (pos. ion) m/z: 638 (M+l).
Example 21
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4-isopropylpiperazin- 1 -yl)-4-methylpent-2-enenitrile
Figure imgf000082_0001
Proceeding as above in example 20 but substituting 1-isopropylpiperazine for 1- ethylpiperazine in step 1 , (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- djpyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4-isopropylpiperazin- 1 -yl)-4-methylpent-2- enenitrile. MS (pos. ion) m/z: 653 (M+l ).
Example 22
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4 -methylpent-2-enenitrile
Figure imgf000082_0002
Proceeding as above in example 20 but substituting l-(tert-butyl)piperazine for 1- ethylpiperazine in step 1 , (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- djpyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-mefhylpent-2- enenitrile is obtained. MS (pos. ion) m/z: 668 (M+l).
Example 23
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile
Figure imgf000083_0001
Proceeding as above in example 20 but substituting l-(2-methoxyethyl)piperazine for 1 -ethylpiperazine in step 1, (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)- 4-methylpent-2-enenitrile is obtained. MS (pos. ion) m/z: 668 (M+l ).
Example 24
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-me azin- 1 -yl)pent-2-enenitrile
Figure imgf000083_0002
Proceeding as above in example 20 but substituting l-methylpiperazin-2-one for 1- ethylpiperazine in step 1 , (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2- enenitrile is obtained. MS (pos. ion) m/z: 638 (M+l).
Example 25
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(methylsulf onyl)piperazin- 1 -yl)pent-2-enenitrile
Figure imgf000084_0001
Proceeding as above in example 20 but substituting l -(methylsulfonyl)piperazine for 1 -ethylpiperazine in step 1, (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H- pyrazolo[3,4-d]pyrirnidin-l-yl)piperidine-l-carbonyl)-4-methyl-4-(4-(rnethylsulfonyl)- piperazin-l-yl)pent-2-enenitrile is obtained. MS (pos. ion) m/z: 688 (M+l).
Example 26
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2-
Figure imgf000084_0002
Proceeding as above in example 20 but substituting l-methyl-4-(2,2,2- trifluoroethyl)piperazine for 1 -ethylpiperazine in step 1, (R)-2-(3-(4-amino-3-(2-fluoro-4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4- (2,2,2-trifluoroethyl)piperazin-l-yl)pent-2-enenitrile is obtained. MS (pos. ion) m/z: 692 (M+l).
Example 27
Synthesis of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile
Figure imgf000085_0001
Proceeding as above in example 20 but substituting (2S,6R)-l,2,6-trimethylpiperazine for 1 -ethylpiperazine in step 1 , 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrirnidin-l-yl)piperidine-l-carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethyl- piperazin-l -yl)pent-2-enenitrile is obtained. MS (pos. ion) m/z: 652 (M+l).
Example 28
Synthesis of 2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- l -yl)piperidine-l -carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin-l-yl)-4-methylpent-2- enenitrile
Figure imgf000085_0002
Steps 1 and 2Proceeding as above in example 20 but substituting (2S,6R)-tert-butyl 2,6-dimethylpiperazine-l-carboxylate for 1 -ethylpiperazine in step 1, (2S,6R)-tert-butyl 4-(5- ((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- l-yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)-2,6-dimethylpiperazine-l-carboxylate is obtained.
Step 3 The (2S,6R)-tert-butyl 4-(5-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)-2,6- dimethylpiperazine-l-carboxylate (103.5mg, 0.1400mmol) was dissolved in 4N HC1 in dioxane, and stirrred at rt for 3 hours. The solvent was removed and 2mL of MeOH was added to the residues. The mixture was neutralized to pH around 7-8 and extracted with DCM. The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and the solvent evaporated to get pure product 2-((R)-3-(4-amino-3-(2-fluoro-4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-((3S,5R)-3,5- dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile as a white solid. MS (pos. ion) m/z: 638 (M+l).
Example 29
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(5,6-dihydroimidazo[ 1 ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile
Figure imgf000086_0001
Proceeding as above in example 20 but substituting 5,6,7, 8-tetrahydroimidazo[l,2- a]pyrazine for 1 -ethylpiperazine in step 1, (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-(5,6-dihydroimidazo[l,2- a]pyrazin-7(8H)-yl)-4-methylpent-2-enenitrile is obtained. MS (pos. ion) m z: 647 (M+l).
Example 30
Synthesis of (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)methyl)pyrrolidine- 1 -carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile
Figure imgf000087_0001
Proceeding as in Example 5, step 2, but substituting 2,2-dimethyl-3-morpholino- propanal for 2-methyl-2-(pyrrolidin- l -yl)propanal affords (S)-2-(2-((4-amino-3-(2-fluoro-4- phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)methyl)pyrrolidine-l -carbonyl)-4,4- dimethyl-5-morpholinopent-2-enenitrile. MS (pos. ion) m/z: 625 (M+l ).
Example 31
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile
Figure imgf000087_0002
Step 1
A solution of 2-bromo-2-methyl-propanal (696.6 mg, 4.61 mmol) in DCM (10 mL) was cooled with an ice bath and l -(oxetan-3-yl)piperazine (328 mg, 2.31 mmol), diluted with 5-10 mL of DCM, was slowly added via addition funnel over a 15 min period. Next, Hunig's base (0.4 mL, 2.31 mmol) was added and then the cooling bath was removed. The reaction mixture was stirred at room temperature overnight and the DCM layer was washed three times with 0.5N HC1. The combined aqueous layer was neutralized with NaOH to pH 10-11 and extracted with DCM. The combined organic layer was washed with brine and dried over Na?S04. Filtration and removal of solvent afforded 2-methyl-2-[4-(oxetan-3-yl)piperazin-l- yl]propanal as a light yellow liquid, which was used directly in the next step without further purification.
Step 2
To a cooled (0 °C) solution of 3-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)- pyrazolo[3,4-d]pyrimidin-l-yl]-l-piperidyl]-3-oxo-propanenitrile (80 mg, 0.17 mmol), was added 2-methyl-2-[4-(oxetan-3-yl)piperazin-l-yl]propanal (-108 mg, 0.51 mmol) in DCM (10 mL) followed by pyrrolidine (0.08 mL, 1.02 mmol) and TMS-C1 (0.09 raL, 0.68 mmol.) The ice bath was removed, and the reaction stirred 1 hour. Most of the solvent was removed and the residues were purified by chromatography, using 95:5 CH2Cl2:MeOH to obtain 79 mg of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile as a white solid. MS (pos. ion) m/z: 666 (M+l).
Example 32
Synthesis of (R)-4-(4-acetylpiperazin-l-yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methylpent-2-enenitrile
Figure imgf000088_0001
Proceeding as above in example 31 but substituting l-(piperazin-l-yl)ethanone for 1- (oxetan-3-yl)piperazine in step 1, (R)-4-(4-acetylpiperazin-l -yl)-2-(3-(4-amino-3-(2-fluoro-4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methylpent-2- enenitrile is obtained. MS (pos. ion) m/z: 652 (M+l).
Example 33
Synthesis of (R)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate
Figure imgf000089_0001
Proceeding as above in example 31 but substituting methyl piperazine-l-carboxylate for l-(oxetan-3-yl)piperazine in step 1, (R)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4- phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5- oxopent-3-en-2-yl)piperazine-l-carboxylate is obtained. MS (pos. ion) m/z: 668 (M+l ).
Example 34
Synthesis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4- -ethyl-3-oxopiperazin- 1 -yl)-4-methylpent-2-enenitrile
Figure imgf000089_0002
Step 1
To a slurry of tert-butyl 3-oxopiperazine-l-carboxylate (10 g, 49.9 mmol ) in 250 mL of DMF, NaH (60% in mineral oil) (2.1 g, 52.4 mmol ) was added in portions. The mixture was stirred for 15 min after completion of addition, cooled to 0 °C and iodoethane (5.62 mL, 69.92 mmol ) slowly added over ~3 min. The resultant suspension was stirred at rt for 2h. Water was slowly added (400 mL) and then 250 mL of 1 : 1 ethyl acetate: diethyl ether. The layers were separated and then the organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated to afford tert-butyl 4-ethyl-3-oxopiperazine-l-carboxylate as a colorless oil weighing 6.4 g which was used directly in the next step.
Step 2
To a solution of tert-butyl 4-ethyl-3-oxo-piperazine-l-carboxylate (4.5 g, 19.9 mmol ) in 1,4-Dioxane (10 mL) was added 10 mL of 4.0 M HCl/dioxane. After stirring lh at rt, an additional 5 mL of HC1 in dioxane was added and a few mL of MeOH. The reaction was stirred another hour and then concentrated under reduced pressure. Dichloromethane was added and solvent removed to obtain the product as a foam weighing 2.2 g. This was partitioned between dichloromethane and aqueous sodium carbonate. The organic phase was washed with water, dried over sodium sulfate, filtered and concentrated to afford 1- ethylpiperazin-2-one as a foam.
Step 3 and 4
Proceeding as in example 31 but substituting 1 -ethylpiperazin-2-one for l-(oxetan-3- yl)piperazine in step 1, (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-(4-ethyl-3-oxopiperazin- 1 -yl)-4-methylpent-2- enenitrile is obtained. MS (pos. ion) m/z: 652 (M+l).
Example 35
esis of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin 1 -yl)piperidine- 1 -carbonyl)- -methyl-4-(3-oxopiperazin- 1 -yl)pent-2-enenitrile
Figure imgf000090_0001
Proceeding as above in example 31 but substituting piperazin-2-one for l-(oxetan-3 yl)piperazine in step 1, (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(3-oxopiperazin- 1 -yl)pent-2-enenitrile is obtained. MS (pos. ion) m/z: 624 (M+l).
Biological Examples
Example 1
Btk enzymatic activity assay
A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, MA) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μΜ) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μΜ) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated. This value is presented as the IC50. The IC5o for certain compounds of the disclosure are provided below.
Compound in IC50 (μπι) Compound in IC50 (μ ι) Synthetic Synthetic Example #
Example #
1 0.0031 9 0.0047
2 0.0041 10 0.0021
3 0.0081 1 1 0.0161
4 0.0003 12 0.004
5 0.0019 13 0.0006
6 0.0004 14 0.0204
7 0.0009 15 0.0041
8 0.0038 18 0.0007
19 0.0015 8A 0.0009
13a 0.0009 13b 0.026
19a 0.0056 20 0.0009 Compound in IC50 (μιη) Compound in IC50 (μτη)
Synthetic Synthetic Example #
Example #
21 0.0007 22 0.0006
23 0.001 24 0.0012
25 0.0014 30 0.0052
31 0.0015 33 0.0020
32 0.0019 34 0.0013
35 0.0013
Example 2
Measurement of BTK engagement in human Ramos B cell line The potency of compounds for inhibition of BTK activity can be assessed by binding of compounds to the target in human Ramos B cells that contain BTK. The extent of BTK occupancy is measured after treating the cells with compounds and detecting unoccupied BTK through binding of N-(2-(4-((E)-4-((R)-3-(4-amino-3-(4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-oxobut-2-en- 1 -yl)piperazin- 1 -yl)ethyl)-6-(6- (5-(2-oxohexahydro-lH-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanamido)hexanamide as the probe.
Briefly, Ramos cells were added to 96 well plates at a density of 106 cells per well. Serial dilutions of the compounds to be tested for potency were added such the final concentrations started at 1 μΜ and were serieally diluted 3 fold for a total of 8 serial dilutions. The final DMSO concentration was 0.09% in each well. The compounds were allowed to interact with the cells for 1 hr. A BTK selective probe was then added to each well for a final concentration of 330 nM. Treatment with the probe was for 1 hr. The cells were then collected centrifugation and lysed for 15 - 30 minutes on ice. The binding of the probe to BTK was then detected by Alphascreen (Perkin Elmer) using a kit for the specific label on the BTK probe.The percent occupancy of BTK at each compound concentration was then calculated based on detection of unoccupied BTK bound by the labeled probe. BTK occupancy was then plotted as a function of the log of the compound concentration and the IC50 values were calculated. The assay to measure BTK occupancy was modified to measure the durability of BTK binding in cells by removing the compound from the culture medium and incubating the cells for varying time periods followed by measurement of remaining occupancy as described above. For the durability measurements, the range of occupancy for the compounds disclosed herein (except for compounds disclosed in examples nos. 9, 14, 15, 3, 16, 17, 10a, 13b, 30, 22 and 26) after 18 hrs of washout was about 3 - 80%.
Example 3
Blockade of CD69 expression in human whole blood samples Activation of the B cell receptor leads to increased BTK activity, calcium
mobilization and B cell activation (see Honigberg L. A., et. al, Proc Natl Acad Sci U S A. 107: 13075-80. 2010). BTK inhibitors have been shown to block B cell activation as measured by CD69 expression (see Karp, R., et. al, Inhibition of BTK with AVL-292
Translates to Protective Activity in Animal Models of Rheumatoid Arthritis. Inflammation Research Association Meeting, Sept, 2010). CD69 was expressed following B cell activation as a measure of BTK activity in whole blood. Aliquots of whole blood were pre-incubated with serial dilutions of test compound for 30 minutes followed by activation with anti-IgM (goat Fab'2, 50 μg/ml). Samples were incubated overnight at 37° C and then stained with PE labeled anti-CD20 and APC labeled anti-CD69 (BD Pharmingen) for 30 minutes according to the manufacturer's directions. Whole blood was then lysed and cells gated on CD20 expression were quantified for CD 69 expression by FACS. The percent inhibition was calculated based on a DMSO control for no inhibition and plotted as a function of test compound concentration from which an IC50 value was calculated. The range of IC50 values for the compounds disclosed herein (except for compounds disclosed in examples nos. 2, 5, 17, 13b, 30, and 22),was about 1.4 - 0.08 μΜ.
Example 4
Inhibition of mouse collagen-induced arthritis
Inhibition of murine collagen-induced arthritis (mCIA) is a standard animal disease model for rheumatoid arthritis. Previous studies have demonstrated that inhibition of BTK is efficacious in blocking mCIA (see Honigberg L.A., et. al., Proc Natl Acad Sci U S A.
107: 13075-80. 2010). Starting on day 0 DBA/1 mice are injected with an emulsion of Type II collagen in Complete Freund's Adjuvant. Mice are boosted 21 days later to synchronize development of disease. After development of mild disease, animals are enrolled in the study and randomized. Dosing is oral, Q.D. typically for 1 1 days with test compound or dexamethasone (0.2 mg/kg) as control. One group receives vehicle alone. Clinical scoring (0 - 4) is based on the extent of swelling and severity of arthritis. Scores for all four paws are added for maximum score of 16. Anti-collagen antibodies and total Ig are measured for each animal by Elisa at the end of the study (Bolder BioPath, Boulder, CO). Example 5
Recovery of kinase activity upon dialysis to evaluate irreversible vs reversible covalent binding
A compound and/or pharmaceutically acceptable salt of the present disclosure at a concentration 10 times greater than its IC50 value was added to a solution of protein kinase (5 nM) in a buffer containing 20 mM Hepes [pH 7.5], 5 mM MgCl2, 0.01 % Triton X-100, and 1 mM dithiothreitol. After 60 min at 22° C, the reactions were transferred to a dialysis cassette (0.1-0.5 mL Slide- A-Lyzer, MWCO 10 kDa, Pierce) and dialyzed against 1 L of buffer (20 mM Hepes [pH 7.5], 5 mM MgCl2, 0.01 % Triton X-100, and 1 mM dithiothreitol.) at 22° C. The dialysis buffer was exchanged twice per day until the end of the experiment. Aliquots were removed from the dialysis cassettes every 24 h and analyzed for protein kinase activity. Kinase activity for each sample was normalized to the DMSO control for that time point and expressed as the mean ± SD.
Results: Kinase activity recoverd from inhibition by compounds of the present disclosure upon dialysis. Upon extensive dialysis at room temperature, kinase activity partially or completely recovered in a time-dependent manner from inhibition by an excess of compounds of the present disclosure.
Example 6
Mass spectral analysis
A protein kinase that is inhibited by compound and/or pharmaceutically acceptable salt of the present disclosure may be subjected to mass spectral analysis to assess the formation of permanent, irreversible covalent adducts. Suitable analytical methods to examine intact full protein or peptide fragments generated upon tryptic cleavage of the protein kinase are generally known in the art. Such methods identify permanent, irreversible covalent protein adducts by observing a mass peak that corresponds to the mass of a control sample plus the mass of an irreversible adduct. Two such methods are described below. Mass spectral analysis of intact full kinase
Method: A protein kinase (5 μΜ) is incubated with a compound of the present disclosure (25 μΜ, 5 equiv) for 1 h at room temperature in buffer (20 mM Hepes [pH 8.0], 100 mM NaCl, 10 mM MgC12). A control sample isalso prepared which does not have a compound of the present disclosure. The reaction isstopped by adding an equal volume of 0.4% formic acid, and the samples are analyzed by liquid chromatography (Microtrap CI 8 Protein column [Michrom Bioresources], 5% MeCN, 0.2% formic acid, 0.25 mL/min; eluted with 95% MeCN, 0.2% formic acid) and in-line ESI mass spectrometry (LCT Premier, Waters).
Molecular masses of the protein kinase and any adducts may be determined with MassLynx deconvolution software.
Results: High-resolution intact mass spectrometry analysis of a kinase that is inhibited by a compound of the present disclosure will reveal a spectrum similar to the kinase in the absence of inhibitor (e.g. control sample). There will be no formation of a new peak in the mass spectrum corresponding to the molecular mass of the kinase plus the molecular mass of the compound of Formula I. On the basis of this experiment, as can be applied to a compound and/or pharmaceutically acceptable salt as disclosed herein, no permanent, irreversible protein adduct will be apparent to one skilled in the art.
Mass spectral analysis of kinase tryptic digest
Method:
A protein (10-100 pmols) is incubated with a compound and/or pharmaceutically acceptable salt of the present disclosure (100-1000 pmols, 10 equiv) for 3h prior to tryptic digestion. Iodoacetamide may be used as the alkylating agent after compound incubation. A control sample isalso prepared which does not utilize the compound and/or pharmaceutically acceptable salt of the present disclosure. For tryptic digests a 1 μΐ aliquot (3.3 pmols) ise diluted with 10 μΐ of 0.1 % TFA prior to micro C 18 Zip Tipping directly onto the M ALDI target using alpha cyano-4-hydroxy cinnamic acid as the desorption matrix (5mg/mol in 0.1% TFA:Acetonitrile 50:50) or Sinapinic acid as the desorption matrix (lOmg/mol in 0.1% TFA:Acetonitrile 50:50).
Results: High-resolution mass spectrometry analysis of the tryptic fragments of a kinase that is inhibited by a compound and/or pharmaceutically acceptable salt of the present disclosure will reveal a spectrum similar to the kinase in the absence of inhibitor (e.g. control sample). There will be no evidence of any modified peptides that are not present in the control sample. On the basis of this experiment, no permanent, irreversible protein adducts will be apparent to one skilled in the art.
Cellular assays are also optionally used to assess the inhibiting properties of a compound of the present disclosure . Cellular assays include cells from any appropriate source, including plant and animal cells (such as mammalian cells). The cellular assays are also optionally conducted in human cells. Cellular assays of BTK inhibition are well known in the art, and include methods in which an inhibitor is delivered into the cell (e.g. by electroporation, passive diffusion, microinjection and the like) and an activity endpoint is measured, such as the amount of phosphorylation of a cellular substrate, the amount of expression of a cellular protein, or some other change in the cellular phenotype known to be affected by the catalytic activity of BTK. For example, phosphorylation of a particular cellular substrate is optionally assessed using a detection antibody specific or the
phosphorylated cellular substrate followed by western blotting techniques and visualization using any appropriate means (e.g. fluorescent detection of a fluorescently labeled antibody).
Measuring the reduction in the BTK catalytic activity in the presence of the present disclosure relative to the activity in the absence of the present disclosure is optionally performed using a variety of methods known in the art, such as the assays described in the Examples section below. Other methods for assaying BTK activity are known in the art. Example 7
Determination of Drug-Kinase Residence time
The following is a protocol that can be used to distinguish whether a compound displays a slow or non-existent dissociation rate from BTK, such as typically would occur if a covalent bond is formed between the compound and the target. The read-out for slow dissociation is the ability of the compound of interest to block binding of a high affinity fluorescent tracer molecule to the kinase active site, as detected using time-resolved fluorescence resonance energy transfer (TR-FRET). The experiment was conducted in a buffer consisting of 50 mM Hepes pH 7.5, 10 mM MgCl2, 0.01 % Triton X-100, and 1 mM EGTA.
The first step of the procedure was incubation of 500 nM BTK (Invitrogen Cat.
#PV3587) with 1.5 μΜ of a compound of the present disclosure for 30 minutes in a volume of 10 μί. The mixture was then diluted 5-fold by addition of 40 μί of buffer. A lO L volume of the diluted kinase/compound solution was then added to a well of a small volume 384 well plate (such as Greiner Cat. #784076). In order to probe for reversibility of the kinase-compound binding interaction, a competition solution containing both a high affinity fluorescent tracer and an antibody coupled to Europium was prepared. For BT , the competition solution contained 1.5 μΜ Tracer 178 (Invitrogen Cat. #PV5593), which is a proprietary high affinity ligand for BTK coupled to the fluorophore AlexaFluor 647. The competition solution also contained 80 nM of an Anti-polyhistidine antibody coupled to Europium (Invitrogen Cat. #PV5596) which is designed to bind the polyhistidine purification tag in BTK.
After addition of 10 of the competition solution to the Greiner plate, the mixture was incubated for one hour or greater to allow time for dissociation of non-covalent inhibitors and binding of the high affinity tracer. It is to be expected that covalent and slow
dissociating inhibitors will block binding of the tracer while rapidly dissociating non-covalent inhibitors will not. Binding of the tracer to BTK is detected using TR-FRET between the Europium moiety of the Anti-histidine antibody and the AlexaFluor 647 group of Tracer 178. Binding was evaluated using a Perkin Elmer Envision instrument (Model 2101) equipped with filters and mirrors compatible with LA CE-type TR-FRET experiments. Data were plotted at percentage of signal obtained in the absence of competitor compound. The background signal was obtained by omission of BTK from the reaction. If the compound is an irreversible covalent inhibitor, tracer will be completely blocked from binding to the target throughout the entire course of the experiment. If the compound is a reversible covalent inhibitor, the tracer will bind the target as the compound dissociates from the target.
Example 8
Reversibility of Binding
The following approach was developed to differentiate compounds that form irreversible covalent bond with their targets, such as non-cyano containing acrylamide compounds, from compound that form reversible covalent bond i.e., compounds and/or pharmaceutically acceptable salts of the present disclosure. Reactions were prepared with the protein target at a higher concentration than the compounds of interest. Both irreversible and reversible covalent compounds bound the target and became depleted from solution. The reactions were then treated with perturbations including both denaturation with 5 M guanidine hydrochloride and digestion with trypsin, disrupting proper folding of the target. It was found that the perturbation returned reversible covalent compounds to solution due to dissociation from the target while irreversible covalent compounds remained bound to the target. The concentration of compound in solution was assessed both preceding and following perturbation using high performance liquid chromatography (HPLC) coupled to tandem mass spectrometry. Using this technique, it was demonstrated that irreversible covalent compound is depleted from solution in both the native and perturbed state, while compounds and/or pharmaceutically acceptable salts disclosed herein were depleted in the folded state but returned to solution following perturbation of the target evidencing that compounds and/or pharmaceutically acceptable salts disclosed herein form reversible covalent bond.
Figure imgf000098_0001
Formulation Examples
The following are representative pharmaceutical formulations containing a compound disclosed herein.
Parenteral Composition
To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound disclosed herein is dissolved in 2% HPMC, 1 % Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL. The mixture is incorporated into a dosage unit form suitable for administration by injection.
Oral Composition
To prepare a pharmaceutical composition for oral delivery, 400 mg of a compound disclosed herein and the following ingredients are mixed intimately and pressed into single scored tablets. Tablet Formulation
The following ingredients are mixed intimately and pressed into single scored tablets.
Ingredient Quantity per tablet
mg compound of this disclosure 400 cornstarch 50 croscarmellose sodium 25 lactose 120
magnesium stearate 5
Capsule Formulation
The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
Ingredient Quantity per capsule
mg compound of this disclosure 200 lactose spray dried 148
magnesium stearate 2 Inhalation Composition
To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
Topical Gel Composition
To prepare a pharmaceutical topical gel composition, 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropyl celluose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topical
administration. Ophthalmic Solution Composition
To prepare a pharmaceutical opthalmic solution composition, 100 mg of a compound disclosed herein is mixed with 0.9 g of NaCI in 100 mL of purified water and filterd using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.
Nasal spray solution
To prepare a pharmaceutical nasal spray solution, 10 g of a compound disclosed herein is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 μΐ of spray for each application.

Claims

What is Claimed:
1. A compound of Formula (IA):
Figure imgf000101_0001
(a) -C(CH3)2-(4-R4-piperazin-l -yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, cycloalkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(c) -C(CH3)2-NRboxetan-3-yl where R is hydrogen, alkyl, alkoxyalkyl, or cycloalkyl;
(d) -C(CH3)2-RC where Rc is
Figure imgf000101_0002
where one or two of X1, X2 and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4-yl; or and/or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 and/or a pharmaceutically acceptable salt thereof wherein
Rc is:
-C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4- ethylpiperazin-l-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-N(CH2CH3)oxetan-3-yl, - C(CH3)2-N(cyclopropyl)-oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, -C(CH3)2-2-oxa-6- azaspiro[3.3]heptan-6-yl, -C(CH3)2-CH2morpholine-4-yl, -C(CH3)2-(4-methylsulfonyl- piperazin-l-yl), -C(CH3)2-(3-oxo-4-methylpiperazin-l-yl), -C(CH3)2-[4-(2-methoxyethyl)- piperazin-l-yl], -C(CH3)2-(4-tert-butylpiperazin- 1 -yl), -C(CH3)2-(4-acetylpiperazin-l -yl), - C(CH3)2-(4-2,2,2-trifluoroethyl -piperazin- 1 -yl),-C(CH3)2-(4-isopropylpiperazin- 1 -yl), - C(CH3)2-(2,5-dimethyl-piperazin-l -yl), -C(CH3)2-(3,5-dimethylpiperazin-l-yl), -C(CH3)2- (3,4,5-trimethylpiperazin-l -yl), -C(CH3)2-(2,4,5-trimethylpiperazin- l-yl), -C(CH3)2-(4- oxetan-3-ylpiperazin- 1 -yl), -C(CH3)2-(4-methoxycarbonylpiperazin- 1 -yl), -C(CH3)2-(3,5- dimethylpiperazin- 1 -yl),
Figure imgf000102_0001
3. The compound of Claim 1 and/or a pharmaceutically acceptable salt thereof wherein R° is -C(CH3)2-(3-oxo-4-methylpiperazin-l -yl), -C(CH3)2-[4-(2-methoxyethyl)-piperazin-l- yl], -C(CH3)2-(4-tert-butylpiperazin-l -yl), -C(CH3)2-(4-isopropylpiperazin-l-yl), -C(CH3)2- (2,5-dimethyl-piperazin- 1 -yl), -C(CH3)2-(3,5-dimethylpiperazin- 1 -yl), -C(CH3)2-(3,4,5- trimethylpiperazin- 1 -yl), -C(CH3)2-(2,4,5-trimethylpiperazin- 1 -yl), -C(CH3)2-(4-oxetan-3- ylpiperazin-l-yl), -C(CH3)2-(4-methoxycarbonylpiperazin-l-yl), -C(CH3)2-(3,5-
Figure imgf000102_0002
4. The compound of Claim 1 and/or a pharmaceutically acceptable salt thereof wherein
Rc is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l-yl), -C(CH3)2-(4- ethylpiperazin-l-yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2-N(CH2CH3)oxetan-3-yl, -C(CH3)2-N(cyclopropyl)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, or -C(CH3)2-2-oxa-6- azaspiro[3.3]heptan-6-yl.
5. The compound of Claim 1 and/or a pharmaceutically acceptable salt thereof wherein the compound is chosen from: 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyljpyrrolidine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine- 1 -carbonyl] -4-methyl-4-piperazin- 1 -yl-pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine- 1 -carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l -yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l -yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl] -piperidin- 1 -yl] carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; (S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)methyl)pyrrolidine- 1 -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- raethyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2- [ [(3R)-3- [4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d] -pyrimidin- 1 - yl]-piperidin-l -yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-isopropylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-isopropylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3 -(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-raethylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-((R)-hexahydropyrazino[2, 1 -c] [ 1 ,4] oxazin-8 ( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((R)-hexahydropyrazino[2, 1 -c] [ 1 ,4]oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino [2, 1 -c] [ 1 ,4] oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino [2, 1 -c] [ 1 ,4] oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((3S ,5R)-3 ,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- l-carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin-l -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((2R,5S)-2,5-dimethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-((2R,5S)-2,5-dimethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-((2S,5R)-2,4,5-trimethylpiperazin-l-yl)pent-2- enenitrile; 2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l -carbonyl)-4-methyl-4-((2S,5R)-2,4,5-trimethylpiperazin-l-yl)pent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-(5,6-dihydroimidazo[ 1 ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(5,6-dihydroimidazo[ 1 ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(methylsulfonyl)piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l -carbonyl)-4-methyl-4-(4-(methylsulfonyl)piperazin-l-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2-enenitrile;
(R)-4-(4-acetylpiperazin- 1 -yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-methylpent-2-enenitrile;
(S)-4-(4-acetylpiperazin- 1 -yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l -carbonyl)-4-methylpent-2-enenitrile;
(R)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(S)-raethyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l -carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
or a mixture of R and S isomers thereof; or
an (E) or (Z) isomer of any of the above compounds.
6. An E isomer of any of:
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2- [(2R)-2- [ [4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3 ,4-d]pyrimidin- 1 - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2- [(3R)-3- [4-amino-3 -(2-fluoro-4-phenoxy-phenyl)pyrazolo [3 ,4-d]pyrimidin- 1 - yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l -carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2- [ [(3R)-3- [4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d] -pyrimidin- 1 - yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2- [ [(3S)-3- [4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d] -pyrimidin- 1 - yl] -piperidin- 1 -yl] carbonyl]-4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile ;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; (S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(S)-2-(2-((4-araino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-raethyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l -yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine- 1 -carbonyl] -4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l - yl]-piperidin- 1 -yl]carbonyl]-4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)raethyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(4-isopropylpiperazin-l-yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-araino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-(4-isopropylpiperazin- 1 -yl)-4-methylpent-2-enenitrile ;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-araino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((R)-hexahydropyrazino[2,l-c] [l ,4]oxazin-8(lH)-yl)-4- methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((R)-hexahydropyrazino[2, 1 -c] [ 1 ,4]oxazin-8( 1 H)-yl)-4- methylpent-2-enenitri le ;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino [2, 1 -c] [ 1 ,4] oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino[2, 1 -c] [ 1 ,4]oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- 1 -carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l -carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin-l -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-((2R,5S)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin- l - yl)piperidine-l-carbonyl)-4-((2R,5S)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2S,5R)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile; 2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2S,5R)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(5,6-dihydroimidazo[ 1 ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbon yl)-4-(5,6-dihydroimidazo[ 1 ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(methylsulfonyl)piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(4-(methylsulfonyl)piperazin-l-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- l -carbonyl)-4-rnethyl-4-(4-rnethyl-3-oxopiperazin-l-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-raethyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2-enenitrile;
(R)-4-(4-acetylpiperazin- 1 -yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H- pyrazolo[3,4-d]pyrirnidin-l-yl)piperidine-l-carbonyl)-4-methylpent-2-enenitrile;
(S)-4-(4-acetylpiperazin-l-yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-methylpent-2-enenitrile;
(R)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(S)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyriraidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyriraidin-l- yl)piperidine-l-carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
and/or of any pharmaceutically acceptable salt thereof.
7 .A Z isomer of any of: 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl]pyrrolidine- 1 -carbonyl] -4-methyl-4-piperazin- 1 -yl-pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l -carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-t(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l -carbonyl]-4-raethyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl] -piperidin- 1 -yl]carbonyl] -4-methyl -4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; (S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]pyrimidin-l - yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine- 1 -carbonyl] -4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile ;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2- [ [(3R)-3- [4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d] -pyrimidin- 1 - yl]-piperidin- 1 -yl]carbonyl]-4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l -yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-raethyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(4-isopropylpiperazin-l -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-isopropylpiperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(4-(tert-butyl)piperazin-l -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(tert-butyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-p enoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrirnidin-l - yl)piperidine- 1 -carbonyl)-4-(4-(2-methoxyethyl)piperazin- 1 -yl)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((R)-hexahydropyrazino [2, 1 -c] [ 1 ,4] oxazin-8 ( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((R)-hexahydropyrazino[2, 1 -c] [ 1 ,4]oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino[2, 1 -c] [ 1 ,4]oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-((S)-hexahydropyrazino [2, 1 -c] [ 1 ,4] oxazin-8( 1 H)-yl)-4- methylpent-2-enenitrile; (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(2,2,2-trifluoroethyl)piperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-raethyl-4-((3S,5R)-3,4,5-trimethylpiperazin-l-yl)pent-2- enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-((3S,5R)-3,4,5-trimethylpiperazin-l-yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-((3S,5R)-3,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((2R,5S)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((2R,5S)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3 -(4-amino-3 -(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3 ,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin-l-yl)pent-2- enenitrile;
2-((S)-3-(4-araino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-((2R,5S)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-((2S,5R)-2,5-dimethylpiperazin-l-yl)-4-methylpent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-((2S,5R)-2,4,5-trimethylpiperazin-l-yl)pent-2- enenitrile; 2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-raethyl-4-((2S,5R)-2,4,5-trimethylpiperazin- 1 -yl)pent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(5,6-dihydroimidazo[l ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-(5,6-dihydroimidazo[ 1 ,2-a]pyrazin-7(8H)-yl)-4-methylpent-2- enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3',4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(4-(methylsulfonyl)piperazin-l-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(4-(rnethylsulfonyl)piperazin-l-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-methyl-3-oxopiperazin- 1 -yl)pent-2-enenitrile;
(R)-4-(4-acetylpiperazin- 1 -yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-methylpent-2-enenitrile;
(S)-4-(4-acetylpiperazin- 1 -yl)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l -carbonyl)-4-methylpent-2-enenitrile;
(R)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(S)-methyl 4-(5-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- djpyrimidin- 1 -yl)piperidin- 1 -yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)piperazine- 1 - carboxylate;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4,4-dimethyl-5-morpholinopent-2-enenitrile;
and/or of any pharmaceutically acceptable salt thereof.
8. The compound of Claim 5 and/or a pharmaceutically acceptable salt thereof wherein the compound is chosen from:
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l -yl)pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine- 1 -carbonyl]-4-methyl-4-piperazin- 1 -yl-pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile; 2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin- 1 -yl]-piperidin- 1 -yl]carbonyl]-4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-((RS)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(piperazin-l-yl)pent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyriraidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-(ethyl(oxetan-3-yl)araino)-4-methylpent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile; (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyljpyrrolidine- 1 -carbonyl]-4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l -yl)pent-2-enenitrile;
2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]-pyrimidin- l-yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l - yl] -piperidin- 1 -yl] carbonyl] -4-methyl-4-(4-ethylpiperazin- 1 -yl)pent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(oxetan-3-yl)arainopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile; (RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l -carbonyl)-4-(cyclopropyl(oxetan-3-yl)arnino)-4-methylpent-2-enenitrile; (S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; or an (E) or (Z) isomer of any of the above compounds.
9. An E isomer of any of:
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l -yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-methylpiperazin-l -yl)pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l -yl-pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l - yl]methyl]pyrrolidine- 1 -carbonyl]-4-methyl-4-piperazin- 1 -yl-pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2- [(2R)-2- [ [4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo [3 ,4-d]pyrimidin- 1 - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile; 2-[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l -carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin- l-yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl] -piperidin- 1 -yl] carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-((RS)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine- 1 -carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-raethyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile; (S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l -carbonyl]-4-raethyl-4-(4-ethylpiperazin-l -yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- raethyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l -yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l -yl]- methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyriraidin- l-yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile; (RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)raethyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; and/or a pharmaceutically acceptable salt of any of the foregoing.
10. A Z isomer of any of:
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyljpyrrolidine- 1 -carbonyl]-4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2- [(2R)-2- [ [4-amino-3-(2-fluoro-4-phenoxypheny l)pyrazolo [3,4-d]pyrimidin- 1 -yl] - methyl]pyrrolidine- 1 -carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine- 1 -carbonyl]-4-methyl-4-piperazin- 1 -yl-pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-piperazin-l-yl-pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin- 1 - yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile; 2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]methyl]pyrrolidine-l -carbonyl]-4-methyl-4-(oxetan-3-ylamino)pent-2-enenitrile;
2-[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-raethyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l- yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2-enenitrile;
2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin- l -yl]-piperidin-l -yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l - yl] -piperidin- 1 -yl]carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2-enenitrile ;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l-yl)pent-2-enenitrile;
2-((RS)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
2-((S)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine- 1 -carbonyl)-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine- 1 -carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(ethyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; (RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l -carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-l H-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(ethyl(oxetan-3-yl)amino)pent-2-enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- l -carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyriraidin- 1 - yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l-carbonyl)-4-methyl-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pent-2- enenitrile;
2-[(2RS)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-rnethyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-l-yl]- methyl]pyrrolidine-l-carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3RS)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin- 1 -yl]-piperidin- 1 -yl]carbonyl]-4-methyl-4-(4-ethylpiperazin- l-yl)pent-2-enenitrile;
2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrirnidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile;
2-[[(3S)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l- yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(4-ethylpiperazin-l-yl)pent-2-enenitrile; (RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)piperidine-l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(R)-2-(3 -(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo [3 ,4-d]pyrimidin- 1 - yl)piperidine- l-carbonyl)-4-methyl-4-(oxetan-3-yl)aminopent-2-enenitrile;
(RS)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l- yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l -carbonyl)-4-(cyclopropyl(oxetan-3-yl)araino)-4-methylpent-2- enenitrile;
(S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)methyl)pyrrolidine-l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2- enenitrile;
(RS)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l - yl)piperidine- l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile;
(S)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 - yl)piperidine- l-carbonyl)-4-(cyclopropyl(oxetan-3-yl)amino)-4-methylpent-2-enenitrile; and/or a pharmaceutically acceptable salt of any of the foregoing.
1 1. A compound chosen from 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4- [methyl(oxetan-3-yl)amino]pent-2-enenitrile, or an (E) or (Z) isomer thereof, and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
12. An E isomer of 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3- yl)amino]pent-2-enenitrile and/or a pharmaceutically acceptable salt thereof.
13. A Z isomer of 2-[(2S)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]methyl]pyrrolidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3- yl)amino]pent-2-enenitrile and/or a pharmaceutically acceptable salt thereof.
14. A compound chosen from 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3- yl)amino]pent-2-enenitrile, or an (E) or (Z) isomer thereof, and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
15. An E isomer of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2- enenitrile and/or a pharmaceutically acceptable salt thereof.
16. A Z isomer of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[methyl(oxetan-3-yl)amino]pent-2- enenitrile and/or a pharmaceutically acceptable salt thereof.
17. A compound chosen from 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo [3,4-d] -pyrimidin- 1 -yl] -piperidin- 1 -yl] carbonyl] -4-methyl-4-(4-methylpiperazin- 1 - yl)pent-2-enenitrile, or an (E) or (Z) isomer, and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
18. An E isomer of 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d] -pyrimidin- 1 -yl] -piperidin- 1 -yl] carbonyl] -4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2- enenitrile and/or a pharmaceutically acceptable salt thereof.
19. A Z isomer of 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]-pyrimidin- 1 -yl] -piperidin- 1 -yl]carbonyl]-4-methyl-4-(4-methylpiperazin- 1 -yl)pent-2- enenitrile and/or a pharmaceutically acceptable salt thereof. 20. A compound chosen from 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4-d]-pyrimidin-l-yl]- piperidin-l-yl]carbonyl]-4-methyl-4-(piperazin-l -yl)pent-2-enenitrile, or an (E) or (Z) isomer, and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
21. An E isomer of 2-[[(3R)-3-[4-amino-3-(2-fIuoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]-pyrimidin- 1 -yl] -piperidin- 1 -yl]carbonyl]-4-methyl-4-(piperazin- 1 -yl)pent-2-enenitrile and/or a pharmaceutically acceptable salt thereof.
22. A Z isomer of 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]-pyrimidin-l-yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(piperazin-l-yl)pent-2-enenitrile and/or a pharmaceutically acceptable salt thereof.
23. A compound chosen from (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- l-yl)pent-2-enenitrile; or an (E) or (Z) isomer, and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
24. An E isomer of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2- enenitrile and/or a pharmaceutically acceptable salt thereof.
25. A Z isomer of (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH-pyrazolo[3,4- d]pyrimidin- 1 -yl)piperidine- 1 -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- 1 -yl)pent-2- enenitrile and/or a pharmaceutically acceptable salt thereof.
26. A compound chosen from (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]pyrimidin-l-yl)piperidine-l -carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin- l-yl)pent-2-enenitrileand/or a pharmaceutically acceptable salt of any of the foregoing compounds.
27. A compound chosen from 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]-pyrimidin-l-yl]-piperidin-l -yl]carbonyl]-4-methyl-4-(4-methylpiperazin-l- yl)pent-2-enenitrile and/or a pharmaceutically acceptable salt of any of the foregoing compounds.
28. A compound chosen from 2-[[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-lH- pyrazolo[3,4-d]-pyrimidin-l-yl]-piperidin-l-yl]carbonyl]-4-methyl-4-(piperazin-l-yl)pent-2- enenitrile and/or a pharmaceutically acceptable salt of any of the foregoing compounds. 29. A pharmaceutical composition comprising a compound and/or a pharmaceutically acceptable salt of any one of Claims 1 to 28 of any of the foregoing compounds, and a pharmaceutically acceptable excipient.
30. A method of treating a disease treatable by inhibition of a tyrosine kinase in a patient which method comprises administering to the patient in recognized need of such treatment, a pharmaceutical composition comprising a compound, or an (E) or (Z) isomer thereof, and/or pharmaceutically acceptable salt of any of Claims 1 to 28 and a pharmaceutically acceptable excipient in a therapeutically effective amount.
31. The method of claim 30 wherein the tyrosine kinase is BTK.
32. The method of Claim 31 wherein the disease is chosen from autoimmune diseases, inflammatory diseases, and cancers.
33. The method of Claim 31 wherein the disease is chosen from rheumatoid arthritis, psoriatic arthritis, lupus, uveitis, myasthenia gravis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, Sjogren's disease, Sjogren's dry eye, non-Sjogren's dry eye disease, psoriasis, and asthma.
34. The method of Claim 31 wherein the disease is chosen from B-cell proliferative disorders.
35. The method of Claim 34 wherein the proliferative disorders are chosen from diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplamascytic
lymphomaAValdenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt
lymphoma/leukemia, and lymphomatoid granulomatosis.
36. The method of Claim 34 or 35 wherein the compound amd/or pharmaceutically acceptable salt is administered in combination with one or more anti-cancer or antiinflammatory agents.
37. The compound of any one of Claims 1 to 28 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease mediated by a tyrosine kinase.
38. The use of Claim 37 wherein the tyrosine kinase is BTK.
39. The use of Claim 38 wherein the disease is chosen from autoimmune diseases, inflammatory diseases, and cancers.
40. The use of Claim 39 wherein the disease is chosen from rheumatoid arthritis, psoriatic arthritis, lupus, uveitis, myasthenia gravis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, Sjogren's disease, Sjogren's dry eye, non-Sjogren's dry eye disease, psoriasis, and asthma.
41. The use of Claim 38 wherein the disease is chosen from B-cell proliferative disorders.
42. The use of Claim 41 wherein the proliferative disorders are chosen from diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplamascytic lymphomaAValdenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, and lymphomatoid granulomatosis.
43. The use of claim 41 or 42 wherein the compound or pharmaceutically acceptable salt is administered in combination with one or more anti-cancer or anti-inflammatory agents. 44. The compound of any one of Claims 1 to 28 or a pharmaceutically acceptable salt thereof for use as a medicament.
45. A process of preparing a compound of Formula (IA):
Figure imgf000131_0001
(IA)
where:
Figure imgf000131_0002
(a) -C(CH3)2-(4-R4-piperazin-l-yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
(b) -C(CH3)2-(3-oxo-4-Ra-piperazin-l-yl) where Ra is hydrogen, alkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl;
-C(CH3)2-NRboxetan-3-yl where Rb is hydrogen, alkyl, or cycloalkyl;
Figure imgf000131_0003
and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with two substituents independently selected from alkyl, haloalkyl, or halo; or (e) -C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or -C(CH3)2-CH2morpholine-4- yl; ((in one embodiment Rc is -C(CH3)2-(piperazin-l-yl), -C(CH3)2-(4-methylpiperazin-l- yl), -C(CH3)2-(4-ethylpiperazin-l -yl), -C(CH3)2-N(CH3)oxetan-3-yl, -C(CH3)2- N(CH2CH3)oxetan-3-yl, -C(CH3)2-NHoxetan-3-yl, or -C(CH3)2-2-oxa-6- azaspiro[3.3]heptan-6-yl); and/or
a pharmaceutically salt thereof;
comprising:
(a) reacting a compound
Figure imgf000132_0001
(1 )
-Z- is as defined above;
with an aldehyde of formula ReCHO where Rc is as defined above;
(b) reacting a compound of formula (2):
Figure imgf000132_0002
(2)
where:
-Z- is as defined above;
with a compound of formula RcCH=C(CN)C02H or RcCH=C(CN)COX (where Rc is as defined above and X is a leaving group capable of being displaced by the nitrogen atom of the Z group under amide coupling reaction conditions;
(c) optionally making an acid addition salt of a compound obtained from Steps (a) or (b) above; (d) optionally making a free base of a compound obtained from Steps (a), (b), or (c) above;
(e) optionally separating individual stereoisomers of the compounds obtained from Steps (a), (b), (c), or (d) above; and
(f) optionally separating individual (E) and (Z) isomers of the compounds obtained from Steps (a), (b), (c), (d), or (e) above.
46. The process of Claim 45 wherein Z
Figure imgf000133_0001
C(CH3)2-(4-methylpiperazin-l-yl).
47. The process of Claim 45 wherein Z is
Figure imgf000133_0002
or and R is -C(CH3)2
(piperazin-l-yl).
48. The process of Claim 45 wherein Z
Figure imgf000133_0003
C(CH3)2-N(CH3)oxetan-3-yl.
The process of Claim 45 wherein Z is
Figure imgf000133_0004
and
C(CH3)2-N(ethyl)piperazin- 1 -yl .
50. The process of Claim 45 wherein Z is
Figure imgf000133_0005
and Rc is
C(CH3)2-4-(oxetan-3-yl)-piperazin- 1 -yl.
PCT/US2013/058614 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors WO2014039899A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
EP13762703.0A EP2892900B1 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
CA2882367A CA2882367C (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
AU2013312296A AU2013312296B2 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
ES13762703.0T ES2644964T3 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
US14/374,788 US9266895B2 (en) 2012-09-10 2013-09-06 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
PL13762703T PL2892900T3 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
BR112015003859-0A BR112015003859B1 (en) 2012-09-10 2013-09-06 COMPOUND AND/OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITION
JP2015531259A JP6203848B2 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
EA201590230A EA027213B9 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
PL17152898T PL3181567T3 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
MX2015002955A MX361815B (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors.
SI201330822T SI2892900T1 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
NZ630925A NZ630925A (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
CN201380046810.4A CN104822681B (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compound as kinase inhibitor
EP17152898.7A EP3181567B1 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
KR1020157008939A KR102203990B1 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
SG11201501815UA SG11201501815UA (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors
US14/464,602 US8940744B2 (en) 2012-09-10 2014-08-20 Pyrazolopyrimidine compounds as kinase inhibitors
IL237285A IL237285B (en) 2012-09-10 2015-02-17 Pyrazolopyrimidine compounds as kinase inhibitors
ZA2015/01615A ZA201501615B (en) 2012-09-10 2015-03-10 Pyrazolopyrimidine compounds as kinase inhibitors
HK16100044.8A HK1211942A1 (en) 2012-09-10 2016-01-05 Pyrazolopyrimidine compounds as kinase inhibitors
US14/997,330 US9994576B2 (en) 2012-09-10 2016-01-15 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
HRP20171601TT HRP20171601T1 (en) 2012-09-10 2017-10-19 Pyrazolopyrimidine compounds as kinase inhibitors
US15/978,041 US10533013B2 (en) 2012-09-10 2018-05-11 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
IL26500719A IL265007B (en) 2012-09-10 2019-02-24 Pyrazolopyrimidine compounds as kinase inhibitors
CY20191100638T CY1122611T1 (en) 2012-09-10 2019-06-19 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
US16/708,340 US11040980B2 (en) 2012-09-10 2019-12-09 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US17/324,674 US20220073522A1 (en) 2012-09-10 2021-05-19 Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors
US18/344,167 US20240174676A1 (en) 2012-09-10 2023-06-29 Pyrazolopyrimidine compounds as kinase Inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261699038P 2012-09-10 2012-09-10
US61/699,038 2012-09-10
US201261728693P 2012-11-20 2012-11-20
US61/728,693 2012-11-20
US201361782605P 2013-03-14 2013-03-14
US61/782,605 2013-03-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/374,788 A-371-Of-International US9266895B2 (en) 2012-09-10 2013-09-06 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US14/464,602 Continuation US8940744B2 (en) 2012-09-10 2014-08-20 Pyrazolopyrimidine compounds as kinase inhibitors
US14/997,330 Continuation US9994576B2 (en) 2012-09-10 2016-01-15 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
WO2014039899A1 true WO2014039899A1 (en) 2014-03-13

Family

ID=49170940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/058614 WO2014039899A1 (en) 2012-09-10 2013-09-06 Pyrazolopyrimidine compounds as kinase inhibitors

Country Status (27)

Country Link
US (7) US9266895B2 (en)
EP (2) EP3181567B1 (en)
JP (1) JP6203848B2 (en)
KR (1) KR102203990B1 (en)
CN (1) CN104822681B (en)
AU (1) AU2013312296B2 (en)
BR (1) BR112015003859B1 (en)
CA (1) CA2882367C (en)
CY (1) CY1122611T1 (en)
DK (1) DK3181567T3 (en)
EA (1) EA027213B9 (en)
ES (2) ES2731833T3 (en)
HK (1) HK1211942A1 (en)
HR (2) HRP20171601T1 (en)
HU (1) HUE044146T2 (en)
IL (2) IL237285B (en)
LT (1) LT3181567T (en)
ME (1) ME03455B (en)
MX (1) MX361815B (en)
NZ (1) NZ630925A (en)
PL (2) PL3181567T3 (en)
PT (2) PT3181567T (en)
RS (1) RS58956B1 (en)
SG (1) SG11201501815UA (en)
SI (2) SI2892900T1 (en)
WO (1) WO2014039899A1 (en)
ZA (1) ZA201501615B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127310A1 (en) * 2014-02-21 2015-08-27 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
CN105017256A (en) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 Polyfluorinated compound Bruton tyrosine kinase inhibitor
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2016105582A1 (en) * 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
WO2016105531A1 (en) * 2014-12-24 2016-06-30 Philip Nunn Site specific dosing of a btk inhibitor
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP2018509458A (en) * 2015-03-27 2018-04-05 ファーマサイクリックス エルエルシー Co-crystals of breton-type tyrosine kinase inhibitors
WO2019208805A1 (en) 2018-04-27 2019-10-31 小野薬品工業株式会社 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
US10533013B2 (en) 2012-09-10 2020-01-14 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US10537587B2 (en) 2015-03-19 2020-01-21 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2020021447A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
JP2020073561A (en) * 2015-06-03 2020-05-14 プリンシピア バイオファーマ インコーポレイテッド Tyrosine kinase inhibitor
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020234715A1 (en) 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
WO2021072095A1 (en) 2019-10-09 2021-04-15 Principia Biopharma Inc. Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021076514A1 (en) 2019-10-14 2021-04-22 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021127231A1 (en) 2019-12-20 2021-06-24 Principia Biopharma Inc. Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021142124A1 (en) * 2020-01-08 2021-07-15 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021216696A1 (en) 2020-04-22 2021-10-28 Principia Biopharma Inc. Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors
WO2022034529A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022221527A1 (en) 2021-04-16 2022-10-20 Principia Biopharma, Inc. Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds
US11622965B2 (en) 2017-10-27 2023-04-11 Zhejiang DTRM Biopharma Co. Ltd. Methods for treating lymphoid malignancies
WO2023244562A1 (en) 2022-06-14 2023-12-21 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1- yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2023249980A1 (en) * 2022-06-22 2023-12-28 Genzyme Corporation Methods of making modified btk inhibitors
US11872229B2 (en) 2016-06-29 2024-01-16 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2024028782A1 (en) 2022-08-03 2024-02-08 Novartis Ag Nlrp3 inflammasome inhibitors
US11969418B2 (en) 2020-01-20 2024-04-30 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (RMS)
WO2024097667A1 (en) 2022-10-31 2024-05-10 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-l-yl]pent-2-enenitrile
WO2024124113A1 (en) 2022-12-09 2024-06-13 Principia Biopharma Inc. Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib
US12049463B2 (en) 2020-12-10 2024-07-30 Genzyme Corporation Crystalline form of Tolebrutinib

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279284A (en) * 2016-08-08 2017-01-04 上海孚璞生物科技有限公司 Three replacement phosphinimine compounds and preparation method thereof, purposes
CN108101905A (en) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 Pyrimido [5,4-b] indolizine or pyrimido [5,4-b] pyrrole biopterin compound, preparation method and the usage
CA3071405A1 (en) * 2017-08-01 2019-02-07 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
KR102653681B1 (en) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 SPRAY-DRIED DISPERSIONS AND FORMULATIONS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUORO PROPAN-2-YL)-lH-PYRAZOLE-4-CARBOXAMIDE

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
WO2008039218A2 (en) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2012158764A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS428308Y1 (en) 1964-09-09 1967-04-27
US4082819A (en) 1977-03-02 1978-04-04 The Standard Oil Company Rubber-modified acrylonitrile-vinyl ether-indene polymers
JPS5617367A (en) 1979-07-23 1981-02-19 Fuji Xerox Co Ltd Magnetic brush developing unit
JPS5663950A (en) 1979-10-30 1981-05-30 Mitsubishi Chem Ind Ltd Cyclopropanecarboxylic ester
FR2535721A1 (en) 1982-11-08 1984-05-11 Sanofi Sa PIPERIDINEDIONE DERIVATIVES OF MYOCARDIAL PROTECTORS WITH ANTIARRHYTHMIC ACTICITY, PROCESS FOR PREPARING THEM AND MEDICAMENTS CONTAINING SAID DERIVATIVES
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
JPS623848A (en) 1985-06-28 1987-01-09 Nippon Steel Corp Studded and flash-welded anchor chain having excellent resistance to fatigue
FR2588189B1 (en) 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
JPH0731201B2 (en) 1987-12-31 1995-04-10 トロピックス・インコーポレーテッド Chemiluminescence measurement method
JP2518353B2 (en) 1988-06-09 1996-07-24 住友化学工業株式会社 Cyanoacetic acid amide derivative and its production intermediate
CA2018801C (en) 1990-06-12 2000-08-22 Pierre Louis Beaulieu Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
JPH04177244A (en) 1990-11-10 1992-06-24 Konica Corp Silver halide photosensitive material
CA2033447C (en) 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH05301838A (en) 1991-10-15 1993-11-16 Mitsubishi Kasei Corp Styrene derivative
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
JPH0827090A (en) 1994-05-13 1996-01-30 Sumitomo Chem Co Ltd Cyanoacetamide derivative, the use thereof and synthetic intermediate
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
BR9808261A (en) 1997-03-14 2000-05-16 Basf Ag Cycloalkylalkanecarboxamide, use of it, process for its preparation, derived from carboxylic acid, composition, and, process to control harmful fungi.
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
IL125947A0 (en) 1997-09-17 1999-04-11 American Cyanamid Co 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
RU2312860C2 (en) 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Cyclic inhibitors of protein-tyrosine kinase
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
MXPA03008560A (en) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Single-stage pfc + ballast control circuit/general purpose power converter.
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
JP3991812B2 (en) 2001-12-11 2007-10-17 住友化学株式会社 Ester compounds and uses thereof
AU2003210983A1 (en) 2002-02-11 2003-09-04 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
NI200300043A (en) 2002-03-28 2003-11-05 Warner Lambert Co AMINO ACIDS WITH AFFINITY FOR THE PROTEIN a2DELTA.
GB0219024D0 (en) 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
BRPI0407618A (en) 2003-02-21 2006-02-21 Pfizer cycloalkyl-substituted amino thiazole derivatives containing n and pharmaceutical compositions for inhibiting cell proliferation and methods for their use
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1648564B1 (en) 2003-08-01 2007-10-17 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-coa decarboxylase inhibitors
WO2005023773A1 (en) 2003-09-04 2005-03-17 Pfizer Limited Process for the preparation of substituted aryl pyrazoles
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
BRPI0414798A (en) 2003-09-25 2006-11-21 Warner Lambert Co methods for using affinity amino acids for alpha2delta protein
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
JP4552456B2 (en) 2004-02-27 2010-09-29 住友化学株式会社 Ester compounds and uses thereof
US20070197510A1 (en) 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
US7807719B2 (en) 2004-09-14 2010-10-05 Chaim Roifman Compounds useful for modulating abnormal cell proliferation
US20060079494A1 (en) * 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
CA2603105A1 (en) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
CN101208089A (en) 2005-06-03 2008-06-25 泽农医药公司 Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080176865A1 (en) 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
ES2338699T3 (en) 2005-06-15 2010-05-11 Pfizer Limited SUBSTITUTED ARILPIRAZOLES FOR USE AGAINST PARASITES.
US20070149464A1 (en) 2005-06-15 2007-06-28 Pfizer Inc. Combination
US20080146643A1 (en) 2005-06-15 2008-06-19 Pfizer Limited Combination
CN101282936B (en) 2005-10-07 2012-05-16 橘生药品工业株式会社 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
US8338594B2 (en) 2005-12-02 2012-12-25 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
RU2008133161A (en) 2006-01-13 2010-02-20 Фармасайкликс, Инк. (Us) Tyrosine kinase inhibitors and their use
BRPI0709916B8 (en) 2006-03-31 2021-05-25 Univ Texas anticancer drugs associated with orally bioavailable caffeic acid and the use of these drugs
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California Purine analogs
WO2008005954A2 (en) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
AU2007269052B2 (en) 2006-07-06 2014-10-23 Array Biopharma Inc. Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
US8987233B2 (en) 2006-11-03 2015-03-24 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
JP2010519178A (en) 2006-11-23 2010-06-03 ノバルティス アーゲー Pyrimidines and their use as CXCR2 receptor antagonists
CN101730699A (en) * 2007-03-21 2010-06-09 百时美施贵宝公司 Can be used for treating the condensed heterocyclic compouds of proliferative, allergy, autoimmunity and diseases associated with inflammation
GB2447933A (en) 2007-03-27 2008-10-01 Chemence Ltd Cyanoacrylate monomer for forming an adhesive polymer
EP2543375A1 (en) 2007-03-28 2013-01-09 Pharmacyclics, Inc. Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase
EP2250172B1 (en) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
RU2503676C2 (en) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Pyrrolopyrazine kinase inhibitors
EA019507B1 (en) 2008-05-13 2014-04-30 Айрм Ллк Fused nitrogen containing heterocycles and compounds thereof as kinase inhibitors
CA2724715A1 (en) 2008-05-22 2009-11-26 Amgen Inc. Heterocycles as protein kinase inhibitors
EP2289273A4 (en) 2008-06-19 2013-11-13 Ericsson Telefon Ab L M Bit-rate prediction
JP5369183B2 (en) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
NZ590922A (en) 2008-08-01 2012-09-28 Biocryst Pharm Inc Piperidine derivatives as jak3 inhibitors
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
US20100113520A1 (en) 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
AU2010292198A1 (en) 2009-09-09 2012-04-05 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX2012005678A (en) 2009-11-16 2012-09-07 Univ California Kinase inhibitors.
BR112012029437A2 (en) 2010-05-20 2017-03-07 F Hoffmann - La Roche Ag pyrrolo [2,3-b] pyrazine-7-carboxamide derivatives and their use as jak and syk inhibitors
WO2011152351A1 (en) 2010-05-31 2011-12-08 小野薬品工業株式会社 Purinone derivative
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
MX2020004438A (en) 2010-06-03 2021-03-25 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk).
CN101880243A (en) 2010-06-04 2010-11-10 贵阳柏丝特化工有限公司 Fluorocyanogen-containing pyrethroid compound and synthesis method and application thereof
NZ607845A (en) 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012275275A1 (en) 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
EA201490265A1 (en) 2011-07-13 2014-12-30 Фармасайкликс, Инк. BLUTON TYROSINKINASE INHIBITORS
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
BR112014001255B1 (en) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Compound, use of a compound, combination, pharmaceutical composition, and pharmaceutically acceptable salt of a compound
JP2014522860A (en) 2011-07-19 2014-09-08 メルク・シャープ・アンド・ドーム・ベー・フェー 4-Imidazopyridazin-1-yl-benzamide and 4-Imidazotriazin-1-yl-benzamide as BTK inhibitors
CA2849340A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
AU2012325804B2 (en) 2011-10-19 2017-09-07 Pharmacyclics Llc Use of inhibitors of Bruton's tyrosine kinase (Btk)
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
MX368112B (en) 2012-06-18 2019-09-18 Principia Biopharma Inc Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases.
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
ES2731833T3 (en) 2012-09-10 2019-11-19 Principia Biopharma Inc Pyrazolopyrimidine compounds as kinase inhibitors
GEP201606597B (en) 2012-11-02 2017-01-10 Pfizer Bruton's tyrosine kinase inhibitors
BR112015011171A2 (en) 2012-11-15 2017-07-11 Pharmacyclics Inc pyrrolopyrimidine compounds as kinase inhibitors
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
JO3377B1 (en) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co Pyridinyl and fused pyridinyl triazolone derivatives
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
BR112016016844A2 (en) 2014-02-03 2017-08-08 Cadila Healthcare Ltd HETEROCYCLIC COMPOUNDS
EA033900B1 (en) 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. SALT AND AMORPHOUS FORMS OF 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE, PHARMACEUTICAL COMPOSITION BASED THEREON AND METNOD OF TREATING PEMPHIGUS VULGARIS AND PEMPHIGUS FOLIACEUS USING SAME
ES2843323T3 (en) 2014-12-18 2021-07-16 Principia Biopharma Inc Pemphigus treatment
HUE061809T2 (en) 2014-12-24 2023-08-28 Principia Biopharma Inc Compositions for ileo-jejunal drug delivery
SG11201705026UA (en) 2014-12-24 2017-07-28 Principia Biopharma Inc Site specific dosing of a btk inhibitor
PE20180521A1 (en) 2015-06-03 2018-03-14 Principia Biopharma Inc TYROSINE-KINASE INHIBITORS
TW201718572A (en) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 Tyrosine kinase inhibitors
CN105753863B (en) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 Oxo-dihydro Imidazopyridine compound and its application
CA3008653A1 (en) 2015-10-14 2017-04-20 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
MX2018016056A (en) 2016-06-29 2019-07-04 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phen oxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]- 4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
WO2008039218A2 (en) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2012158764A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
"Remington's Pharmaceutical Sciences", 2000, MACK PUBLISHING COMPANY
BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, January 1977 (1977-01-01), pages 1 - 19
BYRD J. C. ET AL.: "Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase lb/II study", J CLIN ONCOL, vol. 29, 2011, pages 6508
COPELAND RA; POMPLIANO DL; MEEK TD.: "Drug-target residence time and its implications for lead optimization", NAT. REV. DRUG DISCOV., vol. 5, no. 9, 2006, pages 730 - 739
DÖRNER T ET AL.: "Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers", PHARMACOL THER., vol. 125, 2010, pages 464 - 75
FOWLER, N ET AL.: "The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory Bcell malignancies: results from a phase I study", BLOOD, vol. 116, no. 21, 2010, pages 425
GAULD S. B. ET AL.: "B cell antigen receptor signaling: roles in cell development and disease", SCIENCE, vol. 296, 2002, pages 1641 - 2
GRAVALLESE E. M. ET AL.: "Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor", ARTHRITIS RHEUM., vol. 43, 2000, pages 250 - 8
GUO S. ET AL.: "Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy", PLOS ONE., vol. 6, 2011, pages E 17778
HONIGBERG L. A.: "The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy", PROC. NATL. ACAD. SCI., vol. 107, 2010, pages 13075 - 13080
HONIGBERG L.A., PROC NATL ACAD SCI U S A., vol. 107, 2010, pages 13075 - 80
HONIGBERG, L.: "The selective BTK inhibitor PCI-32765 blocks B cell and mast cell activation and prevents mouse collagen indiced arthritis", CLIN. IMMUNOL., vol. 127, 2008, pages S1 - S111
ITO I ET AL.: "Association of the FAM167A-BLK region with systemic sclerosis", ARTHRITIS RHEUM., vol. 62, 2010, pages 890 - 5
IYER A. S. ET AL.: "Absence of Tec Family Kinases Interleukin-2 Inducible T cell Kinase (Itk) and Bruton's Tyrosine Kinase (Btk) Severely Impairs Fc{epsilon}RI-dependent Mast Cell Responses", J. BIOL CHEM., vol. 286, 2011, pages 9503 - 13
KARP, R.: "Inhibition of BTK with AVL-292 Translates to Protective Activity in Animal Models of Rheumatoid Arthritis", INFLAMMATION RESEARCH ASSOCIATION MEETING, September 2010 (2010-09-01)
LEE S. H.: "The tec family tyrosine kinase BTK Regulates RANKL-induced osteoclast maturation", J. BIOL. CHEM, vol. 283, 2008, pages 11526 - 34
PAN Z. ET AL.: "Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase", J. MED. CHEM., vol. 2, 2007, pages 58 - 61
PEROSA F. ET AL.: "CD20-depleting therapy in autoimmune diseases: from basic research to the clinic", J INTERN MED., vol. 267, 2010, pages 260 - 77
QUEK L. S ET AL.: "A role for Bruton's tyrosine kinase (BTK) in platelet activation by collagen", CURR. BIOL., vol. 8, 1998, pages 1137 - 40
ROSEN F. S. ET AL.: "The primary immunodeficiencies", N ENGL J MED., vol. 333, 1995, pages 431 - 40
SAHU N ET AL.: "Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine-mediated migration", J. IMMUNOL., vol. 180, 2008, pages 3833 - 8
SETOGUCHI R. ET AL.: "Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and BTK-deficient mice", IMMUNOL LETT., vol. 64, 1998, pages 109 - 18
SHLOMCHIK M. J.: "The role of B cells in lpr/lpr-induced ' autoimmunity", J. EXP MED., vol. 180, 1994, pages 1295 - 1306
TU T ET AL.: "Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium", CANCER RES., vol. 6, 2008, pages 2861 - 9
YAN LOU ET AL: "Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 10, 6 March 2012 (2012-03-06), pages 4539 - 4550, XP055080230, ISSN: 0022-2623, DOI: 10.1021/jm300035p *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US10533013B2 (en) 2012-09-10 2020-01-14 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US11040980B2 (en) 2012-09-10 2021-06-22 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US20220370459A1 (en) * 2014-02-21 2022-11-24 Principia Biopharma, Inc. Salts and Solid Form of a BTK Inhibitor
WO2015127310A1 (en) * 2014-02-21 2015-08-27 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
EP3795158A1 (en) * 2014-02-21 2021-03-24 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
US20170065591A1 (en) * 2014-02-21 2017-03-09 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
US10828307B2 (en) 2014-02-21 2020-11-10 Principia Biopharma Inc. Salts and solid form of a BTK inhibitor
US11369613B2 (en) 2014-02-21 2022-06-28 Principia Biopharma Inc. Salts and solid form of a BTK inhibitor
AU2015218713B2 (en) * 2014-02-21 2019-10-10 Principia Biopharma Inc. Salts and solid form of a BTK inhibitor
US10092569B2 (en) * 2014-02-21 2018-10-09 Principia Biopharma Inc. Salts and solid form of a BTK inhibitor
EA033900B1 (en) * 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. SALT AND AMORPHOUS FORMS OF 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE, PHARMACEUTICAL COMPOSITION BASED THEREON AND METNOD OF TREATING PEMPHIGUS VULGARIS AND PEMPHIGUS FOLIACEUS USING SAME
US10456403B2 (en) 2014-02-21 2019-10-29 Principia Biopharma Inc. Salts and solid form of a BTK inhibitor
AU2015252654C1 (en) * 2014-04-29 2020-01-23 Zhejiang Dtrm Biopharma Co., Ltd. Polyfluorinated compounds acting as Bruton's tyrosine kinase inhibitors
CN105017256A (en) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 Polyfluorinated compound Bruton tyrosine kinase inhibitor
US10300066B2 (en) 2014-04-29 2019-05-28 Zhejiang DTRM Biopharma Co. Ltd. Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
AU2015252654B2 (en) * 2014-04-29 2019-10-03 Zhejiang Dtrm Biopharma Co., Ltd. Polyfluorinated compounds acting as Bruton's tyrosine kinase inhibitors
US10946008B2 (en) 2014-12-18 2021-03-16 Principia Biopharma Inc. Treatment of pemphigus
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
KR102524212B1 (en) 2014-12-24 2023-04-21 프린시피아 바이오파마, 인코퍼레이티드 Site-specific administration of BTK inhibitors
WO2016105531A1 (en) * 2014-12-24 2016-06-30 Philip Nunn Site specific dosing of a btk inhibitor
AU2015371254B2 (en) * 2014-12-24 2021-06-24 Principia Biopharma Inc. Site specific dosing of a BTK inhibitor
CN107427468A (en) * 2014-12-24 2017-12-01 普林斯匹亚生物制药公司 The site specific administration of BTK inhibitor
EA036351B1 (en) * 2014-12-24 2020-10-29 Принсипиа Биофарма Инк. Solid oral dosage form for inhibiting btk and methods of treatment
KR20170105524A (en) * 2014-12-24 2017-09-19 프린시피아 바이오파마, 인코퍼레이티드 Site-specific administration of BTK inhibitors
WO2016105582A1 (en) * 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
US11369620B2 (en) 2015-03-19 2022-06-28 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US10596183B2 (en) 2015-03-19 2020-03-24 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US10537587B2 (en) 2015-03-19 2020-01-21 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
JP2018509458A (en) * 2015-03-27 2018-04-05 ファーマサイクリックス エルエルシー Co-crystals of breton-type tyrosine kinase inhibitors
JP2021075540A (en) * 2015-03-27 2021-05-20 ファーマサイクリックス エルエルシー Cocrystals of bruton's tyrosine kinase inhibitor
JP2020073561A (en) * 2015-06-03 2020-05-14 プリンシピア バイオファーマ インコーポレイテッド Tyrosine kinase inhibitor
EP4112618A1 (en) * 2015-06-03 2023-01-04 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
US11155544B2 (en) * 2015-06-24 2021-10-26 Principia Biopharma Inc. Heterocycle comprising tyrosine kinase inhibitors
US11872229B2 (en) 2016-06-29 2024-01-16 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US11622965B2 (en) 2017-10-27 2023-04-11 Zhejiang DTRM Biopharma Co. Ltd. Methods for treating lymphoid malignancies
WO2019208805A1 (en) 2018-04-27 2019-10-31 小野薬品工業株式会社 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
WO2020021447A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020234715A1 (en) 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
WO2021072095A1 (en) 2019-10-09 2021-04-15 Principia Biopharma Inc. Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021076514A1 (en) 2019-10-14 2021-04-22 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021127231A1 (en) 2019-12-20 2021-06-24 Principia Biopharma Inc. Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US11708370B2 (en) 2019-12-20 2023-07-25 Principia Biopharma Inc. Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US11583533B2 (en) 2020-01-08 2023-02-21 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
WO2021142124A1 (en) * 2020-01-08 2021-07-15 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
US11969418B2 (en) 2020-01-20 2024-04-30 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (RMS)
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN115461341A (en) * 2020-01-22 2022-12-09 普林斯匹亚生物制药公司 Crystalline forms of 2- [3- [ 4-amino-3- (2-fluoro-4-phenoxy-phenyl) -1H-pyrazolo [3,4-D ] pyrimidin-1-yl ] piperidine-1-carbonyl ] -4-methyl-4- [4- (oxetan-3-yl) piperazin-1-yl ] pent-2-enenitrile
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11814390B2 (en) 2020-01-22 2023-11-14 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021216696A1 (en) 2020-04-22 2021-10-28 Principia Biopharma Inc. Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors
WO2022034529A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US12049463B2 (en) 2020-12-10 2024-07-30 Genzyme Corporation Crystalline form of Tolebrutinib
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022221527A1 (en) 2021-04-16 2022-10-20 Principia Biopharma, Inc. Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds
WO2023244562A1 (en) 2022-06-14 2023-12-21 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1- yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2023249980A1 (en) * 2022-06-22 2023-12-28 Genzyme Corporation Methods of making modified btk inhibitors
WO2024028782A1 (en) 2022-08-03 2024-02-08 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024097667A1 (en) 2022-10-31 2024-05-10 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-l-yl]pent-2-enenitrile
WO2024124113A1 (en) 2022-12-09 2024-06-13 Principia Biopharma Inc. Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib

Also Published As

Publication number Publication date
US20240174676A1 (en) 2024-05-30
AU2013312296A1 (en) 2015-03-05
SG11201501815UA (en) 2015-05-28
CY1122611T1 (en) 2021-03-12
EP3181567A1 (en) 2017-06-21
RS58956B1 (en) 2019-08-30
CN104822681A (en) 2015-08-05
HRP20171601T1 (en) 2017-12-29
KR102203990B1 (en) 2021-01-18
BR112015003859A8 (en) 2022-06-07
US10533013B2 (en) 2020-01-14
EP2892900B1 (en) 2017-08-16
HRP20191126T1 (en) 2019-09-20
PT3181567T (en) 2019-06-24
NZ630925A (en) 2016-10-28
US9266895B2 (en) 2016-02-23
EP2892900A1 (en) 2015-07-15
EA027213B1 (en) 2017-06-30
PT2892900T (en) 2017-11-06
BR112015003859A2 (en) 2017-07-04
US11040980B2 (en) 2021-06-22
US20150094295A1 (en) 2015-04-02
MX2015002955A (en) 2015-06-05
JP2015527401A (en) 2015-09-17
EA201590230A1 (en) 2015-08-31
HK1211942A1 (en) 2016-06-03
JP6203848B2 (en) 2017-09-27
ZA201501615B (en) 2017-11-29
KR20150053965A (en) 2015-05-19
US20200190092A1 (en) 2020-06-18
US20180327413A1 (en) 2018-11-15
PL3181567T3 (en) 2019-09-30
IL237285A0 (en) 2015-04-30
EA027213B9 (en) 2017-09-29
BR112015003859B1 (en) 2023-04-11
PL2892900T3 (en) 2018-02-28
IL237285B (en) 2019-03-31
SI3181567T1 (en) 2019-09-30
DK3181567T3 (en) 2019-06-11
EP3181567B1 (en) 2019-03-20
CA2882367C (en) 2021-11-09
US20160251358A1 (en) 2016-09-01
LT3181567T (en) 2019-07-25
CN104822681B (en) 2018-01-30
ES2644964T3 (en) 2017-12-01
US9994576B2 (en) 2018-06-12
US8940744B2 (en) 2015-01-27
US20140364410A1 (en) 2014-12-11
CA2882367A1 (en) 2014-03-13
SI2892900T1 (en) 2018-01-31
AU2013312296B2 (en) 2017-06-22
US20220073522A1 (en) 2022-03-10
HUE044146T2 (en) 2019-09-30
ES2731833T3 (en) 2019-11-19
IL265007B (en) 2019-11-28
ME03455B (en) 2020-01-20
MX361815B (en) 2018-12-17

Similar Documents

Publication Publication Date Title
US11040980B2 (en) Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US9376438B2 (en) Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US9187487B2 (en) Azaindole derivatives as tyrosine kinase inhibitors
WO2012158810A1 (en) Tyrosine kinase inhibitors
US20160257686A1 (en) Purinone Derivatives as Tyrosine Kinase Inhibitors
US9676778B2 (en) Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors
WO2015120049A1 (en) Quinolone derivatives as fibroblast growth factor receptor inhibitors
WO2016191172A1 (en) Quinolone derivatives as fibroblast growth factor receptor inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13762703

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14374788

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 201590230

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2882367

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 237285

Country of ref document: IL

REEP Request for entry into the european phase

Ref document number: 2013762703

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013762703

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013312296

Country of ref document: AU

Date of ref document: 20130906

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015531259

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/002955

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20157008939

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015003859

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015003859

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150223

ENPC Correction to former announcement of entry into national phase, pct application did not enter into the national phase

Ref document number: 112015003859

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.3 NA RPI NO 2426 DE 04/07/2017 POR TER SIDO INDEVIDA.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112015003859

Country of ref document: BR

Kind code of ref document: A2

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, NOVAS FOLHAS DE RELATORIO DESCRITIVO, REIVINDICACOES E RESUMO ADAPTADAS AO ART. 39 DA INSTRUCAO NORMATIVA 31/2013 UMA VEZ QUE O CONTEUDO ENVIADO NA PETICAO NO 860150030158 DE 23/02/2015 ENCONTRA-SE FORA DA NORMA, APRESENTANDO OUTRAS INFORMACOES NO CABECALHO DAS PAGINAS E NAO APENAS A NUMERACAO DAS MESMAS.

ENP Entry into the national phase

Ref document number: 112015003859

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150223